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Abstract	  	  	  
A wide variety of cellular processes are regulated via the post-
translation modification of substrate proteins by either ubiquitin or the small 
ubiquitin-like modifier, SUMO.  In recent years, points of convergence 
between the once thought distinct and independent SUMO- and ubiquitin-
conjugation pathways have been identified.  The ubiquitin E3 ligase RNF4 
catalyses the addition of ubiquitin modifications to previously SUMO modified 
proteins.  This results in hybrid chains of SUMO and ubiquitin decorating 
target substrates.  Do these SUMO-ubiquitin hybrid chains act as unique 
signals, distinct from the SUMO and ubiquitin chains that make them?  Are 
there proteins that recognise them as such?  The first part of this thesis 
details a protocol to identify and characterise the affinity of cellular proteins for 
‘baits’ consisting of hybrid chains of SUMO and ubiquitin.  This affinity 
chromatography based approach when coupled with high resolution mass 
spectrometry identified 30 proteins from HEK 293 cellular extracts that were 
putatively identified as showing affinity specifically for SUMO-ubiquitin hybrid 
chains.  Validation of this approach comes from the identification of the 
recently postulated SUMO-ubiquitin hybrid chain interacting protein RAP80 
amongst the proteins identified as putative SUMO-ubiquitin hybrid chain 
interacting proteins.  SUMO-ubiquitin hybrid chains are then evaluated in an in 
vivo context.  A proximity ligation assay was developed to probe the 
association between SUMO, ubiquitin and RAP80, suggesting a tight 
association between the three after DNA damage inducing stimuli. Interesting, 
the SUMO targeted ubiquitin E3 ligase RNF4 was shown not to be required 
for the recruitment of RAP80 to sites of DNA damage.  The association 
between RAP80, SUMO, and ubiquitin was probed further by 
immunoprecipitaion of RAP80 from cell extracts after a SUMO specific 
proteases treatment.  This SUMO specific protease treatment resulted in the 
loss of high molecular weight ubiquitin conjugates from the RAP80 associated 
material suggesting that some RAP80 associated material is carrying 
SUMOylation dependent ubiquitin modifications.  A SILAC based gel shift 
assay utilising both ubiquitin and SUMO-specific proteases was then 
developed to identify proteins that may anchor SUMO-ubiquitin hybrid chains. 
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Although technically challenging, S100A8 was identified as a protein that after 
the action of ubiquitin and SUMO proteases shifts in a pattern consistent with 
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1	  Introduction	  
 
 Protein function is not only controlled by amino-acid sequence, but by a 
multitude of post-translational modifications (PTMs) that can alter the function 
of the modified protein.  PTMs come in many forms ranging from proteolytic 
processing, to the addition of molecular adducts to specific amino acids.  
Common PTMs of the latter class include phosphorylation, methylation, 
acetylation and glycosylation.  However, a growing number of PTMs are 
themselves polypeptides that provide scope for a very complex, interactive 
and often reversible system of protein regulation.  Protein ubiquitylation, or the 
covalent modification of a protein by ubiquitin, is the classical example of this 
polypeptide class PTM.   
1.1	  Ubiquitin	  
1.1.1	  Ubiquitin	  and	  the	  ubiquitin-­‐like	  modifiers	  	  
Ubiquitin is a small 76 amino acid 8.5 kDa protein that is ubiquitously 
expressed and highly conserved in eukaryotes, differing by only a few amino 
acids from yeast to humans (Goldstein et al., 1975).  Four human genes 
encode ubiquitin; UBB, UBC, UBA52, and RPS27A (Redman & Rechsteiner 
1989).  UBA52 and RPS27A express single ubiquitin moieties fused to 
ribosomal polypeptides, whereas UBB and UBC express linear fusion proteins 
containing multiple ubiquitin moieties (Finley et al., 1989).  Discovered in the 
late 1970’s as a trigger for non-lysosomal protein degradation (Ciechanover et 
al 1978), it is now known that the ubiquitylation machinery recognises and 
targets thousands of proteins, with implications on almost all cellular systems; 
the most well characterised action of protein ubiquitylation being the marking 
of proteins for degradation by the 26S proteasome (Hershko et al., 1984).  
 
Ubiquitin belongs to a wider family known as the ubiquitin-like modifiers 
(Ubls).  Since the identification of ubiquitin in the 1970’s the mammalian Ubl 
family of proteins has grown to contain around 20 members including NEDD8, 
SUMO1, SUMO2, SUMO3, and FAT10 (Kerscher et al., 2006).  Members of 
the Ubl family of proteins share variable levels of sequence similarity to 
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ubiquitin, but all contain a conserved β-grasp fold (β-GF) that is characteristic 
of the founding member ubiquitin (Hochstrasser 2009). 
 
1.1.2	  The	  ubiquitin	  conjugation	  pathway	  and	  associated	  enzymes	  	  
Protein ubiquitylation involves an enzymatic cascade resulting in the 
production of an isopeptide bond between the C-terminal Gly76 of ubiquitin 
and most commonly the ε-amino group of a lysine residue contained in a 
target substrate (Figure 1.1-1).  The enzymatic cascade typically involves 
three distinct sets of enzymes; firstly, in an ATP-dependent step, a thioester 
bond is formed between the C-terminal Gly76 of ubiquitin and a cysteine of an 
E1 activating enzyme.  Subsequently, ubiquitin is transferred to the active site 
cysteine of an E2-conjugating enzyme before finally being transferred to a 




Figure 1.1-1 The Ubl conjugation cycle. 
A 3-step enzymatic cascade involving E1, E2 & E3 enzymes resulting in the conjugation of 
Ubl family members to range of target substrates, modification of Ubl family members results 
in the formation of polymeric chains of some Ubl proteins.  Proteases antagonise E3 enzymes 
by facilitating the removal and recycling of the Ubls from target substrates.  
            
 
The human genome encodes two ubiquitin E1 activating enzymes; 
Uba1 and the more recently identified Uba6 (Jin et al., 2007).  Uba1 is thought 
to be the apical E1 enzyme for the majority of ubiquitylation event in vivo, as 
such, it has been shown that Uba1, but not Uba6, is critical for the formation 
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of ionising radiation induced foci formation at the sites of DNA damage 
(Moudry et al., 2012).   
 
Around 40 ubiquitin E2 enzymes have so far been identified.  E2 
enzymes are recognisable by a highly conserved ~150 amino acid ubiquitin-
conjugating domain (Ubc), containing the active-site cysteine to which 
ubiquitin becomes conjugated.  Along with the conserved Ubc domain, most 
E2 enzymes also contain N- and/or C- terminal extension (Burroughs et al., 
2008).  E2 enzymes must perform a number of functions during ubiquitin 
conjugation.  Firstly, they must act to recognise and then transiently receive 
ubiquitin from an E1 enzyme; this results in the formation of an E2-ubiquitin 
thioester.  Secondly, this E2-ubiquitin thioester must then interact with an E3 
ligase enzyme to catalyse the ubiquitylation of a target substrate (Figure 1.1-
1).  Additional E2-variant (Uev) enzymes have been identified which also 
contain the Ubc domain (Burroughs et al., 2008).  These enzymes lack the 
catalytic active site cysteine required for ubiquitin conjugation and so are 
thought to be conjugation dead pseudo enzymes.  However some E2-variants 
are known to aid E2 enzymes in positioning ubiquitin for linkage-specific 
conjugation.  For example, the E2/E2-variant pair Ubc13/Ube2v2, Ube2v2 has 
been observed to be responsible for recognising and binding the acceptor 
ubiquitin and positioning the acceptor K63 lysine for attack on the linkage 
between Ubc13 and the donor ubiquitin which is held in place by the E3 ligase 
RING finger protein 4 (RNF4) (Branigan et al., 2015).  
 
Approximately 600 ubiquitin E3 enzymes have been identified in 
humans.  There are two main classes of ubiquitin E3 enzyme: RING (Really 
Interesting New Gene) domain containing proteins, and HECT (Homologues 
to E6-AP C-terminus) domain containing proteins (Metzger et al., 2012).  
RING domain containing ubiquitin E3 ligases function to catalyse the direct 
transfer of ubiquitin from an E2-ubiquitin thioester to a target protein.  This 
mechanism was first observed in crystal structures of the E2-ubiquitin 
thioester, UbcH5a-Ub with the RING domain of RNF4 (Plechanovova et al., 
2011).  In contrast, HECT domain containing ligases contain an active-site 
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cysteine residue that accepts ubiquitin from an E2 prior to substrate 
modification (Hung et al., 1999). 
1.1.3	  Ubiquitin	  chain	  types	  	  	  	   The ubiquitylation of target substrates can result in a diverse set of 
signals (Figure 1.1-2).  Proteins can be singly mono-ubiquitiylated, multiply 
mono-ubiquitylated, or due to the presence of seven lysine residues (K6, K11, 
K27, K29, K33, K48, K63) (Figure 1.1-3, A) contained within the sequence of 
ubiquitin, ubiquitin can modify other ubiquitin proteins resulting in the 
formation of polymeric chains of ubiquitin (poly-ubiquitin) (Kultha & 
Kommander 2012) (Figure 1.1-2, B).  Furthermore, linear poly-ubiquitin can 
also be formed through the N-terminal amino group of Met1 (Iwai et al., 2009) 
(Figure 1.1-2, B).  All eight ubiquitin linkage types have been observed in vivo 
(Peng et al., 2003; Xu et al., 2009).  It is thought that different combinations of 
ubiquitin E2/E3 pairs are responsible of the addition of specifically linked poly-
ubiquitin chains to specific substrate proteins.  K48 linked and K63 linked 
poly-ubiquitin chains are the most well characterised examples of poly-
ubiquitin.  K48 linked poly-ubiquitin chains are thought to make up around 
30% of the total number of polymeric ubiquitin chains present in any cell at 
any one time (Xu et al., 2009).  The addition of a K48 linked poly-ubiquitin 
chain, of at least 4 ubiquitin moieties, to any protein functions to target that 
protein for destruction by the 26S proteasome (Thrower et al., 2000). K63 
linked poly-ubiquitin chains have been observed to mark proteins from a wide 
variety of cellular processes including the DNA damage response, but do not 
appear to have a function in targeting proteins for destruction by the 
proteasome, instead this linkage type is thought to act as a wider signalling 
mechanism (Hofmann & Pickart 1999).  In comparison to K48 linked and K63 
linked poly-ubiquitin chains, little is known about the remaining linkage types.  
K11 linked poly-ubiquitin chains are less well studied but under certain 
circumstances are almost as abundant as K48 linked poly-ubiquitin chains (Xu 
et al., 2009; Matsumoto et al., 2010), and have also been observed to have a 
role in proteasomal degradation (Wickliffe et al., 2011). K6 linked poly-
ubiquitin chains can be catalysed by the breast cancer susceptibility type 1 
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(BRCA1) and BRCA1-associated RING domain protein 1 (BARD1) (BRCA1-
BARD1) E3 ligase complex and so may have a role in the DNA damage 
response (Wu-Baer et al., 2003).  Several putative roles have been ascribed 
to K27, K29, and K33 linked poly-ubiquitin chains, with all three linkage types 
appearing to be important signalling mechanisms in T-cells (Chastagner et al., 
2006; Peng et al., 2011).  Interestingly, two of the four genes that encode 
ubiquitin in the human genome are essentially Met1 linked poly-ubiquitin 
chains and as such act as precursors for all poly-ubiquitin linkage types in the 
cell.  However, a large 600 kDa protein complex known as the Linear 
Ubiquitin Assembly Complex (LUBAC) has also been observed to catalyse 
the addition of Met1 linked poly-ubiquitin chains to proteins including NF-
kappa-B essential modulator (NEMO) and other substrates important for the 
activation of nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) which plays a key role in the cellular immune response (Iwai et al., 
2009; Tokunaga et al., 2009; Niu et al., 2011). 
 
	  
Figure 1.1-2 Ubiquitin modifications. 
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A) Depending on the number and availability of lysine residues, substrate proteins can be 
mono-ubiquitylated, multiply mono-ubiquitylated, poly-ubiquitylated or combinations of both. 
Substrate proteins can also anchor heterologous poly-ubiquitin modifications known as 
branched chain modifications.  
B) Branched chain modifications can be made up from any combination of the eight different 
poly-ubiquitylation types. K6 linked pUb is denoted by purple Ub moieties. K11 linked pUb is 
denoted by orange Ub moieties. K27 linked pUb is denoted by green Ub moieties. K29 linked 
pUb is denoted by dark blue Ub moieties. K33 linked pUb is denoted by red Ub moieties. K48 
linked pUb is denoted by yellow Ub moieties. K63 linked pUb is denoted by light blue Ub 
moieties. M1 linked pUb is denoted by grey Ub moieties. 
 	   	   	   	   	   	   	   	   	   	   	  
 
Differences in topology of the eight different ubiquitin linkage types 
allow for a wide range of signals to be generated by poly-ubiquitin chains. 
Homotypic poly-ubiquitin chains are thought to primarily adopt one of two 
structural conformations; a compact confirmation where the ubiquitin moieties 
composing the chain interact with each other via hydrophobic surface on 
ubiquitin along with the linkage site; or an open confirmation where the 
ubiquitin moieties comprising the chains are only interfacing via the linkage 
site (Komander & Rape 2012).  It has been reported that K48 linked ubiquitin 
moieties form a compact conformation (Tenno et al., 2004).  The compact 
nature of linkages suggests that some of the binding surface of ubiquitin may 
be closed off to interacting partners (Dikic et al., 2011).  Conversely, K63 and 
Met1 linked ubiquitin moieties form open conformations (Tenno et al., 2004; 
Varadan et al., 2004).  The open conformation allows these linkage types to 
be more flexible with a high degree of conformational freedom that is likely 
exploited by any interacting partners of these chain types (Tenno et al., 2004; 
Varadan et al., 2004). 
 
1.1.4	  Recognition	  of	  ubiquitin	  chains	  types	  by	  ubiquitin	  binding	  domains	  	  
Ubiquitin contains several distinctive interaction surfaces (Figure 1.1-3, 
B).  Ubiquitin is predominantly recognised via a hydrophobic patch centred on 
Ile44, known as the Ile44 patch.  It is predominantly through interactions with 
this hydrophobic patch that K48 linked poly-ubiquitin chains form a compact 
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conformation.  However, hydrophobic patches including the Ile36 patch, Phe4 
patch and the TEK box are also known to act as sites for non-covalent 
interactions with ubiquitin (Dikic et al., 2011) (Figure 1.1-3, B).  Indeed it has 
been observed that the closed conformation of K48 linked poly-ubiquitin 
chains can also be facilitated via the Ile36 patch, freeing up the Ile44 patch to 
non-covalent interactions with other ubiquitin interacting partners (Eddins et 
al., 2007). 
 
 In recent years a wide variety of proteins have been found to contain 
distinct domains that facilitate a non-covalent interactions with ubiquitin, 
known as ubiquitin-binding domains (UBDs).  The UBD family is composed of 
a wide variety of domains that between them have the ability to interact with 
all types of ubiquitin modifications from mono-ubiquitin through all the specific 
poly-ubiquitin chain types.  One of the best characterised types of UBD is the 
ubiquitin interaction motif (UIM).  UIMs were first identified as the UBD 
contained within the S5a (RPN10) subunit of the 26S proteasome (Young et 
al., 1998; Hofmann & Flaquet., 2001).  The conserved UIM motif is composed 
of 15 residues e-e-e-e-x-Ψ-x-x-A-x-x-x-S-x-x-e (where “e” is any negatively 
charged residue and Ψ is a hydrophobic residue) and have been observed to 
form a α-helice (Hofmann & Flaquet., 2001;Swanson et al., 2003).  UIMs are 
some times referred to as the “LALAL” motif due to its Leu and Ala rich core 
region, while a block of four preferentially acidic residues precedes this core 
region (Hofmann & Flaquet., 2001; Swanson et al., 2003).  Single UIMs show 
low affinity for mono-ubiquitin.  However, many proteins identified containing 
UIMs have been shown to contain multiple UIMs, and show high-affinity for 
poly-ubiquitin, including the BRCA 1A complex component, RAP80 that 
contains two UIM domains.  These two UIMs allow RAP80 to interact non-
covalently with a dimer of K63 linked ubiquitin (Figure 1.1-3, C). UIMs are 
thought to interact with Ile44 patch of ubiquitin (Swanson et al., 2003).  Many 
of the UBDs identified so far are known to interact with this hydrophobic patch 
of ubiquitin including the 26S proteasome (Dikic et al., 2011).  However, there 
are exceptions, including the A20 type Znf domain of RAB5.  The A20 type 
Znf domain of RBA5 forms interactions not only with the Ile44-containing 
surface, but also the TEK box and a polar surface of ubiquitin centred on 
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Asp58 (Lee et al., 2006) (Figure 1.1-3, B).  The list of UBDs is likely to be 
incomplete, with new domains being regularly described. 
	  
Figure 1.1-3 Interacting with ubiquitin.	  
A) Structure of ubiquitin highlighting the seven internal lysine and Met1 residues involved in 
covalent poly-ubiquitin modifications.  Met1/N-terminus (N-term) highlighted in cyan.  C-
terminus (c-term) is highlighted in red.  Protein Data Bank identifier 1ubq.  
B) Structure of ubiquitin highlighting hydrophobic non-covalent interaction surfaces.  Ile36-
patch highlighted in green.  Ile44-patch highlighted in blue.  TEK-box highlighted in grey. 
Phe4-patch highlighted in cyan. 
C) Structure of the non-covalent interaction between a K63-linked ubiquitin dimer (orange and 
yellow) and a RAP80 UIM dimer (cyan) via the Ile44-patch (Blue) located on each of the 
ubiquitin moieties (Komander & Rape 2012).  Protein Data Bank identifier 3a1q. 
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1.1.5	  Ubiquitin	  deconjugating	  enzymes	  	  	  	   Ubiquitylation is a dynamic, and importantly, a reversible process.  The 
removal of mono- and poly-ubiquitin is facilitated by a large group of enzymes 
known as deubiquitinases (DUbs) (Nijman et al., 2005).  DUbs carry out a 
number of essential roles including processing ubiquitin precursors, 
antagonising ubiquitin E3s (Figure 1.1-1) and recycling K48 linked poly-
ubiquitin chains from proteins targeted to the proteasome just prior to the 
target protein being destroyed (Kommander et al., 2009).  The human 
genome encodes approximately 100 DUb enzymes, which can be classified 
into five subfamilies; Ubiquitin C-terminal hydrolases (UHC), Ubiquitin-specific 
proteases (USPs), Otubain domain ubiquitin binding proteins (OTU), 
Machado-Joseph domain-containing proteases (MJD), and the 
Jab1/Pab1/MPN domain containing proteases (JAMM).  Four of these 
subfamilies UHC, USP, OTU, and MJDs are classed as cysteine-specific 
proteases with the JAMM family classed as Zinc metalloproteases (Nilman et 
al., 2005).  The USP family is the largest single subfamily of DUbs, containing 
56 members, thus the majority of reported DUb enzymes are cysteine-specific 
proteases.  Cysteine specific proteases contain a catalytic triad of Cys-His-
Asp/Asn.  USP2 is a member of the USP family of DUb enzymes and is highly 
active both in vitro and in vivo (Renatus et al., 2006).  USP2 is thought to play 
a role in regulating p53 “the guardian of the genome” by deubiquitylating the 
p53 regulating protein Mdm2 (Stevenson et al., 2007).  Mdm2 is a ubiquitin E3 
ligase important for the proteasome mediated degradation of p53 (Brady et 
al., 2005).  Deubiquitylaion of Mdm2 by USP2, and USP7 another member of 
the USP family of DUbs, leads to the stabilisation and activation of Mdm2 and 
thus inhibition of p53 (Stevenson et al., 2007).  USP2, consisting of 605 amino 
acids, is a relatively small USP protein, as many of the USP family proteases 
are composed of ~1000 amino acids.  The catalytic triad of USP2, Cys276-
His557-Asp574, is located in its C-terminal USP domain, which is a 
characteristic of the USP family of proteases (Renatus et al., 2006).  The 
JAMM domain containing proteases are classed as Zn metalloproteases and 
conform to a catalytic active-site consensus motif of Glu-X-[N]-His-His-X(10)-
Asp.  The BRCA 1A complex component BRCC36, a JAMM domain 
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containing protease, is thought to have a role in deconjugating K63 linked 
poly-ubiquitin from substrate proteins at the sites of DNA damage (Shao et al., 
2009A).  DUbs often have discrete domains that allow them to recognise and 
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1.2 	  SUMO	  	  
1.2.1	  SUMO	  the	  small	  ubiquitin-­‐like	  modifier	  	  
 
In the years following the identification of ubiquitin several other ubiquitin 
like proteins were identified including the small ubiquitin-like modifier (SUMO).  
SUMO was identified in the mid 1990’s as a polypeptide adduct of the 
GTPase-activating enzyme RanGAP1, regulating the transport of RanGAP1 
from the cytoplasm to the nuclear pore complex (Matunis et al., 1996; 
Mahajan et al., 1997).  Since its identification, SUMO has been shown to alter 
the function of a wide variety of proteins in several essential cellular 
processes such as cellular localisation, transcription, heat shock response, 
and the DNA damage response (Gill 2003; Golebiowski et al., 2009; Galanty 
et al., 2009). 
 
The SUMO family of proteins share limited sequence identity with ubiquitin 
(~20%) but contain a similar β-GF structure (Hochstrasser 2009).  In humans, 
there are 3 active forms of SUMO; SUMO1, SUMO2 and SUMO3.  SUMO2 
and SUMO3 are nearly identical, only differing by three amino acids in their N-
terminal region and have not been functionally differentiated; as such they 
form the SUMO2/3 subfamily (referred to as SUMO2 from now on) sharing 
46-48% sequence identity with SUMO1 (Saitoh & Hinchey, 2000; Tatham et 
al., 2001).  Paralog-specific roles have been ascribed to both SUMO1 and 
SUMO2, with some substrates preferentially modified by either SUMO1 or 
SUMO2; RanGAP1, for example is preferentially modified by SUMO1 (Saitoh 
& Hinchey, 2000).  However, SUMO1 and SUMO2 share specificity for a large 
number of substrates and a degree of functional redundancy exists between 
them (Vertegaal et al., 2006).  For example, mice lacking SUMO1 are still 
viable suggesting that SUMO2 can functionally compensate for SUMO1 in 
some instances (Zang et al., 2008).  Interestingly a more recent study has 
suggested that SUMO3 null mice are viable but SUMO2 null mice were 
embryonic lethal (Wang et al., 2014).  The authors of this report suggested 
that this difference between SUMO2 and SUMO3 was not due to a functional 
difference between the two proteins, but rather because SUMO2 is the 
predominantly expressed SUMO isoform during embryogenesis (Wang et al., 
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2014).  The majority of SUMO1 in cells is found conjugated to proteins under 
normal growth conditions, but interestingly, free pools of SUMO2 exist under 
normal cell growth conditions.  Under cellular stress condition such as heat 
shock, rapid conjugation of this pool of free SUMO2 to a variety of proteins is 
required for cellular survival (Golebiowski et al 2009).  Humans contain a 
fourth SUMO gene, SUMO4, the product of which shares 85% sequence 
identity with SUMO2. SUMO4 has been suggested to have a role in signalling 
stress response in kidney cells and a role in the pathogenesis of type-1 
diabetes (Brohen et al., 2004).  However, it is unclear if this protein can be 
actively conjugated to proteins and so it is thought SUMO4 may in fact be a 
pseudo gene (Owerbach et al., 2005).  
1.2.2	  SUMO	  conjugation	  pathway	  	  	  
SUMO1 and SUMO2, like ubiquitin, are conjugated to target substrates 
through an enzymatic cascade involving a distinct set of E1, E2 and E3 
enzymes characteristic of the Ubl family of proteins (Figure 1.1-1).  All SUMO 
proteins are expressed as inactive precursor proteins before SUMO-specific 
proteases act to cleave the C-terminal regions of SUMO1, SUMO2 and 
SUMO3 to reveal a Gly-Gly motif capable of covalent linkage to the ε-amino 
side chain of a lysine residue found within an acceptor substrate (Hay 2005).  
The presence of Pro90 in SUMO4 impairs the cleavage of its C-terminal, thus 
inhibiting the activation and conjugation of SUMO4 to target substrates 
(Owerbach et al., 2005).  A heterodimer of SAE1 and SAE2 forms the SUMO 
activating E1 enzyme.  The ATP-dependent action of SAE1/SAE2 results in 
the formation of a thioester bond between a cysteine residue of SAE2 and the 
C-terminus of SUMO.  SUMO is then transesterified to the SUMO conjugating 
E2 enzyme.  Unlike the ubiquitin conjugation system where ~40 E2 enzymes 
have been identified, only one functional E2 enzyme has been identified in the 
SUMO conjugation pathway, Ubc9.  Another differentiating factor in the 
SUMO conjugation pathway is that unlike the ubiquitin conjugation pathway, 
Ubc9 is able to recognise and transfer SUMO directly to target proteins in the 
absence of an E3 ligase enzyme (Desterro et al., 1997).  This is due to Ubc9’s 
ability to recognise lysine residues capable of accepting SUMO modification.  
Ubc9 is so functionally important for SUMO conjugation that mice deficient in 
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Ubc9 are embryonic lethal, highlighting the functional importance of the 
SUMO system to cell survival (Nacerddine et al., 2005).  Although 
SAE1/SAE2 and Ubc9 are sufficient to form an iso-peptide bond between the 
C-terminus of SUMO and the ε-amino group of an acceptor lysine the reaction 
is very inefficient.  Like the ubiquitin conjugation pathway, SUMO E3 ligase 
enzymes act to increase the rate of conjugation.  Less than 20 SUMO E3’s 
have been identified compared to the approximately 600 ubiquitin E3’s.  
However, more than 1600 proteins are known to be SUMO substrates and 
more than 4000 SUMOylation sites have been identified (Tammsalu et al., 
2014; Hendricks et al., 2014).  This suggests that a relatively small number of 
SUMO E3 ligases are capable of modifying large numbers of distinct SUMO 
substrates.  The first group of SUMO E3s identified were the Protein inhibitor 
of activated STAT (PIAS) proteins (Wong et al., 2004).  The PIAS proteins are 
functionally similar to the RING-domain containing ubiquitin E3 ligases.  Four 
human PIAS genes have been identified to encode SUMO E3 ligases; PIAS1, 
PIAS2 (PIASx), PIAS3, and PIAS4 (PIASy).  The PIAS proteins have been 
shown to SUMO modify a wide variety of proteins involved in a number of 
different cellular processes.  Interestingly, however, the substrate specificity of 
the PIAS proteins has been shown to be low, thus it is unclear how exactly 
these proteins actively target substrates for SUMOylation.  Unlike the PIAS E3 
ligase, some SUMO E3s have no comparable ubiquitin counterparts.  
RanBP2 was among the first SUMO E3 ligase enzymes to be identified, but is 
neither comparable to RING or HECT type ubiquitin E3s (Pichler et al., 2004).  
RanBP2 has both SUMO1 and SUMO2 E3 ligase activity, modifying SP100 
with SUMO1 but preferentially modifying PML with SUMO2 in vivo 
(Lallemand-Breitenbach et al., 2001; Tatham et al., 2004).  This apparent 
SUMO paralog-specific activity is due to the way in which RanBP2 recognises 
and interacts with the Ubc9-SUMO1 thioester when compared to the Ubc9-
SUMO2 thioester.  The E3 ligase activity of RanBP2 is contained within a 100 
amino acid region that can be broken down into three distinct motifs IR1, M, 
and IR2.  IR1 has been observed to interact strongly with Ubc9 whereas M-
IR2 has been observed to interact with SUMO1.  Interestingly RanBP2 does 
not interact with SUMO2 alone.  Thus, the Ubc9-SUMO1 thioester is bound 
strongly by tandem interaction of the IR1, M, and IR2 containing domains 
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interacting with both the Ubc9 and SUMO1 moieties, whereas Ubc9-SUMO2 
thioester is bound more weakly solely via the interaction between the IR1 
domain and Ubc9 (Tatham et al., 2004).  Thus the relative affinities for Ubc9-
SUMO1 and Ubc9-SUMO2 thioesters are thought to be responsible in part for 
the paralog specificity shown by RanBP2.  The region of RanBP2 that binds 
Ubc9 is on the opposite binding surface to the cysteine that forms a thioester 
with SUMO.  It is thought that this allows RanBP2 to position the Ubc9-SUMO 
thioester for nucleophilic attack (Reverter and Lima 2005).	  
1.2.3	  Consensus	  SUMO	  modification	  motif	  	  
Initially, SUMO conjugation was thought to be primarily targeted to 
lysine residues contained within a consensus SUMO modification motif, Ψ-K-
x-E or Ψ-K-x-D (where Ψ is any bulky hydrophobic residue and x is any 
residue) (Rodriguez et al., 2001).  Many SUMO modification sites were 
thereafter identified in proteins containing such consensus motifs.  Later, an 
inverted SUMO consensus motif, E-x-K-Ψ or D-x-K-Ψ, was identified by a 
small-scale proteomic study (Matic et al., 2008).  Advances in proteomics 
have greatly increased our understanding of SUMO conjugation sites.  Large-
scale proteomic analysis of SUMO sites has led to a better understanding of 
potential consensus SUMO modification motifs.  A recent study identified 
1002 distinct SUMO2 modified sites of which 70% conformed to either the 
forward or inverted consensus SUMO modification motif (Tammsalu et al., 
2014).  90% of the forward containing consensus motifs were observed to 
contain a Glu at the +2 position suggesting that Ψ-K-x-E is the preferred 
variant of the forward consensus motif.  Glu and Asp were shown to be 
equally likely to be present in -2 position of the inverted consensus motif, but, 
surprisingly, hydrophobic residues did not take preference in the +1 position.  
Interestingly, a fusion of forward and inverted motifs was also observed 
containing Glu or Asp in both the -2 and +2 positions (Tammsalu et al., 2014).  
 
Polymeric modification of Ubls is not restricted to ubiquitin and its eight 
separate internal modification sites.  An internal forward consensus SUMO 
conjugation motif was identified at the N-terminally located K11 (V10-K11-
T12-E13) of SUMO2 allowing the formation of poly-SUMO2 chains and 
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increasing the complexity of signalling via the SUMO modification system 
(Tatham et al., 2001).  SUMO1 does not contain this motif and is not thought 
to readily form poly-SUMO1 chains in vivo, however, SUMO1 has been 
suggested to “cap” the end of poly-SUMO2 chains, acting to halt chain 
polymeric SUMO chain formation (Tatham et al., 2001).  Although K11 of 
SUMO2 is the primary acceptor lysine for modification by SUMO, 
modifications of K5 and K7 have also been reported (Tammsalu et al., 2014).  
This suggests a more complex branched SUMO modification landscape may 
exist.  As of yet no biological role has been suggested for these atypical 
SUMO2 polymers (Tammsalu et al., 2014).  
1.2.4	  SUMO	  interaction	  motifs	  	  
The SUMOylation of proteins can be recognised non-covalently by 
other proteins containing specialised non-covalent binding motifs known as, 
SUMO interaction motifs (SIMs).  In this way SUMOylation can aid in protein-
protein interactions.  This is observed most strikingly in PML nuclear bodies 
(PML-NBs) where the non-covalent interactions between SUMO modified 
PML and associated proteins acts to nucleate the formation of PML-NBs.  If 
the SIMs of PML are mutated out the SUMOylation of PML fails to nucleate 
PML-NBs (Shen et al., 2006A).  From structural studies it is known that SIMs 
form β-strands, which in turn form non-covalent hydrophobic interactions with 
a structural groove conserved in all three active human SUMO isoforms.  This 
groove is situated between the second β-strand and the first alpha helix of 
SUMO (Song et al., 2005).  All SIM domains are thought to interact with this 
same region of SUMO.  The most well characterised “classical” SIM type 
motifs conform to the consensus sequence V/I/L-V/I/L-x-V/I/L or V/I/L-x-V/I/L-
V/I/L, with groups of acidic residues or phosphorylated serine residues often 
observed in close proximity to the hydrophobic core SIM motif.  These acidic 
or phosphorylated (negatively charged) residues are thought to help stabilise 
the interaction between the SIM motif and SUMO, by interacting with a 
positively charged lysine residue located proximal to the second β-strand and 
the first alpha helix of SUMO (Hecker et al., 2006).  The location of these 
negatively charged amino acids is thought to affect the orientation and the 
affinity of the SIM-SUMO interaction, by allowing SIMs to bind SUMO in a 
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parallel or anti-parallel orientation with respect to the second β-strand of 
SUMO (Reverter & Lima 2005; Song et al., 2005).  Interestingly, a “high 
fidelity” SIM type domain has been described conforming to the consensus 
sequence V/I/L/F/Y-V/I-D-L-T, with V-I-D-L-T representing the idealistic high 
fidelity SIM (Sun and Hunter 2012).  The presence of Val, Ile, and Thr, which 
can more easily form β-strands gives this high fidelity SIM type a very rigid 
structure well suited to interacting with all SUMO isoforms (Sun and Hunter 
2012).  
 
Non-canonical SIM domains have also been described in the literature. 
Recent evidence has suggested the MYM-type zinc finger containing proteins 
ZMYM2 and ZMYM3 contain a potential new class of SIM domain (Guzzo et 
al., 2014).  The authors of the study report that a single MYM-type zinc finger 
can interact with SUMO2 in a 1:1 stoichiometry, through the same surface as 
the classical type SIM domain.  Five human proteins have been described to 
contain MYM-type zinc finger; ZMYM2, ZMYM3, ZMYM4, ZMYM5 and 
ZMYM6.  The MYM-type zinc fingers in these proteins confirm to the 
consensus sequence ‘Cys-X2-Cys-X19-22-Cys-X3-Cys-X13-19-Cys-X2-Cys-X19-25-
Cys-X3-Cys’ (Guzzo et al., 2014).  MYM-type zinc fingers were reported to aid 
the recruitment of ZMYM2 to SUMOylated PML in PML-NBs (Guzzo et al., 
2014).  ZMYM3 has been reported to show affinity for SUMO2, however, it is 
still unclear whether the affinity for SUMO2 shown by ZMYM3 is due to the 
presence of MYM-type zinc fingers (Guzzo et al., 2014).  It is interesting to 
note that ZMYM2, ZMYM3, ZMYM4 and ZMYM6 all contain multiple MYM-
type zinc fingers.  It will be interesting to see in the future whether this allows 
these proteins to interact with polymeric SUMO chains.  Other non-canonical 
SIM like domains have been described.  For example, the ubiquitin RING type 
E3 ligase Herpes simplex virus type 1 early intermediate protein ICP0, is 
known to contain SIM like sequence (SLS).  The SLSs of IPC0 are required 
for the IPC0 induced ubiquitin-dependent degradation of SUMOylated PML 
(Boutell et al., 2011).  
 
The list of proteins known to contain SIMs grows rapidly as does our 
understanding of how these proteins interact with SUMO non-covalently.  It is 
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interesting to note that, as in the ubiquitin system, the majority of SIM and 
SIM-like domains that have thus far been described all preferentially interact 
with the same binding surface of SUMO.  How SUMO interacting proteins 
preferentially recognise SUMO modifications of one proteins from another is 
not clear. Certainly, in some cases it may involve secondary interactions with 
other proteins or the SUMO modified protein itself. 
1.2.5	  SUMO	  specific	  proteases	  
 
SUMOylation is a reversible modification.  As with the DUb enzymes of 
the ubiquitin system, the SUMO system has a distinct set of enzymes that can 
actively remove SUMO from target substrates, known as deSUMOylation.  In 
humans, nine SUMO isopeptidases have so far been identified, which can be 
classed into three families; the Sentrin/SUMO-specific proteases (SENPs), 
the DeSUMOylating isopeptidases (Desi), and the USPL1-related 
isopeptidases.  
 
There are six active SENPs in the mammalian system; SENP1, 
SENP2, SENP3, SENP5, SENP6, and SENP7.  All six active SENP enzymes 
contain a highly conserved catalytic cysteine-containing protease domain 
located in their C-terminal region.  This region contains a Cys-His-Asp 
catalytic triad (SENP1; Cys-603, His-533, and Asp-550, Shen et al., 2006B) 
that is critical for the activity of the SENP enzymes.  Hence, mutational 
analysis of these residues has been shown to disrupt the catalytic activity of 
the SENP enzymes (Shen et al., 2006B; Chung et al., 2010; Haindl et al 
2008).  The SENPs can be further characterised into 3 subfamilies based on 
cellular localisation and functional characteristics.  SENP1 and SENP2, form 
the first subfamily, observed to be mainly nuclear in localisation, and 
concentrated in the nuclear pore complex (Gong et al., 2000; Bailey & O’Hare 
2004).  However, due to the presence of nuclear export signals SENP1 and 
SENP2 can shuttle in and out of the nucleus (Itahana et al 2006).  SENP1 and 
SENP2 have been shown to actively deconjugate SUMO from a wide variety 
of substrates and have also been observed to have a role in SUMO 
processing; hydrolysing pre-SUMO1 and pre-SUMO2 into the respective 
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mature forms, unveiling the C-terminal Gly-Gly motif (Xu and Au, 2005).  
SENP1 has been shown to be most efficient at processing SUMO-1 to its 
mature form, whereas SENP2 has been shown to be most efficient at 
processing SUMO2 (Sharma et al., 2013).  In vitro, both SENP1 and SENP2 
are highly efficient at deconjugating both SUMO1 and SUMO2 (Reverter & 
Lima 2006; Shen et al., 2006B).  SENP3 and SENP5 form the second 
subfamily of the SENP enzymes and are mainly located in the nucleolus, 
where they have a role in ribosome biogenesis.  SENP3 and SENP5 act to 
deconjugate SUMO2, showing little activity against SUMO1 (Gong & Yeh 
2006).  SENP5, like SENP1 and SENP2, can process pre-SUMO2 into its 
mature form.  SENP6 and SENP7 form the third SENP subfamily group, 
located in the nucleoplasm.  These enzymes show weak SUMO processing 
activity but are active SUMO deconjugating enzymes, thought to mainly 
depolymerise SUMO chains.  In this respect, SENP6 and SENP7 are thought 
to be SUMO chain editing enzymes (Mukhopadhyay et al 2006; Shen et al., 
2009; Hattersley et al., 2011).  
 
The cytoplasmic DeSUMOylating isopeptidases were first identified in 
2012 as active SUMO deconjugating enzymes, with very limited SUMO 
processing activity (Suh et al., 2012).  Two DeSUMOylating isopeptidase 
have been identified; Desi-1 and Desi-2 and are characterised by the 
presence of permutated papin fold peptidase of the double-stranded RNA 
viruses and eukaryotes (PPPDE) domain (Suh et al., 2012; Shin et al., 2012).  
Interestingly, Desi-1 is thought to be active as a homodimer, where the active 
site is positioned in the groove between two proteins forming a catalytic dyad 
with two conserved cysteine and two histidine residues (Suh et al., 2012).   
Unlike the SENP enzymes, Desi-1 and Desi-2 are concentrated in the 
cytoplasm.  Desi-1 and Desi-2 appear to be highly specific enzymes 
functioning on a very limited substrate selection (Shin et al., 2012). 
 
The most recently identified deSUMOylating enzyme is USPL1, 
identified in late 2012 (Schulz et al., 2012).  USPL1 is distinct from both the 
SENP and Desi proteins, but interestingly shares around 20% sequence 
homology with the ubiquitin specific protease USP1 (Schulz et al., 2012). 
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USPL1 is active in both SUMO processing and SUMO deconjugation but no 
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1.3 Aims	  and	  objectives	  	  	  	   Initial evidence suggested that the SUMO and ubiquitin conjugation 
systems were distinct from one and other.  However, recent evidence has 
suggested points of convergence in the two systems.  The aim of this thesis is 
to explore the overlapping ground between the two systems by investigating 
the notion that polymeric chains composed of both SUMO and ubiquitin can 
act as unique signalling mechanisms within the cell.  These SUMO-ubiquitin 
hybrid chains may be distinct from the homotypic signals generated by the 
SUMO and ubiquitin moieties that make up these chains.  If so, proteins 
containing both SUMO and ubiquitin interacting elements should recognise 
SUMO-ubiquitin hybrid chains with greater affinity than that of SUMO or 
ubiquitin chains alone.  
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2	  Materials	  and	  Methods	  	  
2.1	  Materials	  	  	  
Information on materials can be found in Appendix I. 
2.2	  Methods	  	  
2.2.1	  General	  Methods	  
2.2.1.1	  General	  PCR	  procedure	  for	  Phusion™	  Hot	  Start	  polymerase	  	  
 
List of primers- 2.1.3 in Appendix I 
PCR reaction contents;  
 
DNA template   20-50 ng 
5X buffer (HF or GC)  10 µl 
10 mM dNTPs   1 µl 
10 µM forward primer  1 µl 
10 µM reverse primer  1 µl 
Phusion polymerase  0.5 µl 




Phase    Temp   Duration 
Denaturation   98°C   30s 
 
Denaturation*  98°C   10s 
Annealing*  lowest primer -2°C  30s 
Elongation*   72°C   15s per kb 
*cycle 33 times 
 
Final Elongation  72°C   10 minutes 
Cooling   4°C   ∞ 
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PCR product was then mixed with 6X DNA loading buffer and verified on a 
0.8% agarose gel.  Positive PCR products were then extracted using 
QIAquick Gel Extraction Kit (Qiagen) following manufacturers protocol. 
 
3.2.1.2	  General	  PCR	  procedure	  for	  site-­‐directed	  mutagenesis	  with	  KOD	  polymerase	  	  
 
Primer design required mutations with ~15 bases on either side. List of 
primers- 2.1.3 in Appendix I 
 
PCR reaction contents;  
 
DNA template   20-50 ng 
10X KOD buffer   5 µl 
2 mM dNTPs    5 µl 
10 µM forward primer  1.25 µl 
10 µM reverse primer  1.25 µl 
MgSO4    3 µl 
KOD polymerase   1 µl 




Phase    Temp   Duration 
Denaturation   95°C   2 minutes 
 
Denaturation*  95°C   20s 
Annealing*  Primer specific  30s 
Elongation*   70°C   1 minutes per kb 
*cycle 18 times 
 
Final Elongation  70°C   5 minutes 
Cooling   4°C   ∞ 
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Following PCR reactions 1µl DpnI was added and incubated at 37°C for 1 
hour to digest the parental methylated DNA before transformation into DH5α 
E. coli cells. 
 
2.2.1.3	  Restriction	  digestion	  and	  ligation	  
 
Plasmid DNA or PCR products were digested with restriction and ligation 
enzymes from New England Biolabs with the following procedure; 
 
Plasmid DNA (500ng) or 50% of PCR product was incubated at 37°C for 2 
hours with 1µl each of the two required restriction enzymes and 2.5µl of 10X 
NEB digestion buffer.  H2O was added to total reaction volume of 25µl. 
Restriction digestion was then verified on a 0.8% agarose gel.  
 
Approximately 50µg of digested plasmid vector was added to between 5µl 
and 10µl of digested PCR product insert.  Vector to insert ratio was 
approximately 1:3.  Vector and insert were then incubated with 2.5µl T4 
ligation buffer and 1µl T4 ligase at room temperature for 2 hours.  
 
2.2.1.4	  Transformation	  of	  competent	  E.	  coli	  cells	  
 
Freshly thawed competent E. coli cells (50µl) were incubated with 50µg of 
plasmid DNA or 5-10µl of ligation mix on ice for 20 minutes.  For preparation 
of plasmid DNA, DH5α E. coli cells were used. For protein expression BL21 
(DE3), Rosetta2 (DE3) or BL21 (DE3) (ELaD) strains were used.  The 
competent bacteria/plasmid DNA mix were then heat shocked for 45 seconds 
at 42°C.  Cells were then placed back on ice for 2 minutes before being 
transferred to a 15ml falcon tube containing 500µl of LB medium and 
incubated at 37°C, with shaking, for a minimum of 45 minutes.  Cell 
suspension (250µl) was then spread on agar plates containing the required 
antibiotic resistance (100µg/ml ampicillin, 50µg/ml kanamycin, 35µg/ml 
chloramphenicol) and incubated at 37°C overnight (~16 hours). 
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2.2.1.5	  Plasmid	  DNA	  preparation	  
 
5ml of LB medium with required antibiotic resistance was inoculated with a 
single colony from an agar plate and incubated overnight (~16 hours) at 37°C 
with shaking.  The cultured DH5α cells were then pelleted by centrifugation at 
6800g.  Plasmid DNA was then purified from the resulting cell pellet using 
QIAprep Spin Miniprep Kit (Qiagen) following the manufacturers protocol.  
2.2.1.6	  DNA	  concentration	  measurements	  	  	  
 
DNA concentration was measured on a NanoDrop 2000 spectrophotometer 
by UV absorbance at 260 nm.  NanoDrop was blanked with nuclease-free 
water, all plasmids were stored in nuclease-free water.  
 
2.2.1.7	  DNA	  sequencing	  	  
 
Plasmid DNA sequencing was carried out by the DNA Sequencing Service, 
University of Dundee. 
 
2.2.1.8	  Protein	  concentration	  measurements	  
 
Purified recombinant protein concentrations were measured using NanoDrop 
2000 spectrophotometer by UV absorbance at 280 nm together with extinction 
coefficients determined using the ProtParam tool 
(www.expasy.org/protparam). 
 
Protein concentrations of cell extracts were estimated using DC assay (Bio-
Rad) following manufacturers protocol and measured by UV absorbance at 
750 nm. 
 
2.2.1.9	  Sodium	  dodecylsulphate-­‐polyacrylamide	  gel	  electrophoresis	  
 
Prepared samples for separation by sodium dodecylsulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE) were incubated at 100°C for 5 minutes in 
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SDS loading buffer.  Samples were loaded and run in either Novex NuPAGE 
Bis-Tris 10% gels in MOPS (1X) running buffer or 4-12% gels in MES (1X) 
running buffer.  All gels were run at a constant voltage of 180V, for 45-60 
minutes. 
2.2.1.10	  Coomassie	  Stain/Destain	  Procedure	  
 
Gels containing samples separated by SDS-PAGE were stained in 
appropriate amount of Coomassie stain for 5-15 minutes with constant 
rocking.  Coomassie was then poured off and gels were washed quickly with a 
small amount of Destain 1 to remove residual Coomassie stain, which was 
then discarded.  Destain 1 was then reapplied for 30 minutes before being 
discarded and replaced with Destain 2 for 15 minutes.  Application of Destain 
2 was repeated every 15 minutes until all excess Coomassie staining was 
removed. 
  
2.2.1.11	  Western	  Blotting	  Procedure 
 
Prepared samples denatured in SDS sample buffer were separated by SDS-
PAGE in accordance with 2.2.1.9.  Gels were then loaded into western blot 
sandwich cassettes with polyvinylidene fluoride (PVDF) transfer membranes 
(Immobilon-P Transfer membrane, Millipore).  Before transfer, membranes 
were incubated in ethanol for 2 minutes.  Transfer was performed overnight 
(12-16 hours) in Tris/Glycine transfer buffer, at 25 mA.  Following transfer, 
membranes were removed and blocked in 3% BSA for 1 hour, then incubated 
in 3% BSA containing specified primary antibodies of choice for 2 hours at 
room temperature, or overnight at 4°C.  Membranes were then washed 3 
times with PBST (1X) and then blotted with species specific horse radish 
peroxidase (HRP) secondary antibody diluted in 3% BSA for 2 hours at room 
temperature.  Membranes were again washed 3 times in PBST (1X) before 
application of enhanced chemiluminescence (ECL) solution.  Blots were 
visualised by exposure of X-ray photographic film.  Where necessary, 
membranes were stripped with western blot stripping buffer for 15-30 minutes, 
at room temperature before being re-probed with relevant primary antibodies. 
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2.2.2	  Protein	  Expression	  and	  purification	  protocols	  
2.2.2.1	  Expression	  of	  His6-­‐tagged	  USP2	  catalytic	  domain	  (Asn259-­‐Met605)	  	  
 
The gene encoding USP2 CaD (Asn258-Met605) was subcloned from pGEX-
6p-USP2 (DSTT) and inserted between HindIII/XhoI sites of pHISTEV30a 
vector.  USP2 CaD was expressed as a His6-tagged fusion protein with a TEV 
protease cleavage site situated between the His6-tag and Met1 of USP2 CaD.  
The protein was expressed in E. coli R2 (DE3) ELaD k/o cells.  10-25 ml of LB 
medium supplemented with kanamycin (50 µg/ml), chloroamphenicol (35 
µg/ml) and apramycin (40 µg/ml) were inoculated with a single colony from a 
freshly streaked LB plate supplemented with kanamycin, chloroamphenicol 
and apramycin.  The bacterial culture was then incubated overnight at 37°C 
with shaking at 220 rpm.  The following day, 5 ml of overnight culture was 
used to inoculate 650 ml of LB medium with kanamycin, chloroamphenicol 
and apramycin in a 2-litre flask.  The cell suspensions were then incubated at 
37°C with shaking at 220 rpm until OD600 reached 0.6-0.8.  At this stage, 1 ml 
of culture was taken as pre induction sample.  The 2-litre flasks were then 
cooled down in ice–cold water bath for 10-20 minutes, followed by the 
addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final 
concentration of 100 µM to induce protein expression.  Then cell cultures 
were then incubated at 20°C with shaking at 220 rpm for 17-19 hours until 
OD600 reached >1.8. 
 
2.2.2.2	  Purification	  of	  His6-­‐tagged	  USP2	  CaD	  
 
Buffers for Ni-NTA chromatography: 
Lysis buffer – 50 mM Tris, 150 mM NaCl, 10 mM imidazole, 2 mM 
benzamidine, cOmplete protease inhibitor cocktail (EDTA-free, Roche), pH 
8.0 
Binding buffer – 50 mM Tris, 150 mM NaCl, 10 mM imidazole, pH 8.0 
Washing buffer – 50 mM Tris, 150 mM NaCl, 250 mM imidazole, 0.5 mM 
TCEP, pH 8.0 
 
	   41	  
For USP2 CaD, all stages of the protein purification were carried out where 
possible, at 4°C.  Bacterial cells were harvested by centrifugation at 6200 x g 
for 20 minutes at 4°C.  Cell pellets were then gently resuspeneded in 35 ml of 
lysis buffer per 650 ml of cell culture by shaking.  The cell suspension was 
then flash-frozen in liquid nitrogen, cells could then be stored at -80°C until 
further use.  After thawing, the bacterial cells were lysed by sonication (Digital 
Sonifier, Branson).  The samples were then cleared of insoluble material by 
centrifugation at 27000 x g for 45 minutes, at 4°C.  The supernatant was then 
filtered through a 0.2 µm filter and loaded onto a column containing Ni-NTA 
agarose (DSTT), 5 ml of agarose per 650 ml of culture, pre-equilibrated with 
binding buffer.  The column was then washed with 8 column volumes of 
binding buffer, followed by 8 column volumes of washing buffer to remove any 
unbound proteins.  His6-USP2 CaD was then eluted from the column in 3 
column volumes of elution buffer.  To remove the imidazole from the eluted 
His6-USP2 CaD, dialysis was performed overnight at 4°C against elution 
buffer containing no imidazole, with dialysis buffer exchanged 3 times.  During 
the dialysis, the His-tag was removed from the His6-USP2 CaD fusion protein 
through the addition of TEV protease at a ratio of 100:1 His6-USP2 CaD:TEV 
protease.  After cleavage was completed, His6/USP2 CaD mix was passed 
again over the Ni-NTA column.  Un-tagged USP2 CaD collected from the 
column flow through was then concentrated in spin concentrators (Viaspin).  
USP2 CaD was then check for activity, analysed by SDS-PAGE in 
accordance with 2.2.1.9, and stored at -80°C until use. 
 
2.2.2.3	  Expression	  and	  purification	  of	  4xSUMO2	  and	  Ub-­‐4xSUMO2	  
 
4xSUMO2 and Ub-4xSUMO2 constructs in pHISTEV30a vector were a kind 
gift from Dr. A Plechanovova.  4xSUMO2 and Ub-4xSUMO2 were expressed 
in Rosetta2 (DE3) bacterial cells and purified in accordance with 2.2.2.2.  
Purified 4xSUMO2 and Ub-4xSUMO2 were concentrated, analysed by SDS-
PAGE in accordance with 2.2.1.9, and stored at -80°C until use. 
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2.2.2.4	  Expression	  and	  purification	  of	  Morc3	  and	  Morc3	  mutants	  
 
The gene encoding full length Morc3 was subcloned from pSC-HA-Morc3 
(DSTT) and inserted between HindIII/XhoI sites of pHISTEV30a vector.   
Morc3 truncated fragment mutants A/B/C/D were subsequently subcloned 
from pHISTEV30a-Morc3.  Site directed mutagenesis with KOD polymerase 
was utilised to create the Morc3 4xSIM mutant.  One SIM region was mutated 
in each of four sequential rounds of mutagenesis.  All Morc3 variants were 
expressed in Rosetta2 (DE3) bacterial cells and purified in accordance with 
2.2.2.2.  Purified Morc3 and Morc3 mutants were concentrated, analysed by 
SDS-PAGE in accordance with 2.2.1.9, and stored at -80°C until use. 
 
2.2.2.5	  Expression	  and	  purification	  of	  USP28	  and	  USP28	  mutants	  
 
The gene encoding full length USP28 was subcloned from pGEX-6p-USP28 
(DSTT) and inserted between BamHI/XhoI sites of pHISTEV30a vector.  
USP28 N-terminal fragments mutants SIM-UIM/SIM-ΔUIM/ΔSIM-UIM were 
subsequently subcloned from pHISTEV30a-USP28.  All USP28 variants were 
expressed in Rosetta2 (DE3) bacterial cells and purified in accordance with 
2.2.2.2.  Purified USP28 and USP28 variants were concentrated, analysed by 
SDS-PAGE in accordance with 2.2.1.9, and stored at -80°C until use. 
 
2.2.2.6	  Expression	  and	  purification	  of	  UBE2v2	  
 
His6-MBP-Ube2v2 was a gift from Dr. A Plechanovova.  The protein was 
expressed in E. coli BL21 (DE3) cells.  His6-/MBP-tags were removed from 
the His6-MBP-Ube2v2 fusion protein through the addition of TEV protease at 
a ratio of 100:1 His6-MBP-Ube2v2:TEV protease.  After cleavage was 
completed, UBE2v2/MBP/His6 mix was separated by gel filtration on an Akta 
system using a HiLoad 16/60 Superdex75 column. Peaked fractions were the 
analysed by SDS-PAGE in accordance with 2.2.1.9 and fractions containing 
UBE2v2 were pooled, concentrated and stored at -80°C until use. 
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2.2.2.7	  In	  vitro	  transcription/translation	  
 
35S labelled proteins were generated using in vitro transcription/translation, 
from 1 µg plasmid DNA and a wheat germ or rabbit reticulocyte 
transcription/translation system with 35S as follows: - 
  
Wheat germ lysate/rabbit retics   12.5 µl 
Reaction buffer (25X)    1 µl 
T7 RNA polymerase    0.5 µl 
Amino acid mixture minus methionine  0.5 µl 
DNA template     1 µg 
35S methionine     1.25 µl 
Nuclease free water     to total 25 µl 
 
Reactions were incubated at 30°C for 2 hours before 1 µl of each reaction 
was separated by SDS-PAGE in accordance with 2.2.1.9.  Gels were 
dehydrated onto 3mm chromatography paper and exposed to imaging plates 
overnight.  Imaging plates were then scanned through a FujiFilm FLA-5100 
and analysed using Aida Image Analyzer software. 
 
2.2.3	  Biochemical	  assays	  
2.2.3.1	  In	  vitro	  ubiquitylation	  assay	  of	  Ub-­‐4xSUMO2	  and	  4xSUMO2	  
 
35 nM Uba1 (E1), 35 nM Ubc13/Ube2v2 (E2 pair), 35 nM RNF4 (E3) and 10 
µM ubiquitin were incubated together with 2 µM 4xSUMO2 or Ub-4xSUMO2 
in 50 mM Tris, 200 mM NaCl, 5 mM MgCl2, 3 mM ATP, 0.1% NP-40 at 37°C.   
Samples were taken at several different time points, and reactions were 
stopped via the addition of 2x SDS-PAGE loading buffer.  Samples were 




	   44	  
2.2.3.2	  In	  vitro	  deubiquitylation	  assays	  for	  recombinant	  proteins	  
 
0.01, 0.05, 0.1, 0.5, 1 and 5 µM concentrations of deubiquitinases; USP2 CaD 
or USP28 were incubated with 5 µM substrate protein; 4xSUMO2, Ub-
4xSUMO2, K63 pUB or K48 triUb for 4 hours.  Reactions were carried out in 
50 mM Tris, 150 mM NaCl, 0.05 mM TCEP.  Samples were taken at several 
time points, reactions were stopped by the addition of 2xSDS-PAGE loading 
buffer at 4 hours, and analysed by SDS-PAGE in accordance with 2.2.1.9.  
For control sample USP2 or USP28 were absent from reaction. 
 
2.2.3.3	  In	  vitro	  deSUMOylation	  assays	  	  
 
0.01, 0.05, 0.1, 0.5, 1 and 5 µM concentrations of sentrin-specific protease 
SENP1 (Dr L. Shen) were incubated with 5 µM substrate proteins; 4xSUMO2, 
Ub-4xSUMO2 and K63 pUB or K48 triUb for 4 hours.  Reactions were carried 
out in 50 mM Tris, 150 mM NaCl, 0.05 mM TCEP.  Samples were taken at 
several time points, reactions were stopped by the addition of 2xSDS-PAGE 
loading buffer at 4 hours and analysed by SDS-PAGE.  For control samples 
SENP1 was absent from the reaction. 
 
2.2.3.4	  TCA	  precipitation	  	  
 
Sample proteins were precipitated in 20% TCA of equal volume to sample 
and incubated on ice for 30 minutes.  TCA/sample mixes were then 
centrifuged at 17000 x g for 30 minutes, at 4°C.  Supernatants were carefully 
removed from pellets.  100% ethanol was added to the pellets, mixed by 
inversion and then centrifuged at 17000 x g for 30 minutes at 4°C.  Ethanol 
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2.2.4	  Pull-­‐down	  experiments	  
2.2.4.1	  Linkage	  of	  recombinant	  SUMO,	  ubiquitin	  and	  SUMO	  ubiquitin	  hybrid	  chains	  
to	  NHS-­‐activated	  resin	  
 
4xSUMO2, K63 pUb, Ub-4xSUMO2, pUb-4xSUMO2 protein were dialysied 
against 0.2M NaHCO3, 0.5M NaCl, pH 8.3 overnight, at 4°C with two changes 
of dialysis buffer.  Proteins concentrations were then adjusted to equimolar 
concentrations (>1 mg/ml).  N-hydroxysuccinimide (NHS) resin (GE 
Healthcare) was activated by rinsing with 1 mM HCl before washing with 0.2M 
NaHCO3, 0.5M NaCl, pH 8.3.  For each chain type, 1 ml of NHS activated 
resin (50% resin slurry in 0.2M NaHCO3, 0.5M NaCl, pH 8.3) was incubated 
by rotation with 1 ml of protein overnight, at 4°C.  A blank resin control was 
also produced with no protein bound to activated resin.  Any free active sites 
on NHS beads were blocked by sequential incubation with 0.5 M NaCl, 0.5 M 
Ethanolamine, pH 8.3 followed by 0.5 M NaCl, 0.1 NaOAc, pH 4.  Protein 
bound resins were stored as a 50% slurry in PBS, 0.5 M NaCl, 0.1% NaN3-, at 
4°C. 
 
2.2.4.2	   SUMO,	   ubiquitin,	   and	   SUMO	  ubiquitin	   hybrid	   chain	   type	   resin	   pull-­‐downs	  
for	  recombinant	  proteins	  
 
The following resin types (50 µl of each); blank, 4xSUMO2, K63 pUb, Ub-
4xSUMO2, pUb-4xSUMO2 were first washed with Ultrapure H2O before 
equilibration in binding buffer (50 mM Tris, 150 mM NaCl, 0.5 mM TCEP, 
0.05% NP-40).  10 µM of recombinant protein was incubated separately with 
50 µl of each resin type overnight, at 4°C.  After incubation, resins were 
collected by centrifugation at 500 x g for 1 minute.  Supernatants were 
collected.  Resins were then washed once with binding buffer before being 
transferred to fresh Eppendorf tubes and washed again.  Bound proteins were 
eluted with SDS-loading buffer and analysed by SDS-PAGE and western blot 
in accordance with 2.2.1.10.  SDS-PAGE gels were imaged with Bio-Rad 
chemidoc MP imaging system and quantified using ImageJ.  
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2.2.4.3	   SENP1	   and	   USP2	   Elution	   of	   proteins	   from	   SUMO,	   ubiquitin,	   and	   SUMO	  
ubiquitin	  hybrid	  chain	  resin	  types	  	  
 
After either blank, pUb K63, 4xSUMO2, Ub-4xSUMO2, pUb-4xSUMO2 resins 
were incubated with substrates and following washing steps, 5 µM of USP2 
CaD was incubated with each resin at room temperature for 2 hours.  USP2 
CaD containing supernatant was removed and mixed with 6X SDS loading 
buffer.  5 µM of SENP1 was then incubated with each resin at room 
temperature for 2 hours.  SENP1 containing supernatant was then removed 
and mixed with 6X SDS loading buffer.  The five resins types were finally 
incubated with 2X SDS loading buffer for 5 minutes at room temperature, then 
at 100°C for 10 minutes.  Samples for each of the five resin types and for the 
separate elutions were then separated by SDS-PAGE before analysis by 
western blot. 
 
2.2.5	  Cell	  Culture	  	  
2.2.5.1	  Cell	  lines	  
 
All cells, unless stated, were obtained from Hay lab stocks, and maintained at 
37°C and 5% CO2. 
 
Wild type Hela, U20S, HCT116 and 293 N3S cells were cultured in 
monolayers maintained in Dulbecco’s Modified Eagle Medium plus Glutamax 
(DMEM) (Invitrogen) supplemented with 10% fetal calf serum (FCS) and 
100U/ml penicillin and streptomycin (Invitrogen). 
 
293 N3S cells cultured in suspension were maintained in Minimum Essential 
Eagles Medium Spinner Modification (SMEM) (Sigma) supplemented with L-
glutamine, 10% FCS and 100U/ml penicillin and streptomycin.  Cells were 
maintained at 37°C under atmospheric CO2.  
 
U2OS ΔRNF4 and HCT 116 ΔRNF4 clones, a kind gift from Dr Jean-François 
Maure (Hay Lab), were cultured in monolayers maintained in Dulbecco’s 
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Modified Eagle Medium plus Glutamax supplemented with 10% FCS and 
100U/ml penicillin and streptomycin. 
 
U2OS cells expressing GFP-RAP80 (kind gift from Prof. SP Jackson) were 
cultured in monolayers maintained in Dulbecco’s Modified Eagle Medium plus 
Glutamax supplemented with 10% FCS and 100 U/ml penicillin and 
streptomycin.  Cells were maintained under antibiotic selection with 100 mM 
puromycin. 
 
2.2.5.2	   Cell	   extract	   preparation	   –	   for	   the	   preservation	   of	   SUMO	   and	   ubiquitin	  
modification	  of	  proteins	  
 
Buffers for cell extract preparation: 
Hypotonic buffer A -- 10 mM HEPES pH7.9, 1.5 mM MgCl2, 10 mM KCl2, 
0.08% NP-40, Roche cOmplete, EDTA-free protease inhibitor tablets, 20 mM 
iodoacetamide. 
RIPA (5X) -- 250 mM Tris pH 7.5, 750 mM NaCl, 5% NP-40, 2.5% DoC, 
Roche cOmplete, EDTA-free protease inhibitor tablets, 100 mM 
iodoacetamide. 
 
RIPA (1X) -- 50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% DoC, Roche 
cOmplete, EDTA-free protease inhibitor tablets, 20 mM iodoacetamide. 
 
Cells were washed 3 times in ice cold PBS containing 200 mM iodoacetamide 
and pelleted.  Cells were then resuspended in ice cold hypotonic buffer A to a 
final volume of approximately 10x the cell pellet and left on ice for 15 minutes.  
Cells were then lysed by repeatedly being forced through a 25-guage needle.  
Resulting cell lysates were then spun at 500 x g for 5 minutes at 4°C to pellet 
nuclei.  Supernatant was removed. RIPA buffer (5X) was then added to the 
supernatant in a ratio of 1:4, resulting in the cytoplasmic fraction.  The nuclei-
containing pellet was then washed once in hypotonic buffer A, resuspended in 
RIPA buffer (1X) and sonicated low setting (Diagenode, Biorupter) on ice until 
the nuclear membrane was disrupted.  Benzonase 1 Unit (Merek) was added 
to disrupted nuclear extracts for 30 mins on ice to digest any remaining DNA.  
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Both cytoplasmic and nuclear samples were then cleared by centrifugation at 
17000 x g for 15 minutes.  Protein concentrations of nuclear and cytoplasmic 
extracts were estimated using Bio-Rad DC Assay. 
 
2.2.5.3	  Whole	  Cell	  Extract	  Preparation	  
 
Cells were washed 3 times with ice cold PBS, scraped in an appropriate 
volume of ice cold PBS and then pelleted by centrifugation at 500 x g. Cells 
were then lysed in 2X SDS lysis buffer and sonicated at high setting for 180 
seconds (Diagenode, Biorupter). Samples were then incubated at 100°C for 
10 minutes before being cleared by centrifugation at 17,000g for 10 minutes. 
Protein concentration was estimated using Bio-Rad DC Assay.  B-
mercaptoethanol was then added to a final concentration of 200 mM before 
samples were separated by SDS-PAGE for western blotting analysis in 
accordance with in accordance with 2.2.1.10.  
 
2.2.5.4	  SiRNA	  Transfections	  
 
Cells were seeded to be 60% confluent at transfection, one day prior to 
transfection.  For each well of a 6 well plate, 1.25 µl of RNAiMAX (Invitrogen) 
was incubated with 100 µl of opti-MEM serum free medium (Invitrogen) for 5 
minutes.  Separately, 0.25 µl of siRNA 20 µM was incubated with 100 µl of 
opti-MEM serum free medium for 5 minutes.  RNAiMAX and siRNA containing 
opti-MEM solutions were then combined, gently mixed and incubated for 15 
minutes at room temperature.  RNAiMAX/siRNA containing opti-MEM solution 
was then added to cells in 0.8 mL of DMEM containing 10% FBS for a final 
siRNA concentration of 10 nM.  Cells were then incubated at 37°C for 5-6 
hours before DMEM containing RNAiMAX/siRNA opti-MEM solution was 
removed and cells were incubated with DMEM supplemented with 10% FBS 
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2.2.5.5	  Cell	  cycle	  analysis	  by	  flow	  cytometry	  
 
HCT116 cells were harvested by standard techniques and resuspended in 
1ml of PBS supplemented with 1% FCS.  Cells were then transferred to FACS 
tubes and pelleted.  PBS was removed and cells were fixed in 1 ml of ice cold 
70% EtOH for 30 minutes at room temperature with gentle vortexing to 
prevent clumping.  Cells were adjusted to 5 x 105 cells/ml and washed twice in 
PBS supplemented with 1% FCS.  Cells were then incubated in 300µl of 
FACS staining buffer, protected from light, for 20 minutes, at room 
temperature.  Cells were then analysed on a FACS Calibur Analyser by Dr R. 
Clark.  
 
2.2.6	  Immunoprecipitation	  (IP)	  
2.2.6.1	  USP28	  &	  Morc3	  IPs	  
 
Hela cells were seeded on ten 10 cm dishes and grown until 100% confluent.  
Nuclear extracts were generated as described in 2.2.5.3. 5 mg of whole cell 
extracts was precleared by incubation with 50 µl of Protein G Dynabeads 
(Invitrogen) for 1 hour with continuous rolling.  For each IP conditon, 2 µg of 
appropriate antibodies were incubated with 50 µl of Protein G Dynabeads. 5 
mg of whole cell extracts were then incubated with 50 µl of antibody-bound 
Dynabeads overnight at 4°C with continuous rolling.  Dynabeads were then 
removed from cell extracts and washed 3 times with RIPA buffer (1X).  Bound 
proteins were eluted with 2xLDS sample buffer and analysed via western 
blotting in accordance with 2.2.1.10. 
 
2.2.6.2	  RAP80	  IP	  	  
 
For each treatment, 293 N3S cells were seeded on five 10 cm dishes and 
grown until 100% confluent.  Nuclear extracts were generated as described in 
2.2.5.3. 2.5 mg of nuclear extract was precleared by incubation with 50 µl of 
Protein G Dynabeads (Invitrogen) for 1 hour with continuous rolling.  For each 
IP conditon, 2 µg RAP80 antibodies were crosslinked to 50 µl of Protein G 
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Dynabeads with 5 µM BS3 crosslinking agent.  For SENP1 treatment, nuclear 
extracts were incubated with 20 µM SENP1 for 4 hours, at 4°C prior to 
incubation with RAP80 antibody-bound Dynabeads. 2 mg of protein extract 
were then incubated with 50 µl of antibody-bound Dynabeads overnight at 
4°C with continuous rolling. Dynabeads were then removed from cell extracts 
and washed 3 times with RIPA buffer (1X). Bound proteins were then eluted 




2.2.7.1	  Adherent	  cell	  culture	  on	  coverslips	  
 
Cells were cultured on 10 mm glass coverslips in DMEM supplemented with 
10% FCS plus pen/strep until 60% confluent in 30 mm dishes.  Cells were 
then irradiated if required and allowed to recover for specified time.  Cells 
were washed 3 times with ice cold PBS and then fixed to the coverslips with 
2% paraformaldehyde (PFA) for 10 minutes.  Cells were then washed 3 times 
with PBS and permeabilised by incubation with 0.5% NP-40 in PBS for 10 
minutes followed by one wash with PBST.  Cells were incubated with blocking 
agent 3% BSA/PBST, at room temperature with shaking for 30-90 minutes, or 
overnight at 4°C.  Cells were then washed with PBST 3 times.  Coverslips 
were removed from 30 mm dishes and place on parafilm layered in a wet 
chamber.  
 
2.2.7.2	  Immunofluorescence	  	  
 
Adherent cells were processed as described in 2.2.7.1.  Primary antibodies 
diluted in blocking buffer were then incubated on coverslips in a wet chamber 
for 60 minutes at room temperature, followed by 3 washes with PBST.  Away 
from light sources, secondary Alexa fluor antibodies diluted in blocking buffer 
were then incubated on coverslips for 60 minutes at room temperature, 
followed by 3 washes with PBST.  Cells were stained with 1µg/ml DAPI for 5 
minutes.  Cells were then washed 3 times with PBST followed by one wash 
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with PBS.  Any residual liquid was aspirated from coverslips.  Coverslips were 
mounted to glass microscope slides using Vectashield mounting media 
(Vector labs), and sealed down with nail varnish.  Images were then captured 
using a DeltaVision Elite microscope (Applied Precision). 
2.2.7.3	  In	  situ	  Proximity	  Ligation	  Assays	  (PLA)	  
 
Adherent cells were first processed as described 2.2.7.1. All PLA steps for 10 
mm coverslips were carried out in a minimum of 40 µl to ensure total 
coverage of coverslip.  Firstly, Primary antibodies were diluted in blocking 
buffer and incubated on coverslips in a wet chamber for 2 hours at room 
temperature, or overnight at 4°C.  Primary antibody solutions were then 
removed by aspiration and followed by two 5 minute PBST washes with 
gentle shaking.  For each coverslip, 8 µl of PLA probe MINUS stock, 8 µl of 
PLA probe PLUS stock and 24 µl of Antibody Diluent were mixed together 
before incubation on coverslips for 1 hour at 37°C in a wet chamber.  PLA 
probe solutions were then removed by aspiration and coverslips were washed 
three times in PBST for 5 minutes with gentle shaking.  Ligation of the PLA 
probes was then carried out. 8 µl of 5x Ligation stock was added to 31 µl of 
nuclease-free H2O resulting in ligase solution.  Immediately prior to incubation 
with coverslips 1 µl of PLA ligase was added to 39 µl of ligase solution, 
pipetted up and down 5 times and added to coverslips.  Coverslips were 
incubated in a pre-heated wet chamber for 30 minutes at 37°C.  Ligation-
ligase solution was then removed by aspiration and two 1 minutes washes 
with PBST were carried out.  Amplification of the PLA signal was then carried 
out requiring minimal exposure to light for all further experimental steps.  8 µl 
of 5x Amplification stock and 31.5 µl of nuclease-free water were mixed with 
0.5 µl of Polymerase and then added to the coverslips.  Coverslips were then 
incubated in a preheated wet chamber for 100 minutes at 37°C.  Polymerase 
solution was then aspirated off coverslips.  Coverslips were washed twice in 
1x PBST for 10 minutes with shaking followed by one 1 minute wash with 
PBS.  Coverslips were allowed to dry for 15 minutes at room temperature 
protected from light.  Coverslips were then mounted to glass microscope 
slides using Vectashield mounting media and sealed down with nail varnish.  
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Deltavision – Immunofluorescence samples were imaged by widefield 
microscopy using a DeltaVision Elite microscope (Applied Precision).  
Typically, images of multiple z-sections were captured using a coolsnap HQ 
CCD camera and 60x oil immersion lenses.  (Centre for Advanced Scientific 
Technologies, Dundee) 
 
Spinning disk confocal – a subset of PLA assay samples were imaged using a 
MAG Biosystems EnVision spinning disk microscope equipped with 440 nm, 
491 nm and 594 nm laser lines. (Centre for Advanced Scientific Technologies, 
Dundee)  
2.2.7.5	  Image	  analysis	  
 
Images were deconvoluted using the spinlock deconvolution cluster 
(spinlock.openmicroscopy.org.uk).  Deconvolved images were then analysed 
using OMERO software (OME Open Microscope Environment).  Foci counting 
and analysis was performed using mtools plug-ins developed by Mr Michael 
Porter.  Foci were determine as pixel clusters above a given fluorescence 
threshold in maximal intensity projections of multiple Z- sections, and this 
threshold was maintained for the analysis of all images in a given experiment.    
 
2.2.8	  Mass	  spectrometry	  
2.2.8.1	  In-­‐gel	  trypsin	  digestion	  
 
For all mass spectrometry analysis, microwave assisted in-gel trypsin 
digestion of proteins was utilised.  Microwave steps were performed while 
tubes were held in a proprietary container that suspended samples in 1.5 L 
water during irradiation.  Water was changed once temperature was greater 
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than 55°C.  All steps involving the addition or removal of solutions were 
carried out in a fume hood with fresh filter tips used at every stage.  
All protein samples for proteomics were run on NuPAGE Novex 10% Bis-Tris 
in (1X) MOPS buffer and stained/destained according to Coomassie stain 
protocol.  After destaining to the desired level, gels were washed with 15 ml of 
pure H2O for at least 30 minutes.  Gels were then cut as appropriate into 
slices.  Slices were then diced into ~1 mm cubes and stored in Eppendorf 
LoBind tubes at 4°C until processed.  
Gel slices were then further destained by microwaving on full power (700 
Watts) in 500-900 µl 50 mM ammonium bicarbonate (ABC), 50% acetonitrile 
(ACN) until all blue stain was removed from slices.  Slices were then spun 
briefly and liquid was removed from gel pieces.  Gel pieces were then 
dehydrated by adding 200-700 µl 100% ACN with vortexing, liquid was then 
removed and gel pieces were allowed to dry for 10-20 minutes at room 
temperature in a fume hood. 
Disulfide adducts were then reduced through incubation with 500 µl of 10 mM 
DTT in 100 mM ABC with microwaving at (420 watts) for 10 minutes.  DTT 
ABC solution was then removed from gel pieces.  Proteins were then 
alkylated through the addition of 300-700 µl 50 mM iodoacetamide in 100 mM 
ABC with shaking, protected from light, at room temperature.  Gel pieces were 
then washed sequentially at room temperature, with shaking for 15 minutes 
with; 400-900 µl 100 mM ABC; then 400-900 µl of 200 mM ABC, 50% ACN 
and finally dehydrated with 300-700 µl of 100% ACN with vortexing.  All 
residual liquid was then removed and gel pieces were dried for 10-20 minutes.  
Per lane, assuming <25 µg of total protein in that lane, 1.25 µg of trypsin was 
diluted in 400-600 µl 20 mM ABC, 9% ACN.  Trypsin solution was then added 
evenly to gel pieces until fully rehydrated.  Further 20 mM ABC, 9% ACN 
solution was added until gel pieces in each tube were completely covered by 
liquid.  Trypsin solution and gel pieces were then incubated for 12-16 hours at 
37°C. 
Peptides were then extracted by the addition of 100% ACN equal to the 
amount of trypsin solution in each tube and incubation at room temperature 
for 30 minutes, with vortexing.  Liquid was then transferred to a new 
Eppendorf tube.   5% formic acid, 50% ACN was then added to the gel 
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pieces, incubated for 30 minutes with vortexing then transferred to the 
Eppendorf tube containing trypsin ACN solution.  Finally the gel pieces were 
dehybdrated with 50-100 µl of 100% ACN.  Incubated for 10 minutes with 
vortexing then transferred to the Eppendorf containing trypsin ACN solution. 
The peptide-containing trypsin solution was then evaporated by gryovac and 
the peptide pellet resuspended in 35 µl of 0.5% acetic acid/0.1% TFA ready to 
be analysed. 
2.2.8.2	  Non-­‐labelled	  hybrid	  chain	  resins	  pull-­‐down	  experiment	  	  
 
293 N3S cells were initially cultures as monolayers maintained in Dublecco’s 
Modified Eagle Medium plus Glutamax (DMEM) (Invitrogen) supplemented 
with 10% FCS and 100 U/ml penicillin and streptomycin.  Cells were grown in 
three 150 cm2 flasks to 90% confluency and then transferred into 500 ml of  
Minimum Essential Eagles Medium Spinner Modification (SMEM) (Sigma) 
supplemented with L-glutamine, 10% FCS and 100 U/ml penicillin and 
streptomycin.  Cells were maintained at 37°C in a sealed 1 litre Duran under 
non-adjusted CO2 and expanded to a total of 45 litres of cells at a density of 
~1 x106 cells/ml.  Nuclear cell extracts were then isolated as described in 
2.2.5.3. Blank, K63 pUb, 4xSUMO2, Ub-4xSUMO2 and pUb-4xSUMO2 bound 
NHS resins were then each separately incubated with 10 ml of nuclear lysate 
(5.5 mg/ml) overnight at 4°C with rotation.  Resins were washed 3 times with 
RIPA (1X) buffer before SENP1 and USP2 CaD elution was performed as 
described in 2.2.4.3.  Samples for each elution were separated by SDS-
PAGE.  Elutions were each run on a single lane. Each lane was cut into 2 
slices (30 in total).  In-gel trypsin digestion was performed in accordance with 
2.2.8.1.  8 µl of each slice was run on a 90 minute HPLC gradient, Easyspray 
45 cm column.  Samples were analysed by liquid chromatography-tandem MS 
on a Q Exactive mass spectrometer (Thermo Scientific).  RAW MS data files 
were processed using MaxQuant software (version 1.3.0.5) and searched 
against the UniProtKB human proteome.  
2.2.8.3	  RAP80	  IP	  of	  SENP1	  treated	  extract	  samples	  	  
For each treatment, 293 N3S cells were seeded on five 10cm dishes and  
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grown until 100% confluent.  For ionising radiation treatment (IR), Cells were 
treated with 4 Gys of Υ-radiation and left to recover at 37°C for 1 hour. 
Nuclear extracts were generated as described in 2.2.5.3. 2.5 mg (1ml) of 
nuclear extracts were precleared by incubation with 50µl of Protein G 
Dynabeads (Invitrogen) for 1 hour with continuous rolling.  For each IP 
conditon, 2 µg RAP80 antibodies were crosslinked to 50 µl of Protein G 
Dynabeads with 5 µM BS3 crosslinking agent.  For SENP1 treatment, nuclear 
extracts were incubated with 20 µM SENP1 for 4 hours, at 4°C prior to 
incubation with RAP80 antibody-bound Dynabeads.  2 mg of protein extract 
were then incubated with 50 µl of antibody-bound Dynabeads overnight at 
4°C with continuous rolling.  Dynabeads were then removed from cell extracts 
and washed 3 times with RIPA buffer (1X).  Bound proteins were then eluted 
with 2xLDS sample buffer and analysed via western blot.  Samples were run 
on SDS-PAGE and analysed via mass spectrometry.  In-gel trypsin digestion 
was performed in accordance with 2.2.8.1.  Approximately 1 µg of each slice 
was run on a 150 minute HPLC gradient, Easyspray 45 cm column.  Samples 
were analysed by liquid chromatography-tandem MS on a Q Exactive mass 
spectrometer (Thermo Scientific).  RAW MS data files were processed using 
MaxQuant software (version 1.3.0.5) and searched against the UniProtKB 
human proteome. 
 
2.2.8.4	  RAP80	  IP	  of	  SILAC	  labelled	  cell	  extracts	  with	  USP2	  CaD/SENP1	  elution	  
 
293 N3S cells were initially cultured as monolayers maintained in Dulbecco’s 
Modified Eagle Medium plus Glutamax (DMEM) (Invitrogen) supplemented 
with 10% FCS and 100U/ml penicillin and streptomycin prior to amino acid 
labelling.  Cells were then spilt into three 75 cm2 dishes (Light, Medium, 
Heavy) and cultured in SILAC DMEM supplemented with 10% dialysed FCS 
and L-lysine and L-arginine replaced with stable isotope SILAC forms 
(Cambridge Isotope Laboratories).  “Light” cells were grown in SILAC DMEM 
containing isotopically “normal” amino acids, K0R0. “Medium” cells were 
grown SILAC DMEM containing 4,4,5,5-D4 lysine and 13C6 arginine, K4R6. 
“Heavy” cells were grown in SILAC DMEM containing 13C6 15N2 lysine and 
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13C615N4 arginine, K8R10.  Light, Medium and Heavy SILAC labelled cells 
were cultured until 90% confluent in respective SILAC DMEM, then split 1/10.  
This process was repeated five times to allow all proteins within the cultures 
to incorporate labelled amino acids.  Twenty 10 cm dishes were seeded for 
each of the three SILAC labelled cell conditions.  Cells were grown until 100% 
confluent irradiated with 4 Gys of γ-irradiation and before nuclear extracts 
were isolated as described in 2.2.5.3.  RAP80 IPs were performed overnight 
at 4°C, for each of the three SILAC conditions.  Heavy, Medium and Light 
RAP80 IP bound resins were then washed three times with RIPA (1X) 
containing no iodoacetamide.  Heavy RAP80 IPs were then incubated with 10 
µM SENP1 for 4 hours at room temperature.  Medium RAP80 IPs were 
incubated with 10 µM USP2 CaD for 4 hours at room temperature.  Light 
RAP80 IPs were incubated in RIPA (1X) containing no iodoacetamide for 4 
hours at room temperature.  SENP1, USP2 and RIPA control supernatants 
were then removed from RAP80 IP resins and TCA precipitations were 
performed on each supernatant as described in 2.2.3.4. 80 µl of 2XLDS 
sample buffer was then incubated sequentially with each of the three RAP80 
IP resins before resuspending each of the TCA precipitated SENP1, USP2 
and RIPA elutions.  35 µl of the resulting samples were separated by SDS-
PAGE.  The lane containing separated material was then cut into 24 slices. 
The molecular weight range for each slice was noted before in-gel trypsin 
digestion was performed in accordance with 2.2.8.1.  8 µl of each slice was 
run on a 150 minute HPLC gradient, Easyspray 45 cm column.  Samples 
were analysed by liquid chromatography-tandem MS on a Q Exactive mass 
spectrometer (Thermo Scientific).  RAW MS data files were processed using 
MaxQuant software (version 1.3.0.5) and searched against the UniProtKB 
human proteome. 
 
2.2.8.5	  General	  description	  of	  mass	  spectrometry	  	  
 Mass spectrometry analysis was performed by benchtop orbitrap mass 
analyzer (Q Exactive, Thermo Fisher Scientific) equipped with an integrated 
nano-electrospray (Easy-Spray Thermo Fisher Scientific) coupled to a nano-
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uHPLC system (Easy N-LC-1000 Thermo Fisher Scientific).  Peptides were 
fractionated on a 50 cm x 75 µm ID, PepMap RSLC C18, 2 µm reverse phase 
column run at 45°C, fractionating over 1-4 hour gradients (experiment 
specific).  Data were acquired in the data-dependent mode to automatically 
switch between MS and MS/MS acquisition.  Full scan spectra (m/z 300-1800) 
were acquired in the orbitrap with resolution R = 70,000 at m/z 200 (after 
accumulation to target value of 1,000,000 or 60 ms). 
Raw MS data files were processed with the quantitative mass spectrometry 
software MaxQuant (version 1.3.0.5) (Cox et al., 2008).  Enzymes specificity 
was set to trypsin-P.  Gly-gly adducts to lysine were searched as variable 
modification.  The data were searched against the Human protein database. 
Maximum allowed mass deviation was set to 20 parts per million for peptide 
masses and 0.5 da for MS/MS peaks.  The minimum peptide length was set 
to 7 amino acids and the maximum of two missed cleavages.  1% false 
discovery rate (FDR) was required at both protein and peptide level.  In 
addition to the FDR threshold, proteins were considered identified, if they had 
at least 1 razor peptide.  Each raw data file was considered as a single 
‘experiment’, so protein intensity values based on extracted ion 
chromatographs (XICs) were reported for each slice sample.  These 
intensities were used as an approximation of relative protein abundance for 
comparing the same protein among samples.  Protein intensities were 
arimetically converted to ratio values and ratios were normailized to the 
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3	   Establishment	   and	   validation	   of	   approaches	   to	   identify	  




 Initially the SUMO and ubiquitin modification pathways were thought to 
be distinct, with the action of SUMO and ubiquitin E3 ligases working 
antagonistically.  However, more recently the identification of ubiquitin E3 
ligases that are targeted to SUMO modified proteins has begun to lift the veil 
on the interplay between the SUMO and ubiquitin modification pathways, 
revealing a potential new form of signalling motif the SUMO-ubiquitin hybrid 
chain.  
 
3.1.1	  SUMO	  targeted	  ubiquitin	  E3	  ligases	  	  	  
SUMO targeted ubiquitin E3 ligases (STUbLs) are a recently identified 
family of enzymes that are targeted to SUMO modifications via internally 
located SIM domains that are required for substrate modification by the 
ubiquitin E3 ligase.  STUbLs were first identified in the yeast S. cerevisiae 
with the identification of Uls1 and the heterodimeric complex Slx5-Slx8 
(Uzunova et al., 2007).  Both Uls1 and Slx5-Slx8 have been shown to contain 
RING domains, and multiple SIM domains (Uzunova et al., 2007).  RNF4 was 
the first human STUbL identified (Lallemand-Breitenbach et al., 2008; Tatham 
et al., 2008).  RNF4 is a small ~21 kDa protein that belongs to the RING type 
ubiquitin E3 ligases with a RING domain located at it C-terminus.  RNF4 has 
been observed to catalyse the transfer of ubiquitin from ubiquitin loaded E2 
enzymes to substrates only after dimerization of its C-terminal RING domain 
(Liew et al., 2010; Plechanovova et al., 2011; Plechanovova et al., 2012).  In 
addition to its RING domain, RNF4 contains four N-terminally located SIM 
domains (Tatham et al., 2008).  These SIM domains are a mixture of classical 
and high fidelity SIM types; SIM 2 and 3 of RNF4 conform to the high fidelity 
type SIM with SIMs 1 and 4 conforming to the more general classical 
consensus SIM, this allows RNF4 to bind poly-SUMO2 chain of four or more 
SUMO moieties with high affinity (Figure 3.1-1) (Tatham et al., 2008).  This 
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affinity for poly-SUMO has been observed to be critical for the function of 
RNF4.  In vivo, RNF4 has been observed to bind poly-SUMOylated PML and 
subsequently catalyse the addition of K48 linked poly-ubiquitin chains to the 
previously poly-SUMOylated PML protein; this poly-SUMO poly-ubiquitin 
modified PML protein is then degraded by the proteasome (Tatham et al., 
2008).  This action of RNF4 is dependent on the SIM domains located within 
RNF4 as mutants of RNF4 containing disrupted SIM domains fail catalyse the 
ubiquitylation of PML (Tatham et al., 2008).  This apparent SUMO dependent 
activity of RNF4 was further demonstrated in a recent paper by Rojas-
Fernandez and colleagues where by it was observed that, at physiologically 
relevant concentrations, RNF4 is found as a monomer with no ubiquitin E3 
ligase activity.  The presence of poly-SUMO chains however resulted in the 
dimerization of RNF4, with this SUMO interacting homodimer of RNF4 
functioning as a fully active ubiquitin E3 ligase (Rojas-Fernandez et al., 2014).  
Thereby further cementing that the ubiquitin E3 ligase activity of RNF4 is 
dependent on its ability to dimerize in the presence of SUMO.  
	  
Figure 3.1-1 Domain schematic of RNF4.   
RNF4 contains two high fidelity type SIM domains; SIM2 & SIM3 and two general consensus 
type SIM domains; SIM1 & SIM4.  The SIM domains sequences are highlighted in purple. 
RNF4 also contains a C-terminal RING domain. 
            
 
More recent work has suggested roles outwith tagging SUMOylated 
proteins for degradation by the proteasome.  RNF4 has been observed to be 
recruited to SUMO modified mediator of damage checkpoint 1 (MDC1) at 
sites of DNA damage and play a critical role in the subsequent response to 
DNA double strand breaks (DSBs) (Galanty et al., 2012; Yin et al., 2012).  
Depletion of RNF4 in both human and chicken cells shows decrease of K63 
linked poly-ubiquitin, but not K48 linked poly-ubiquitin deposited at the sites of 
DNA damage, an increase in sensitivity to ionising radiation and a reduction in 
	   60	  
the efficiency of DNA repair by homologous recombination and non-
homologous end joining.  This is thought to be due to a failure to load RPA 
and Rad51 onto DNA at the damage site and thus an inability to efficiently 
carry out end resection at the DSBs (Yin et al., 2012).  
 
As a result of the action of STUbLs like RNF4, and the more recently 
described RNF111/Arkadia (Poulsen et al., 2012), hybrid chains of SUMO and 
ubiquitin are thought to be present at the sites of DNA damage as well as 
proteins destined for destruction by the proteasome.  Thus, these proteins act 
as points of convergence in the once thought independent SUMOylation and 
ubiquitylation systems.  However, it is still unclear as to the form this 
convergence takes and whether the signals generated by hybrid chains of 
SUMO and ubiquitin are distinct to that of homotypic chains of SUMO and 
ubiquitin modifying the same substrate.  Recent evidence has suggested a 
role for RNF4-dependent SUMO-ubiquitin hybrid chains in the recruitment of 
the BRCA-1A complex, via the adaptor protein RAP80 to the sites of DNA 
damage (Guzzo et al., 2012).   It was known previously that RAP80 targeted 
BRCA-1 to the sites of DNA double strand breaks through recognition of K63 
linked poly-ubiquitin chains by two UIM domains located in the N-terminal 
region of RAP80 (Yan et al., 2002).  Another key observation is that 
SUMOylation is required for the recruitment of BRCA-1 to damage sites 
(Morris et al., 2009).  A SIM domain has been identified in close proximity to 
the two previously characterised UIMs of RAP80, forming a tandem SIM 
UIMUIM SUMO-ubiquitin binding element that allows RAP80 to bind to 
SUMO-ubiquitin hybrid chains with higher affinity than either to SUMO or 
ubiquitin alone (Guzzo et al., 2012) (Figure 3.1-2).   The discovery of this high 
affinity binding element in the N-terminal region of RAP80 is intriguing- 
suggesting that the SUMO-ubiquitin hybrid chain is a novel type of signalling 
motif distinct to that of separate modifications by homotypic chains of both 
SUMO and ubiquitin on the same substrate.  
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Figure 3.1-2 RAP80 contains a tandem SIM UIM UIM domain. 
Schematic representation of BRCA 1A complex component RAP80.  RAP80 contains a 
tandem SIM UIMUIM domain located in its N-termini.  Red dashed line represents SIM 
domain.  SIM sequence is highlighted below in red.  Blue boxes represent RAP80s two UIM 
domains.  UIM sequences are highlighted in below in blue. 
            
 
3.1.2	  SUMO-­‐ubiquitin	  hybrid	  chain	  assembly	  	  
The SUMO-ubiquitin hybrid chain assembly pathway suggests a high 
level of specificity for this signal.  This specificity is due to the multiple SUMO 
and ubiquitin E1, E2 and E3 enzymes that would be required to conduct the 
initiation of hybrid chain synthesis and create the signal (Figure 3.1-3).  The 
affinity of protein receptors for hybrid chains would also be high due to the 
requirement of both SUMO and ubiquitin interaction elements, as seen in the 
tandem SIM UIMUIM of RAP80 (Guzzo et al., 2012).  
	  
Figure 3.1-3 SUMO-ubiquitin hybrid chain formation pathway. 
SUMO-ubiquitin hybrid chain formation requires the orchestration of both the SUMO and 
ubiquitin conjugating pathways. 
            
 
The number of potential combinations of covalent interactions between 
SUMO and ubiquitin is vast.  SUMO polymers primarily form on K11 within 
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SUMO2, however both K5 and K7 of SUMO2 are known to be capable of 
accepting SUMO modification (Tammsalu et al., 2014).  Ubiquitin could 
potentially modify SUMO2 on any one of eight internal lysine residues, with 
ubiquitin also known to modify the amino group of the N-terminal Met1 of 
SUMO2 (Tatham et al., 2013).  Ubiquitin chains can then form on any one of 
seven lysine residues found within ubiquitin or linear chains of ubiquitin could 
form via Met1.  Conversely SUMO is also known to modify ubiquitin thereby 
creating the possibility of mixed chains of SUMO and ubiquitin (Figure 3.1-4) 
(Tammsalu et al., 2014).  Depending on the number of SUMO and ubiquitin 
moieties involved this could create a huge number of potential combinations 
of SUMO-ubiquitin hybrid chain, and thus the potential for a great number of 
very specific signals.  However, to date, with the potential exception of 
RAP80, it is unclear if specific receptors have evolved to recognise SUMO-
ubiquitin hybrid chains. 
 
	  
Figure 3.1-4 Possible hybrid chain types. 
SUMO is capable of modifying ubiquitin, and ubiquitin is capable of modifying SUMO.  In 
theory this could allow for multiple forms of SUMO-ubiquitin hybrid chain to be formed, 
including mixed and branched hybrid chain types. 
            
 
The possibility of SUMO-ubiquitin hybrid chains acting, as a unique 
signalling device in cells is of interest because of the specificity required to 
interact with these chains and the affinity that this then suggests.  It is 
interesting to note that STUbLs are not restricted to the mammalian system, 
and in fact were first identified in yeast (Uzunova et al., 2007).  Thus 
suggesting some evolutionary pressure to conserve mechanisms capable of 
constructing such signals.  RNF4 is known to have many cellular roles and 
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has the potential to deposit hybrid chains on target substrates in these 
processes, with the possible result being that SUMO-ubiquitin hybrid chains 
could play an important role in many cellular processes.  Therefore, 
investigation into the role of SUMO-ubiquitin hybrid chains is worthy of further 
investigation, and may reveal some important biological functions at the 
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3.2	  Results	  	  
 Initial experiments were designed to elucidate a role for RNF4 
generated hybrid chains of SUMO and ubiquitin by identifying novel proteins 
that interact non-covalently, yet specifically to polymeric chains that contain 
ubiquitin covalently linked to SUMO known as SUMO-ubiquitin hybrid chains.   
Here, a mass spectrometry based approach was used to identify a wide 
variety of proteins that appear to show affinity for ‘baits’ consisting of 
recombinant protein chains of poly-SUMO, poly-ubiquitin, or hybrid chains of 
poly-SUMO mono-ubiquitin or poly-SUMO poly-ubiquitin. 
 
3.2.1	  Generating	  SUMO-­‐ubiquitin	  hybrid	  chains.	  
 
The ability to generate pure hybrid chains consisting of both SUMO 
and ubiquitin is critical to allow the preparation of affinity tools as bait for 
proteomic studies.  In pursuit of this goal, recombinant chains of poly-SUMO 
and hybrid chains of SUMO and ubiquitin were generated (Figure 3.2-1).  
Recombinant linear HisSUMO2-3xSUMO2ΔN11 (referred to as 4xSUMO2) 
(Figure 3.2-1 A, upper) and HisUb-SUMO2-3xSUMO2ΔN11 (referred to as 
Ub-4xSUMO2) (Figure 3.2-1 A, lower) were expressed in BL21 (DE3) 
bacterial cells and purified firstly via Ni-NTA agarose, before a secondary size 
exclusion chromatograph purification through Superdex75 columns (Figure 
3.2-1 B).  The resulting purified recombinant proteins represented a simplistic, 
yet biologically relevant (Tatham et al., 2013), linear head-to-tail poly-SUMO 
chain (4xSUMO2), and a hybrid chain consisting of a linear head-to-tail poly-
SUMO chain N-terminally modified with one ubiquitin (Ub-4xSUMO).  To 
generate a poly-SUMO poly-ubiquitin hybrid chain, 4xSUMO2 and Ub-
4xSUMO2 were used as substrates in an in vitro ubiquitylation assay (Figure 
3.2-1 C).  The K63-specific ubiquitin conjugating E2 pair Ubc13/UBE2v2 
(Mckenna et al., 2003) were used in conjunction with the SUMO-targeted 
ubiquitin E3 ligase RNF4 to generate K63 linked poly-ubiquitin chains.  
4xSUMO2 was unable to be ubiquitylated in this assay, with only unanchored 
ubiquitin chains formed.  However, the ubiquitin containing Ub-4xSUMO2 
substrate was efficiently ubiquitylated after 60 minutes, as poly-ubiquitin 
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chains were formed on the acceptor lysines found on the N-terminally located 




Figure 3.2-1 Generating hybrid chains of SUMO and ubiquitin. 
A) Schematic diagram of linear 4xSUMO2 and Ub-4xSUMO2 constructs. Linear 4xSUMO2 
construct contains 1 mature SUMO2 linked via peptide bonds sequentially to 3 modified 
SUMO2s with the first 11 N-terminal residues truncated.  Ub-4xSUMO2 construct contains 1 
ubiquitin moiety linked to the N-terminal of the mature full length SUMO of the linear 
4xSUMO2 construct. 
B) BL21 DE3 E.coli cells expressing either 4xSUMO2 or Ub-4xSUMO2 constructs were lysed. 
4xSUMO2 and Ub-4xSUMO2 were then purified on Ni-NTA column before a further 
purification through a Superdex75 column (see 2.2.2.3). 
C) Coomassie stained SDS PAGE gel analysis of in vitro Ubiquitination of linear 4xSUMO2 
and Ub-4xSUMO2.  Ubiquitination reaction was performed using E2 enzymes Ubc13 and 
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UBE2v2 in conjunction with E3 enzyme RNF4. Reactions were carried out over the course of 
4 hours at 37°C in the presence or absence of E2/E3 enzymes.  
            
 
Unanchored K63 linked poly-ubiquitin chains, sourced from the Divison 
of Signal Transduction Therapy (DSTT, University of Dundee), consisting of 
chain lengths varying from ~3-10 ubiquitin moieties were used as a poly-
ubiquitin chain type completing the required ‘bait’ proteins for our proteomic 
study.  The four different chain types; poly-ubiquitin, poly-SUMO, mono-
ubiquitin poly-SUMO, and poly-ubiquitin poly-SUMO (Figure 3.2-2 A) were 
then cross linked at equimolar concentrations to N-Hydroxysuccinimidyl 
activated agarose beads (NHS).  This resulted in four different protein-
containing resin types; K63 pUb, 4xSUMO2, Ub-4xSUMO2 and pUb-
4xSUMO2.  A protein free blank resin was also generated as a control against 
proteins interacting non-specifically with the NHS resins.  
 
To test the efficacy of these resins as reagents capable of extracting 
proteins with affinities for SUMO and ubiquitin, recombinant proteins with 
known affinities for either SUMO or ubiquitin were used in pull-down assays to 
test each resin.  RNF4 with its four N-terminally located SIM domains was 
used to test the affinity of the SUMO resins, while GST fusion protein 
containing two ubiquitin interacting motifs, GST-UIM dimer, was used to test 
the affinity for the ubiquitin portion of the resins.  5 µM of either RNF4 or GST-
UIM dimer were incubated with 10 µl of each resin separately, any unbound 
proteins were washed from the resins before any protein interacting with the 
resins was eluted with SDS sample buffer.  As expected, RNF4 was found to 
interact only with the three SUMO containing resin types; 4xSUMO2, Ub-
4xSUMO2 and pUb-4xSUMO2 but was not found to interact with the ubiquitin-
only containing K63 pUb or the blank resin (Figure 3.2-2 B, left). GST-UIM 
dimer was found to interact only with the ubiquitin containing resin types; K-63 
pUb, pUb-4xSUMO2, and to a lesser extent Ub-4xSUMO2 but did not interact 
with the SUMO-only containing 4xSUMO2 or blank resins (Figure 3.2-2 B, 
right).  The results of these pull-down assays with recombinant SUMO or 
ubiquitin interacting proteins demonstrates that the K63 pUb, Ub-4xSUMO2 
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and pUb-4xSUMO2 bound resins are all capable of capturing proteins that 
show affinity for ubiquitin, while 4xSUMO2, Ub-4xSUMO2 and pUb-4xSUMO2 
are all capable of capturing proteins that show affinity for SUMO, as expected. 
 
	  
Figure 3.2-2 Interacting with ‘bait’ SUMO-ubiquitin hybrid chains. 
A) Four different chain configurations were used to provide insight into SUMO, ubiquitin and 
SUMO-ubiquitin hybrid chain interacting proteins. Coomassie stained SDS PAGE gel analysis 
of the four different chain types; Ub-4xSUMO, pUb-4xSUMO2, K63 pUb, 4xSUMO2 prior to 
coupling to NHS-activated agarose resin. Schematic cartoon represents four different chain 
types used as bait in proteomic experiment; two hybrid chain types, Ub-4xSUMO2 and pUb-
4xSUMO2; poly ubiquitin chain type, K63 pUb and poly SUMO chain type, 4xSUMO2.  
B) Coomassie stained SDS PAGE gel analysis of pull down assays with SUMO specific 
interacting protein, RNF4, and ubiquitin specific interacting protein, GST-UIM dimer. 10µM 
recombinant RNF4 or GST-UIM dimer were incubated separately with 50µl of each resin type 
+ blank resin before elution in 2xSDS sample buffer. RNF4 bound specifically to SUMO 
containing resins; 4xSUMO2, Ub4xSUMO2 and pUb-4xSUMO2. GST-UIM dimer interacts 
specifically with resins containing ubiquitin. Load control represent 20% of total protein 
incubated with resins. 
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3.2.2	   A	   specific	   elution	   to	   elucidate	   information	   on	   interaction	   characteristic	   of	  
hybrid	  chain	  interacting	  proteins	  
 
As a measure to try and elucidate more information about the affinity 
for SUMO or ubiquitin for any given potential interacting partner, a specific 
elution protocol was devised to dismantle SUMO-ubiquitin hybrid chains by 
sequentially removing the ubiquitin moieties before then removing the SUMO 
moieties of any chain.  This would hopefully discern any solely ubiquitin 
interacting elements from any that were SUMO interacting, by first releasing 
proteins that were non-covalently linked to the ubiquitin portion of a hybrid 
chain before then releasing proteins the were non-covalently linked to the 
SUMO portion of the SUMO-ubiquitin hybrid chains (Figure 3.2-3). 
	  
Figure 3.2-3 Stepwise elution of ubiquitin- then SUMO-interacting proteins by ubiquitin 
and SUMO proteases. 
Cartoon represents sequential deubiquitnase and SUMO-specific protease based elution. 
Specific elution was designed to sequentially release ubiquitin-interacting proteins and then 
SUMO-interacting proteins from hybrid chains through a primary incubation with a highly 
active deubiquitinase enzyme followed by secondary incubation with a SUMO-specific 
protease enzyme. 
            
 
 Highly active, yet specific, SUMO-specific protease and deubiquitinase 
enzymes would need to be obtained to dismantle SUMO-ubiquitin hybrid 
chains in this manner.  To this end, the active catalytic domain of the 
deubiquitinase enzyme, USP2, residues Asn258-Met605 (Referred to as 
USP2 CaD), was cloned and expressed in Rosetta ElaD (DE3) bacterial cells 
as described in 2.2.2.1.  Active SUMO-specific protease, SENP1 protein was 
a kind gift from Dr L. Shen (Shen et al., 2006).  
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Figure 3.2-4 USP2 CaD and SENP1 are capabale of dismantling a SUMO-ubiquitin 
hybrid chain. 
USP2 and SENP1 activity assays.  
Stated concentrations of either SENP1 or USP2 were incubated with 10 µM; 
A) 4xSUMO; B) Ub-4xSUMO2; C) K63 pUB for 0 or 120 minutes at 22° C. Substrate controls 
were incubated with no enzyme. 
            
 
The activity of each enzyme was established against recombinant 4xSUMO2, 
Ub-4xSUMO2 and K63 pUb (Figure 3.2-4).  As expected, after 120 minutes, 
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SENP1 had efficiently degraded the 4xSUMO2 poly-SUMO chain to mono-
SUMO, at concentrations as low as 0.01 µM.  After 120 minutes, USP2 CaD 
had had no effect on the 4xSUMO2 construct (Figure 3.2-4, A).  As with the 
4xSUMO2 poly-SUMO construct, SENP1 deconjugates SUMO from the Ub-
4xSUMO2 construct.  However, SENP1 does not show any activity towards 
ubiquitin-conjugated SUMO and so a secondary product corresponding to one 
ubiquitin covalently bound to one SUMO is also present after 120 minutes 
(Figure 3.2-4, B left panel).  USP2 CaD at concentrations of 0.1 µM or above 
was capable of efficiently removing ubiquitin moiety from the Ub-4xSUMO2 
construct, while not degrading the poly-SUMO element of the Ub-4xSUMO2 
construct (Figure 3.2-4, B right panel).  In line with expectations, SENP1 
was unable to degrade K63 pUb chains in vitro.  USP2 CaD, however, 
efficiently degrades the K63 pUb chains to mono-ubiquitin in 120 minutes at 
concentrations of 0.1 µM or above (Figure 3.2-4, C).  Thus, the purified USP2 
CaD and SENP1 enzymes provide the catalytic activity capable of degrading 
SUMO-ubiquitin hybrid chains efficiently in a stepwise and controlled manner. 
 
 The stepwise USP2 CaD/SENP1 elution protocol was then tested 
against the K63 pUb, 4xSUMO2, Ub-4xSUMO2 and pUb-4xSUMO2 
containing resins incubated with the SUMO- and ubiquitin-interacting proteins, 
RNF4 and GST-UIM dimer.  Resins were incubated with both RNF4 and GST-
UIM dimer overnight prior to elution.  The three-stage elution process was 
then carried out; USP2 CaD was incubated with each resin for 2 hours.  The 
resins were spun down and the USP2 CaD supernatant, containing any 
proteins that were dislodged by the protease treatment were removed.  
SENP1 was then incubated with each resin for 2 hours, again the resins were 
spun down and the SENP1 supernatant and any proteins dislodged by the 
treatment were removed.  Finally the resins were boiled in SDS sample buffer 
to release any proteins still interacting with the resins, before all elution steps 
were analyzed by SDS-PAGE and western blotting separately (Figure 3.2-5) 
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Figure 3.2-5 USP2/SENP1 Specific elution from resins incubated with SUMO or 
ubiquitin specific interacting proteins. 
5 µM RNF4 and GST-UIM dimer were incubated together with 50 µl of each of the 4 resin 
types + Blank resin separately, overnight at 4°C. Step wise elution with 5 µM USP2 followed 
by 5 µM SENP1 and a final SDS boil was carried out for each resin and analysed by western 
blot via indicated antibody.  
            
 
 
As expected, GST-UIM dimer was released from the K63 pUb and pUb-
4xSUMO2 resins after treatment with USP2 CaD.  No GST-UIM dimer was 
recovered from the 4xSUMO2 resin or, surprisingly, from the Ub-4xSUMO2 
resin.  The addition of SENP1 to the resins released a sizeable amount of 
RNF4 from the 4xSUMO2, Ub-4xSUMO2 and pUb-4xSUMO2 resin types, but 
consistent with the previous pull downs, no RNF4 was eluted from the K63 
pUb resin types.  GST-UIM dimer was also present in the SENP1 elution from 
the K63 pUb and pUb-4xSUMO2 resins but this could be accounted for by 
residual GST-UIM dimer left over from the USP2 CaD elution still being 
present.  RNF4 was found in the eluate of the 4xSUMO2, Ub-4xSUMO2 and 
pUb-4xSUMO2 resins after the resins had been boiled in SDS, with GST-UIM 
dimer present in the SDS elution from K63 pUb and pUb-4xSUMO2 resin 
types. 
 
Thus, an elution based around disrupting SUMO ubiquitin hybrid chains 
via the protease activity of USP2 CaD and SENP1 was capable of dislodging 
proteins that were known to be non-covalently interacting specifically with 
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either the ubiquitin moiety or the SUMO moiety of a SUMO-ubiquitin hybrid 
chain.  
 
The identification of hybrid chain interacting proteins from complex cell 
lysates was then key to understanding whether or not the combination of 
SUMO-ubiquitin hybrid chain pull down assay and USP2 CaD/SENP1 elution 
protocol was capable of identifying novel hybrid chain interacting proteins.  As 
such the SUMO-ubiquitin hybrid chain pull down assay and USP2 




Figure 3.2-6 Hybrid chain pull down with HEK 293 N3S nuclear lysates. 
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HEK 293 N3S nuclear extracts were incubated separately with BLANK, K63 pUb, 4xSUMO-2, 
Ub-4xSUMO-2 and pUb-4xSUMO-2 resins.  USP2 CAD, SENP1 and SDS elutions were 
carried out sequentially for each resin before being analyzed by Western blot for indicated 
antibody.   Pre- incubation nuclear extract and a cytoplasmic extract act as loading controls.  	   	   	   	   	   	   	   	   	   	   	   	  
 
HEK 293 spinner cell cultures (5 litres) were grown to a density of 1E6 
cells/ml before the cells were spun down and lysed into cytoplasmic and 
nuclear extracts in accordance with 2.2.5.2.   Each of the five resin types were 
then incubated overnight with HEK 293 nuclear cell extracts before the USP2 
CaD/SENP1 elution protocol was performed.  The elutions were then 
separated by SDS-PAGE and analysed by western blot (Figure 3.2-6) with 
antibodies against ubiquitin, SUMO, RNF4, and the previously identified 
potential SUMO-ubiquitin hybrid chain interacting protein RAP80 (Guzzo et 
al., 2012).  Free monomeric SUMO was found to be present after the 
incubation with SENP1 and the denaturing elution of the SUMO containing 
resin types 4xSUMO2, Ub-4xSUMO2, and pUb-4xSUMO2.  Ubiquitin was 
found in the eluate from the ubiquitin containing resin types, K63 pUb and 
pUb-4xSUMO2 after incubation with USP2 CaD, SENP1, and the denaturing 
elution.  In line with pervious experiments RNF4 was found to be present in 
the eluate from 4xSUMO2, Ub-4xSUMO2 and pUb-4xSUMO2 after the 
SENP1 elution and the denaturing elution, with the most prominent RNF4 
band detected with the 4xSUMO2 resin after SENP1 elution.  RNF4 was not 
found to be present in any elutate from blank or K63 pUb resin types.  
Interestingly, RAP80 was detected in the poly-SUMO poly-ubiquitin hybrid 
chain containing pUb-4xSUMO2 resin type after all three elutions but not in 
any elution from the Ub-4xSUMO2 hybrid chain type, 4xSUMO2, K63 Ub, or 
blank resins.  This suggests that potential hybrid chain interacting proteins 
may only interact with specific forms of SUMO-ubiquitin hybrid chains. 
 
Identifying RAP80 by western blot after SUMO-ubiquitin hybrid chain 
pull-down assay gives credence to the hypothesis that a combination of the 
4xSUMO2, K63 pUb, and Ub-4xSUMO2 and pUb-4xSUMO2 hybrid chain 
resin types along with the specific USP2 CaD/SENP1 elution protocol is 
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capable of identifying novel SUMO-ubiquitin hybrid chain interacting proteins 
from complex human cell lysates.  	  
3.2.3	   Detection	   of	   SUMO-­‐ubiquitin	   hybrid	   chain	   binding	   proteins	   via	   protein	  
affinity	  chromatograph	  coupled	  with	  high	  resolution	  mass	  spectrometry	  	  
 Having identified RAP80 by western blot analysis in the elution’s from 
HEK 293 cells lysates using the SUMO-ubiquitin hybrid chain pull-down assay 
outlined above, samples were then prepared for mass spectrometry analysis 
in the hope of identifying a number of novel potential SUMO-ubiquitin hybrid 
chain interacting proteins.  
 
 In total 45 litres of HEK 293 spinner cells were cultured before nuclear 
extracts were prepared. 150 µl of each resin type was incubated with 10 mL 
nuclear lysates (5.5 mg/ml) with rotation overnight at 4°C.  Resins were then 
washed to remove any proteins not specifically bound before incubation with 
USP2 CaD, SENP1 and a denaturing elution with LDS sample buffer were 
used to elute any bound proteins from the resins.  The eluates from each 
resin for each elution, 15 in total, were then separated by SDS-PAGE (Figure 
3.2-7 A).  After coomassie staining the elution profiles of resin were 
compared. Noticeable differences were apparent in the elution profiles from 
each resin type, with the majority of the material being released from the 
resins by the denaturing LDS sample buffer boil.  The lanes containing each 
elution were then cut into two slices and prepared for mass spectrometry 
analysis by in gel trypsin digestion (2.2.8.1).  Samples were then processed 
using MaxQuant, reporting intensities for 2197 proteins.  The intensities 
reported by MaxQuant can be used as a surrogate for the relative abundance 
for each protein, from each elution, for each resin type.  This can then be 
used to describe the apparent relative affinity that each protein shows for 
each resin type i.e. if after all elutions are carried out a protein is reported to 
have a large intensity in the pUb-4xSUMO2, Ub-4xSUMO2, and 4xSUMO2 
resin types but not in BLANK or K63 pUb resin types then that protein can be 
said to show affinity for the 4xSUMO2 containing resin types.  To remove any 
bias from the analysis of any potential SUMO-ubiquitin hybrid chain 
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interacting protein numerical analysis was undertaken on the mass 
spectrometry data to determine if any proteins identified in the pull-down 
assay could be considered to be interacting specifically with poly-SUMO, poly-
ubiquitin, or with either form of SUMO-ubiquitin hybrid chain.  This was 
achieved by scoring each protein based on which elution, and from which 
resin type that protein was identified in Table 3.1.1 illustrates the scoring 
system.  Firstly, any protein with a missing intensity score was replaced with 
1E6, the lower limit for intensity report.  For each experiment all 10 ratio 
combinations of intensity scores for; blank (A), K63 pUb (B), 4xSUMO2 (C), 
Ub-4xSUMO2 (D), and pUb-4xSUMO2 (E) were calculated, and the data 
normalized from frequency histograms of each log2 ratio.  Using this scheme 
a ‘specificity score’ was calculated for each protein for each resin type.  This 
gives a score for the apparent consistency of the intensity data with that 
expected of a protein binding to the resins with specific characteristics, such 
as ‘binds to any poly-SUMO resin’.  In theory these scores are comparable, 
with the maximum score indicating the predicted specificity of that protein.  
For each protein the maximum specificity score was calculated for each resin.  
These maxima were used to create frequency histograms to see the spread of 
maximum values for each experiment.  These data were used to plot normal 
distributions and create 95% confidence intervals.  So all maximum specificity 
scores >~6 were regarded as significant.  Example specificity score for ‘Any 
polySUMO’ 
‘=((√(log2B/A)2+log2C/A+log2D/A+log2E/A+log2C/B+log2D/B+log2E/B+log2D/C+
√(log2E/C)2+√(log2E/D)2)*log10Total Protein Intensity-6’.  This score takes into 
account all ratio data as well as the abundance of the protein (Total protein 
intensity).  -6 allows for the fact that the minimum protein intensity is 1E6. 
 
 
Table 3.2-1 – Specificity scoring system for protein affinities. 
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Table outlines the predicted ratios expected for a given interaction characteristic. (0) 
Describes a ratio that would not be expected to contribute towards a certain interaction 
characteristic. (–) Describes a ratio that would be expected to be negative for the described 
interaction characteristic. (+) Describes a ratio that would be expected to be positive for the 
described interaction characteristic. Example – specificity score for ‘Any polySUMO’ 
‘=((√(log2B/A)2+log2C/A+log2D/A+log2E/A+log2C/B+log2D/B+log2E/B+log2D/C+√(log2E/C)2+ 
√(log2E/D)2)*log10Total Protein Intensity-6’. This score takes into account all ratio data as well 
as the abundance of the protein (Total protein intensity). -6 allows for the fact that the 
minimum protein intensity is 1E6. 
            
 
This method resulted in a list of 152 proteins that could be described as 
having defined interaction specificity.  For each of these the highest maximum 
of the three elutions from each resin was considered as the predominant 
specificity and reported.  59% of the proteins identified as having an affinity for 
one of the resin types were characterised as any poly-SUMO interacting 
proteins (Appendix II).  25% of the proteins were identified as ubiquitin 
interacting proteins, 5% were interacting with any ubiquitin moiety, with the 
remaining 20% listed as K63 specific i.e. interacting with the poly-ubiquitin 
containing resin types K63 pUb and pUb-4xSUMO2 only (Appendix II).  In 
total, 16% of the total proteins listed as having specificity were suggested to 
be interacting with a form of SUMO-ubiquitin hybrid chain (Figure 3.2-7, B). 
12% of the total number of proteins were said to be interacting specifically 
with the poly-SUMO poly-ubiquitin hybrid chain type.  Only 1% was suggested 
to show specificity for the mono-ubiquitin poly-SUMO hybrid chain type, while 
the remaining 3% had affinity for both the mono- and poly-ubiquitin containing 
hybrid chain types.  Along with the numerical analysis of the data the intensity 
charts for each protein identified by MaxQuant were also checked manually, 
by comparison with that of the known potential SUMO-ubiquitin hybrid chain 
interacting protein RAP80 (Figure 3.2-8, A).  Any protein that was not 
identified by the numerical analysis but had a similar intensity chart to that of 
RAP80 was also added to the list of potential SUMO-ubiquitin hybrid chain 
interacting proteins (denoted by *), bringing the number of potential SUMO-
ubiquitin hybrid chain interacting proteins to 30 (Figure 3.2-7, C).  
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Figure 3.2-7 Mass spectrometry analysis of hybrid chain interacting proteins. 
A) SDS-PAGE analysis of eluate from resins types after incubation with 293 N3S nuclear 
extracts. The three step specific elution was carried out and eluate from each resin type were 
run on 10% SDS-PAGE gel before individual lanes were sliced as shown in black dashed 
boxes.  
B) Pie chart summation of specific SUMO, ubiquitin, or SUMO ubiquitin hybrid chain 
interacting proteins identified by mass spectrometry. PolySUMO describes any protein that 
showed affinity only for the 4xSUMO2 resin. K63 pUb describes any protein that showed 
affinity only for the K63 pUb resin. Any Ub describes proteins that show affinity for any of the 
ubiquitin containing resins. Any Ub-polySUMO describes proteins that showed affinity for both 
the Ub-4xSUMO2 and pUb-4xSUMO resins. Polyubiquitin polySUMO describes any protein 
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that showed affinity only for the pUb-4xSUMO2. Ubiquitin polySUMO describes any protein 
that showed affinity only for ub-4xSUMO2 resin. 
C) Table listing all proteins that showed affinity for a hybrid chain type resin. Proteins 
highlighted with (*) were added to the initial list because of similarity of their intensity charts to 
that of RAP80. Proteins taken for further investigation are highlighted in red, with the BRCA 
1A complex members are highlighted in blue. 
            
 
Along with RAP80, five other BRCA 1A complex components were 
characterized as SUMO-ubiquitin hybrid chain interacting proteins, including 
Abraxas, BRE, BRCC36, BABAM1 (Merit40) and BRCA 1 (Figure 3.2-7, C, 
highlighted in blue).  BRE, Abraxas, and BRCC36 are known to contain 
ubiquitin interacting elements.  BRE contains two ubiquitin-conjugating 
enzyme like (UEV) domains (Wang et al., 2009).  Abraxas and BRCC36 
contain JAMM/MPN ubiquitin binding domain (MPN) like domains (Sobhian et 
al., 2007).  The sequence of each of these proteins was searched for SIM 
domains using the PATTINPROT web tool.  Potential SIMs were found in 
BRE, Abraxas, and BRCC36 (Figure 3.2-8, B, dashed red lines).  This 
suggests that BRE, Abraxas and BRCC36 have the potential, like RAP80, to 
interact with both SUMO and ubiquitin.  The combined intensity charts, which 
report the combined intensities for all elutions for each resin type minus any 
reported intensities from the blank resin, for the BRCA 1A complex 
components all display a similar pattern of affinity for the pUb-4xSUMO2 resin 
(Figure 3.2-8, C).  The intensity charts for each of these proteins would 
suggest that they each show affinity for the same poly-SUMO poly-ubiquitin 
form of SUMO-ubiquitin hybrid chain.  This may suggest that this type of 
SUMO-ubiquitin hybrid chain is very important to the role of the BRCA 1A 
complex.  
 
The identification of RAP80 in the mass spectrometry data as a SUMO-
ubiquitin hybrid chain interacting protein, reinforces the hypothesis that a 
combination of the 4xSUMO2, K63 pUb, and Ub-4xSUMO2 and pUb-
4xSUMO2 hybrid chain resin types along with the USP2 CaD/SENP1 elution 
protocol is capable of identifying novel hybrid chain interacting proteins from 
complex human cell lysates. 
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Figure 3.2-8 Proteomic analysis of BRAC 1A complex components. 
A) MaxQuant reported intensity charts for RAP80 from each of USP2, SENP1 and denaturing 
elutions. Resin type is listed below graph. Elution type is listed below resin type.  
B) Schematic depiction of BRCA1 A complex components RAP80, Abraxas, BRCC36, BRE, 
BABAM/Merit40 and BRCA1. Potential or described SUMO interaction motifs are shown with 
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dashed red line. Ubiquitin interaction motifs are shown by dark blue boxes. Green box 
outlines AIR synthase domain of RAP80. Grey box indicates Zinc fingers of RAP80 and 
BRCA1. Blue boxes indicate MPN domains of Abraxas and BRCC36. Orange boxes indicate 
coiled coil domains. Yellow boxes indicate relative position of UEV1 domains with BRE. 
Purple box of BABAM/Merit40 represents VWFA domain. Red boxes of BRCA1 represent 
BRCT domains. 
C) MaxQuant reported intensity charts for each for the BRCA 1A complex components. 
Reported intensities for each elution combined together for each protein containing resin 
minus the combined intensities from USP2, SENP1 and denaturing elutions from BLANK 
resin in each case. 
            	  
3.2.4	  Verifying	  potential	  hybrid	  chain	  interacting	  proteins	  
 
The remaining proteins identified as showing affinity for SUMO-
ubiquitin hybrid chains were then systematically appraised for the domains 
required to interact with both SUMO and ubiquitin.  Literature and database 
searches were carried out for any known ubiquitin binding domains or proteins 
known to contain SIMs.  This revealed that a number of the proteins in the 
hybrid chain interacting list were already described to contain either SUMO- or 
ubiquitin-interacting elements.  Three of these proteins were selected for 
further analysis C5orf25/SIMC1, RNF168 and MORC3 (Figure 3.2-7, C, 
highlighted in red).  
 
C5orf25/SIMC1 (referred to as C5orf25) is known to contain two high 
fidelity type SIM domains located in its N-terminal region but has no known 
ubiquitin binding domains (Figure 3.2-9, A) (Sun & Hunter 2012).  The 
combined intensity chart for C5orf25 suggests that the protein shows affinity 
for the hybrid chain resin types, Ub-4xSUMO2 and pUb-4xSUMO2, but also 
for the poly-SUMO only containing resin 4xSUMO2 (Figure 3.2-9, B).  
Interestingly, when analysing the intensity chart from the USP2 CaD, SENP1 
and denaturing elution’s separately (Figure 3.2-9, C), intensities are reported 
for C5orf25 in USP2 CaD elution of the hybrid chain resin types pUb-
4xSUMO2 and Ub-4xSUMO2.  This suggests that the ubiquitin moieties of 
those resin types have some affect on the ability of C5orf25 to interact with 
those resins.  No intensity was reported for C5orf25 in the USP2 CaD elution 
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from the poly-SUMO only 4xSUMO2 resin type.  This suggest the C5orf25 
released from the hybrid chain resins after USP2 CaD elution is not due to an 
unspecific effect of USP2 acting on C5orf25.  If this were the case, C5orf25 
would be released from all the resin types by the USP2 CaD elution.  
Intensities are reported for C5orf25 from the 4xSUMO2, Ub-4xSUMO2 and 
pUb-4xSUMO2 resins after the SENP1 elution.  C5orf25 released by this 
elution from the 4xSUMO2 resin type must be due to the disruption of the 
SUMO chains of this resin by the SENP1 enzyme suggesting that as 
expected, C5orf25 has the ability to interact with SUMO, most likely via the 
two previously identified high fidelity SIM domains.  As expected, intensities 
are also reported for C5orf25 from the 4xSUMO2, Ub-4xSUMO2 and pUb-
4xSUMO2 resins after the LDS sample buffer elution.  The highest intensity 
reported for C5orf25 were recorded in eluates from the pUb-4xSUMO2 resin 
type, suggesting C5orf25 was most abundant in the eluate from that resin 
type.  Thus, C5orf25 showed the greatest affinity for the poly-SUMO poly-
ubiquitin hybrid chain resin pUb-4xSUMO2.  
 
These data suggest that C5orf25 can interact with poly-SUMO, but not 
with K63 linked poly-ubiquitin alone.  C5orf25 however, does appear to have 
the greatest affinity for hybrid chains of SUMO and ubiquitin, with the ubiquitin 
moieties of these chains playing some role in the interaction.  With this in 
mind, recombinant [35S] methionine labelled C5orf25 was generated via an in 
vitro transcription/translation reaction.  The recombinant C5orf25 was then 
tested in a SUMO-ubiquitin hybrid chain pull-down assay (Figure 3.2-9, D). 
Recombinant C5orf25 interacts in a similar manner to the C5orf25 from the 
HEK 293 cell extracts, showing affinity for all the SUMO containing resin 
types.  A slight increase in C5orf25 was observed in the SUMO-ubiquitin 
hybrid chain resin types when compared to the 4xSUMO2 resin type.  C5orf25 
does appear to be a bona fide SUMO-ubiquitin hybrid chain interacting 
protein.  However, due to lack of any apparent ubiquitin binding domain 
further study would be required to identify any potential domains that could 
facilitate this interaction. 
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Another hit from the hybrid chain interacting screen was the ubiquitin 
E3 ligase, RNF168.  RNF168 is known to have a role in the DNA damage 
response, potentially upstream of the recruitment of RAP80, making it an 
interesting target for further study (Doil et al., 2009).  RNF168 is known to 
have three UIMs, one canonical UIM and two reverse UIMs, known as MIUs 
(Pinato et al 2009, Panier et al., 2012).  Previous work in our lab carried out 
by Dr. J-F Maure (unpublished data) had suggested that RNF168 has four 
potential SIM domains, two of these potential SIM domains and are located in 
close proximity to the secondary MIU of RNF168 (Figure 3.2-9, E), which is 
required for the recruitment of RNF168 to sites of DNA repair (Doil et al 2009). 
This set up of two SIM domains and one MIU could act in a similar way to the 
tandem SIM UIMUIM domain of RAP80 and facilitate a specific interaction 
between RNF168 and SUMO-ubiquitin hybrid chains.  The combined elution 
profile of RNF168 suggests that it has affinity for the poly-SUMO poly-
ubiquitin hybrid chain containing, pUb-4xSUMO2 resin (Figure 3.2-9, F). 
Intensities were reported for RNF168 in the elutions from the 4xSUMO2 resin 
type but no RNF168 was detected in either the K63 pUb or Ub-4xSUMO2 
resin types.  Only a small amount of RNF168 was detected in the eluate from 
the USP2 CaD elution from the pUb-4XSUMO2 resin type.  The largest 
intensities for RNF168 were reported in the eluate from the denaturing elution 
from the pUB-4xSUMO2 resin, with smaller intensities reported for RNF168 in 
the eluate of the 4xSUMO2 resin after denaturing elution (Figure 3.2-9, G).  
Bacterially expressed recombinant RNF168 was then tested in the SUMO-
ubiquitin hybrid chain pull-down assay (Figure 3.2-9, H).  The most prominent 
RNF168 band was associated with the eluate of the pUb-4xSUMO2 resin, 
agreeing with the data from the mass spectrometry analysis.  Unlike the mass 
spectrometry data the second most prominent RNF168 band was associated 
with the elution from the K63 pUb resin type.  This however agrees with 
current literature that suggests that RNF168 can interact with K63 linked poly-
ubiquitin chains (Panier et al., 2012). 
 
 RNF168 appears to show affinity for poly-SUMO poly-ubiquitin hybrid 
chain types developed for this assay.  This is perhaps not surprising given 
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that RNF168 contains three known ubiquitin interacting motifs and a number 
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Figure 3.2-9 Exploring novel potential hybrid chain interacting proteins. 
A) Schematic diagram represents C5orf25. Two N-terminally located SUMO interaction motifs 
are represented by red box, sequence is shown highlighted in red below. Nuclear localisation 
signal is shown by green line.  
	   85	  
B) Combined intensities reported by MaxQuant for C5orf25 minus intensities reported for 
blank resin. 
C) Reported intensities from MaxQuant for C5orf25 for each resin type from each elution. 
D) Hybrid chain interacting protein pull-down assay performed with recombinant C5orf25 
produced by in vitro transcription and translation  
E) Schematic diagram represents RNF168. Ubiquitin interaction motif represented by blue 
box with reverse ubiquitin interaction motifs shown by purple boxes. Potential SIMs shown by 
dashed red lines, sequence highlighted in red below. 
F) Combined intensities reported by MaxQuant for RNF168 minus intensities reported for 
blank resin. 
G) Reported intensities from MaxQuant for RNF168 for each resin type from each elution. 
H) Hybrid chain interacting protein pull-down assay performed with recombinant RNF168. 
Coomassie stained SDS PAGE gel analysis of hybrid chain pull-down assay with RNF168. 
10µM recombinant RNF168 were incubated with 50µl of each resin type + blank resin. USP2 
and SENP1 elution were carried out before a final elution in 2xSDS sample buffer. Load 
control represents 20% of total recombinant protein incubated with beads 
            
 
Two members of the MORC family CW-type zinc finger proteins, 
MORC3 and MORC4, were identified as potential hybrid chain interacting 
proteins.  Of these two, MORC3 has previously been described to be 
associated with PML in PML-NBs (Mimura et al., 2010).  PML is known to be 
SUMOylated and to be acted on by the STUbL RNF4 (Duprez et al.,1999, 
Tatham et al., 2008) and therefore has the potential to anchor hybrid chains of 
SUMO and ubiquitin.  The apparent affinity of MORC3 for SUMO-ubiquitin 
hybrid chains was therefore very interesting and worth further investigation.  
 
MORC3 is known to be SUMOylated at two positions; K597 and K650 
(Tammsalu et al., 2014).  9 potential SIMs are found throughout the sequence 
of MORC3 (Figure 3.2-10, A).  However, MORC3 contains no known 
ubiquitin binding domains.  The combined elution profile of MORC3 is 
therefore quite surprising, with the largest signal intensity is reported from the 
pUb-4xSUMO2 resin type, and with smaller intensities being reported from the 
elutions from both the 4xSUMO2 and Ub-4xSUMO2 resins (Figure 3.2-10, B).  
This suggests that although MORC3 shows some affinity for poly-SUMO, it 
shows a far greater affinity for poly-SUMO poly-ubiquitin hybrid chains.  To 
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test how reproducible these finding were in vitro, bacterially expressed 
MORC3 was tested in the SUMO-ubiquitin hybrid chain pull-down assay 
(Figure 3.2-10, C).  The apparent affinity of the recombinant MORC3 for each 
resin type was remarkably similar to that shown by the elution profile in the 
combined intensity chart reported for MORC3 (Comparing Figure 3.2-10, B 
to D).  MORC3 was significantly more abundant in the elution from the pUb-
4xSUMO2 resin type when compared to the Ub-4xSUMO2 resin, 4xSUMO2 
resin, or K63 pUb resin type (Figure 3.2-10, D), with MORC3 found to be 
more abundant in the elutions from the SUMO containing resins and showing 
no real affinity for the K63 pUb ubiquitin only resin type.  This agrees with the 
current literature that suggests MORC3 is a SUMO interacting protein 
(Mimura et al., 2010).  The lack of affinity towards the pUb K63 ubiquitin 
chains is not surprising given the lack of a defined ubiquitin binding domain in 
MORC3, however this only adds to the intrigue as to how the apparent affinity 
of MORC3 for hybrid chains of SUMO and ubiquitin is so much more intense 
than for SUMO chains alone.  
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Figure 3.2-10 Morc3 a potential hybrid chain interactor. 
A) Schematic diagram of MORC3 full length protein. N-terminally located GHL-ATPase 
domain represented as red box. CW-type Zinc finger represented as blue box. C-terminally 
located coiled coil domain (CC) represented as green box. Postion of potential SIMs 
represented by dashed black lines. Known SUMOylation sites at K597 and K650 represented 
by dashed red lines. 
B) Combined intensities reproted by MaxQuant for Morc3 minus intenistiies reported for blank 
resin from hybrid chain pull down experiment (Figure 3.2-7) 
C) SDS-PAGE analysis of hybrid chain pull down assay with recombinant full length Morc3. 
50µl of each resin type used in pull down was incubated separately with 10µM of bacterially 
produced recombinant full length Morc3 overnight, before being eulated from the resins with 
SDS loading buffer. Load control represent 20% of total protein incubated with resin. SDS-
PAGE gel is representative of 3 independent experiments with full length Morc3 used in pull 
down stated above and resin type used in pull down below. 
D) Quantification of SDS-PAGE analysis of hybrid chain pull down assay with recombinant 
Morc3. Pull down experiment was carried out in triplicate. ImageJ was used to quantify Morc3 
comassie stained bands for each resin. Error bars represent SEM. P values represent the 
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difference in average intenisties of 3 repeated experiments between * K63 pUb and pUb-
4xSUMO2, ** 4xSUMO2 and pUb-4xSUMO2, and *** ub-4xSUMO2 and pUb-4xSUMO2. 
            
 
To try and elucidate any domains of MORC3 that may be required for 
its apparent affinity for SUMO-ubiquitin hybrid chains, four truncated 
fragments of MORC3 were generated (Figure 3.2-11, A).  These fragments 
were structured around the potential SIMs and known domains of MORC3. 
Fragment A contained the N-terminus of MORC3 that included four of the 
potential SIM domains plus the GHL-ATPase domain.  Fragment B contained 
the GHL-ATPase domain, four SIMs but also included the CW-type Zinc finger 
domain.  Fragment C contained the C-terminal of MORC3 including the 
known SUMOylation sites, the coiled coil domain, the CW-type zinc finger and 
five potential SIMs.  Fragment D contained the C-terminal, coiled coil domain, 
SUMOylation sites and five SIM domains.  These fragments of MORC3 were 
then tested in the SUMO-ubiquitin hybrid chain pull-down assay.  Fragments 
A and B were found to be most abundant in the elutions from the 4xSUMO2 
and Ub-4xSUMO2 resin types.  Both fragments were found to be less 
abundant in the elutions from the pUb-4xSUMO2 and K63 pUb resin types. 
Fragments C and D were found to be present at similar levels in the 
4xSUMO2, Ub-4xSUMO2, and pUB-4xSUMO2 and at lower levels in the K63 
pUb resin types.  The presence of potential SIM domains in all of the 
fragments would allow for the affinity towards SUMO seen in these pull down 
assays however none of the fragments show the great increase in affinity for 
the pUb-4xSUMO2 resin type seen in the full length protein.  This could 
suggest that the affinity for SUMO-ubiquitin hybrid chains seen in the full 
length protein is not based on a discreet sequence domain of MORC3 but is 
perhaps related to the 3D structure of the full length protein.  MORC3 clearly 
shows affinity for SUMO-ubiquitin hybrid chains however these MORC3 
fragments have been unable to serve as tools to identify a discreet domain 
that defines such an affinity. 
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Figure 3.2-11 Dissecting the apparent interaction between MORC3 and hybrid chains of 
SUMO and ubiquitin. 
A) Schematic diagram representing 4 truncated mutants of MORC3. Fragment A contain 
residues 1-400 encompassing the GHL-ATPase domain (red) and 4 potential SIMs (dashed 
black lines). Fragment B contains residues 1-460 encompassing the GHL-ATPase domain, 4 
potential SIMs and the CW-type zinc finger domain (blue). Fragment C contains residues 400-
939 encompassing the CW-type zinc finger 5 potential SIMs and coiled coil domain (green). 
Fragment D contains residues 460-939 encompassing the coiled coil domain and 5 potential 
SIMs. 
B) Quantification of hybrid chain pull down assay with Morc3 fragments. Pull down assays 
were carried out with 50µl of each resin type and 10 µM of stated MORC3 fragment. Load 
controls represent 20% of total protein incubated with resins. SDS-PAGE gels are 
representative of 3 independent experiments with MORC3 fragment used in pull down stated 
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above and resin type used in pull down below. ImageJ was used to quantify MORC3 fragment 
coomassie stained bands for each resin. Error bars represent SEM. 
            
 
3.2.5	   A	   bioinformatic	   approach	   to	   identifying	   proteins	   with	   the	   potential	   to	  
interact	  with	  SUMO-­‐ubiquitin	  hybrid	  chains	  
 
As the SUMO interacting motifs (SIM) and a variety of ubiquitin binding 
domains, including the ubiquitin interacting motif (UIM) are small definable 
sequence specific motifs, it was postulated that by identifying proteins 
carrying both SIMs and UIMs, it could be possible to identify proteins with the 
ability to interact with SUMO-ubiquitin hybrid chains. 
 
 UIMs are thought to be general ubiquitin binding motifs and due to the 
presence of a duplet of UIMs found in RAP80 (Hofamnn & Falquet 2001, 
Sobhian et al., 2007), all human proteins known to contain UIMs were 
searched for SIMs.  A list containing all human proteins thought to contain 
UIMs corresponding to “L-x-x-A-x-x-L-S-x-x-Ac”, where “Ac” is an acidic 
residue, was obtained from Hofamnn & Falquet 2001 deposited at 
smart.embl.de.  This list contains around 90 human proteins.  The sequence 
data for each of these proteins was gained from UNiProt before each 
sequence was searched for the presence of potential SIM domains.  The SIM 
domain searches were carried out using the PATTINPROT web tool at 
http://perso.ibcp.fr/gilbert.deleage/Cours/BIOINFO_NPS@_pattinprot.html. 
Canonical SIMs were searched for using the pattern values “[VILFY]-[VILFY]-
x-[VILFY]” or “[VILFY]-x-[VILFY]-[VILFY]”, were x corresponds to any amino 
acid.  Search similarity criteria was set to; no mismatch=100%, this allowed no 
sequence to be reported that deviated form the queried sequence.  All 
reported SIMs were then checked by eye for other sequence assets 
associated with SIM domains such as patches of negatively charged amino 
acids immediately up or down stream of the SIM domains or the presence of 
phosphorylated serine residues near the motif.  Any SIM domains that met 
these criteria were then recorded.  PATTINPROT was also used to query the 
UIM containing protein list for high fidelity SIM type.  High fidelity SIMs were 
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searched for using the pattern value [VILFY]-[VI]-D-L-T or T-L-D-[VI]-[VILFY], 
search similarity criteria was again set to; no mismatch=100%.  From the list 
of UIM containing proteins only two proteins gave positive hits when searched 
for the high fidelity SIM type, USP25 and USP28 (Figure 3.1.12 B).  USP25, 
a ubiquitin protease, belonging to the USP subfamily has previously been 
reported to contain two high fidelity SIM domains and a doublet array of UIMs 
(Meulmeester et al., 2008, Demuc et al 2009).  However these SIM domains 
are reported to be involved in the recruitment of a Ubc9-SUMO thioester and 
subsequent SUMOylation of a lysine situated within the UIM domains of 
USP25, impairing its non-covalent interaction to poly-ubiquitin and decreasing 
its deubiquitinase activity (Meulmeeester et al 2008).  Therefore, it is unlikely 
that the SIM and UIM domains of USP25 would be involved in interacting with 
hybrid chains of SUMO and ubiquitin.  USP28, a protease closely related to 
USP25, possesses one high fidelity SIM and one UIM in a tandem domain 
within its N-terminal region (Figure 3.1.12 A, lower).  USP28 has previously 
been implicated in the DNA damage response and is known to be an 
interacting partner of 53BP1, making USP28 an appealing target for further 
study (Zang et al., 2006, Popov et al., 2007).  As such, full length USP28 was 
expressed and purified.  The deubiquitinase activity of USP28 was then tested 
against recombinant K63-linked pUb, K48-linked tri Ub, and Ub-4xSUMO2. 
USP28 efficiently reduced K63-linked pUb and K48-linked tri Ub to mono-
ubiquitin after 120 minutes at concentrations of 1 µM and above.  Interestingly 
in the context of SUMO-ubiquitin hybrid chains, USP28 was able to remove 
the ubiquitin moiety from Ub-4xSUMO2 at concentrations of 1 µM and above 
(Figure 3.1.12, C right hand panel).  USP28 therefore has the potential to 
both interact with SUMO ubiquitin hybrid chains and act to remove the 
ubiquitin moiety from the hybrid chain via its deubiquitinase activity.  
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Figure 3.2-12 Identifying potential hybrid chain interacting proteins using primary 
sequence data. 
A) Experimental flow diagram. List of UIM containing proteins from smart.embl.de 
subsequently search for SIM regions via primary sequence search tool PATTINprot. 
Candidates were then inspected by eye before being taken forward for experimental work. 
B) List comprises UIM containing human proteins found to also contain a minimum of one 
viable SIM domain. Number of ticks represents number of either know UIMs, or potential and 
viable SIMs, or known SIM domains 
C) USP28 deubiquination assay. Concentration of USP28 [0-5 µM] shows deubiquitase 
activity against 10 µM; K63 linked poly ubiquitin (K63), K48 linked poly ubiquitin (K48), and 
mono ubiquitylated poly SUMO (Ub-4xSUMO2) 
            
 
The potential high fidelity SIM and UIM domains located within the N-terminal 
of USP28 were then investigated to determine whether they could facilitate an 
interaction between USP28 and SUMO-ubiquitin hybrid chains.  Three N-
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terminal variants of USP28 were generated; SIM UIM which contained the 
putative high fidelity SIM and UIM domains, SIM ΔUIM containing only the 
high fidelity SIM, and MutSIM UIM that contained a mutated SIM and wild type 
UIM (Figure 3.2-13 A).  These N-terminal fragments of USP28 were then 
tested in pull-down assays with the K63 pUb, 4xSUMO2, Ub-4xSUMO2, and 
pUb-4xSUMO2 resins to identify the affinity of each fragment to poly SUMO, 
poly-ubiquitin and SUMO-ubiquitin hybrid chains.  The SIM UIM fragment 
shows affinity for both the 4xSUMO2 and K63 pUb, but shows higher affinity 
for the hybrid chain type resins Ub-4xSUMO2 and pUb-4xSUMO2.  The SIM 
ΔUIM fragment shows affinity for the SUMO containing resin types 4xSUMO2, 
Ub-4xSUMO2, and pUb-4XSUMO2.  A small amount of SIM ΔUIM was 
present in the eluate from the K63 pUb resin.  The ΔSIM UIM fragment 
showed affinity for the ubiquitin containing resin types, K63 pUb, Ub-
4xSUMO2, and pUb-4xSUMO2.  Thus the SIM UIM tandem domain of USP28 
appeared to have the potential to interact non-covalently with SUMO via the 
high fidelity SIM domain and with ubiquitin via the UIM domain and thus with 
SUMO-ubiquitin hybrid chains. 
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Figure 3.2-13 N-terminally located SIM UIM domains of USP28 show affinity for SUMO 
and ubiquitin. 
A) Schematic diagram of USP28 showing the wild type SIM UIM N-terminal residues 1-150 
including wt SIM and UIM domains (top); SIM ΔUIM fragment residues 1-100 (middle); and 
MutSIM UIM residues 1-150 with SIM domain mutated from VIDLT to AAAAT (bottom). 
B) Quantification of USP28 N-terminal fragment in pull down assay SDS-PAGE analysis. 
            
 
However during further investigation of USP28, several papers were 
published suggesting that in a similar fashion to the SIM domains of USP25, 
the SIM domain of USP28 acted in the recruitment of the SUMO-Ubc9 
thioester resulting in the SUMOylation of a lysine residue near the UIM of 
USP28, impairing the non-covalent interaction with ubiquitin (Knobel et al., 
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2014, Zhen et al., 2014).  A further UBA domain in the N-terminal of USP28 
was also confirmed, and although USP28 is recruited to sites of DNA damage 
it seemingly plays only a minor role in any response to the damage (Wu et al., 
2013, Knobel et al., 2014).  As such, study of USP28 and any interaction with 
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3.3	  Discussion	  	  
Post-translational modification by the Ubl family members SUMO and 
ubiquitin are critically important for many cellular processes.  Once thought to 
be distinct pathways, it has now become clear through the action of STUbLs 
such as RNF4 that a direct interaction exists between the SUMOylation and 
ubiquitylation systems.  This is most clearly apparent during the arsenic-
induced degradation of PML where by the critical action of RNF4 results in the 
decoration of target proteins with SUMO-ubiquitin hybrid chains (Tatham et 
al., 2008).  Identifying proteins that interact with these hybrid chains will help 
to elucidate the biological role these chains play in the cell.  Recently 
published literature suggests that proteins such as RAP80 can bind with high 
affinity to SUMO-ubiquitin hybrid chains.  Here for the first time an affinity 
chromatography coupled to mass spectrometry based approach is utilized to 
elucidate novel protein interactions with SUMO-ubiquitin hybrid chains. 
3.3.1	  Generating	  SUMO-­‐ubiquitin	  hybrid	  chains	  	  
Firstly, hybrid chains of SUMO and ubiquitin had to be created.  Two 
distinct types of hybrid chains were designed with the known action of the 
STUbL RNF4 taken into consideration.  A poly-SUMO chain with a single N-
terminal ubiquitin modification and a second hybrid chain type consisting of 
poly SUMO N-terminally modified with ubiquitin that was subsequently poly-
ubiquitylated with K63 linked ubiquitin chains.   As the STUbL RNF4 contains 
4 SIMs, both hybrid chain types contained a poly-SUMO moiety comprised of 
four SUMO2 proteins.  These four SUMO2 moieties have been shown to 
recruit and activate RNF4 in vivo (Tatham et al., 2008, Rojas-Fernandez et 
al., 2014).  In this case, the four SUMO2 moieties were expressed as a single 
linear head-to-tail fusion protein.  This allowed the poly-SUMO portion of each 
of the three poly-SUMO containing resins to be standardized and produced 
quickly, while still retaining the ability to interact with RNF4 (Figure 3.2-2).  
Hybrid chains of poly-SUMO and poly-ubiquitin could theoretically be made 
from any number of possible SUMO and ubiquitin linkages, allowing a vast 
number of variants of hybrid chain types to exist (see 3.1.2).  Recent evidence 
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suggests that the ubiquitin E2 conjugating enzyme Ube2W can act to N-
terminally mono-ubiquitylate SUMO2 (Tatham et al., 2013).  This can act as a 
primer for poly-ubiquitylation of SUMO chains by RNF4 in conjunction with 
other ubiquitin E2 conjugating enzymes.  Currently no receptors are known for 
this N-terminally modified type of SUMO-ubiquitin hybrid chain.  K63 linked 
poly-ubiquitin was chosen as the poly-ubiquitin element of the poly-SUMO 
poly-ubiquitin hybrid chain due to the known role of K63 linked poly-ubiquitin 
in signalling DNA repair pathway and as a recent evidence from our lab 
suggests depletion of RNF4 in cells results in a significant decrease in the 
K63 linked poly-ubiquitin chains present at the sites of DNA damage (Yin et 
al., 2012).  Having both hybrid chain types allowed a differentiation to be 
made between proteins that preferentially interact with N-terminally 
ubiquitylated poly-SUMO such as TULP4 or proteins that require poly-
ubiquitylated poly-SUMO such as RAP80 (Figure 3.2-7, C).  
 
Although the number of theoretical SUMO-ubiquitin hybrid chain types 
is large, the hybrid chain types used in this experiment are relevant in the 
context of the known action of the STUbL RNF4 and proved capable of 
elucidating a number of novel targets for SUMO-ubiquitin hybrid chain 
interacting proteins. 
 
3.3.2	  USP2	  CaD/SENP1	  specific	  elution	  	  
A specific elution step was also investigated to help reduce elution 
complexity and improve protein specificity identification.  The elution based 
around sequentially adding ubiquitin and SUMO proteases, USP2 CAD and 
SENP1 respectively, allows the hybrid chains to be disassembled in manner 
that allows proteins interacting with the ubiquitin element of the hybrid chains 
to be separated from the SUMO interacting proteins of the hybrid chains.  A 
final denaturing elution with SDS/LDS sample buffer acts as the final step of 
the elution process removing any proteins still bound to the partially or 
undigested hybrid chains.  This elution protocol is effective in giving 
information about the potential binding affinities of some proteins bound to the 
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hybrid chains.  For example in the case of C5orf25, the USP2 CaD elution 
suggested that the ubiquitin moieties of the SUMO-ubiquitin hybrid chain 
containing Ub-4xSUMO2 and pUb-4xSUMO2 resins were contributing to the 
affinity C5orf25 showed toward those resin types.  C5orf25 was released from 
those resins after USP2 CaD elution but not from the SUMO only containing 
4xSUMO2 resin (Figure 3.2-9).  This USP2 Cad elution data along with the 
far greater intensity of C5orf25 found in the eluate from the pUb-4xSUMO2 
resin suggested that C5orf25 was indeed interacting with both the SUMO and 
ubiquitin elements of the hybrid chains.  However, additional information could 
not always be gathered via the specific elution as can be seen for RNF168, 
where RNF168 is only detected in significant amounts after the denaturing 
elution step from the pUb-4xSUMO2 resin (Figure 3.2-9).  This is could be 
due to RNF168 and other proteins binding tightly to the hybrid chains blocking 
USP2 CAD and SENP1 from degrading the hybrid chains. 	  
3.3.3	   An	   assessment	   of	   the	   approach	   to	   detect	   SUMO-­‐ubiquitin	   hybrid	   chain	  
interacting	   proteins	   via	   affinity	   baits	   coupled	   with	   high	   resolution	   mass	  
spectrometry.	  	  	  
Of the 2197 proteins identified by mass spectrometry after the SUMO-
ubiquitin hybrid chain pull down assay, 30 were characterised as showing 
specificity for SUMO-ubiquitin hybrid chains with the remaining 122 proteins 
observed to show a specific affinity for K63 linked poly-ubiquitin or poly-
SUMO.  RAP80 was identified as expected as a SUMO-ubiquitin hybrid chain 
interacting protein along with five other members of the BRCA 1A complex 
(Figure 3.2-8) (Guzzo et al., 2012).  This suggests that these proteins may 
have been pulled down as a complex.  Other known members of the BRCA 
1A complex such as Abraxas, BRCC36 and BRE are predicted to also have 
SIMs domains as well as UBDs, so it is very possible that these proteins act 
together with RAP80 to establish an interaction between the BRCA 1A 
complex and SUMO-ubiquitin hybrid chains (Figure 3.2-8).  It may also be 
possible that members of the BRCA 1A complex are themselves modified by 
hybrid chains of SUMO and ubiquitin which then in turn aids the formation and 
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association of the BRCA 1A complex at the sites of DNA damage.  Of the 
remaining interesting candidate proteins three were taken for further validation 
RNF168, C5orf25 and MORC3.  
 
The ubiquitin E3 ligase RNF168 has previously been shown to have a 
role in the DNA damage response recruiting repair proteins to the sites of 
double strand breaks (Doli et al., 2009; Pinato et al., 2009; Mattiroli et al., 
2012).  It is thought the RNF168 is recruited to DNA damage by binding to 
K63 linked poly-ubiquitylated histones via three UBDs- 1UIM and 2 MIUs 
(Pinato et al., 2009).  The action of RNF168 and another RING type ubiquitin 
E3 ligase, RNF8, is then thought to act to recruit other DDR proteins to the 
site of damage including RAP80 (Mattiroli et al., 2012).  Sequence searches 
suggest four potential SIMs in RNF168, with two of these SIMs being located 
proximal to the second UIM of RNF168.  RNF168 interaction with poly-SUMO 
poly-ubiquitin hybrid chains was backed up with data from recombinant 
RNF168 tested in the SUMO-ubiquitin hybrid chain pull down assay (Figure 
3.2-9, H).  In accordance with the data analysed from the mass spectrometry 
experiment, the recombinant RNF168 protein was also found predominantly in 
the elution from the pUb-4xSUMO2 resin type.  In agreement with the current 
literature recombinant RNF168 also appeared in the eluate from the poly-
ubiquitin only, K63 pUb resin type (Doli et al., 2009).  Taking the literature and 
the data presented here into account, RNF168 appears to have the potential 
to interact with SUMO-ubiquitin hybrid chains.  However, further validation of 
the specific domains related to this apparent affinity for hybrid chains would 
be required. RNF4 is known to be present at the sites of DNA damage, so it is 
possible that RNF168 could be recruited to these sites through the formation 
of RNF4-dependent SUMO-ubiquitin hybrid chains. 
 
C5orf25 is suggested to have a role as a regulatory scaffold for the 
skeletal muscle-specific calpain, CAPN3 (Ono et al., 2013) but is not known to 
have any biological role involving SUMO or ubiquitin.  C5orf25 contains two 
N-terminally located high fidelity type SIM domains (Hunter & Sun 2012).  
Unsurprisingly C5orf25 shows evidence of an interaction with poly-SUMO in 
the mass spectrometry data as it is found in the eluate from all of the poly-
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SUMO containing resin types; 4xSUMO-2, Ub-4xSUMO-2 and pUb-4xSUMO-
2.  However, the greatest intensity of C5orf25 is found in the eluates from the 
pUb-4xSUMO2 resin.  The USP2 CAD elution suggests that C5orf25 may 
interact with ubiquitin.  This is also backed up by the data from testing the 
[35S] Methonine labelled recombinant C5orf25 in the SUMO-ubiquitin hybrid 
chain pull-down assay.  The bands present after elution from both hybrid 
chain types, Ub-4xSUMO-2 and pUb-4xSUMO-2 are more prominent than for 
4xSUMO-2 alone suggesting that more C5orf25 bound the hybrid chains 
(Figure 3.2-9).  Unlike RNF168, C5orf25 does not contain a defined ubiquitin 
binding domain.  However, the presence of two high fidelity SIM domains and 
the data presented here suggest that C5orf25 may be a SUMO-ubiquitin 
hybrid chain interacting protein. 
 
MORC3 was identified as a putative poly-SUMO poly-ubiquitin 
interacting protein in the mass spectrometry analysis.  This apparent affinity 
for poly-SUMO poly-ubiquitin hybrid chains was also seen with recombinant 
MORC3 tested in the SUMO-ubiquitin hybrid chain pull-down assay.  MORC3 
belongs to a family of CW-type zinc finger containing proteins.  Interestingly, 
MORC4, another member of this family was also identified as a potential 
hybrid chain binder by the mass spectrometry data.  MORC3 and MORC4 
share 34% sequence identity (Alignment using UniProt align, data not shown), 
showing large amounts of homology in the N-terminal regions of each protein.  
However, when MORC3 N-terminal fragments (Figure 3.2-11, B, MORC3 A 
& B) were tested in the SUMO-ubiquitin hybrid chain pull-down assay, the 
apparent affinity for the poly-SUMO poly-ubiquitin hybrid chain type shown 
with the full length protein was not apparent.  This suggests that although 
MORC3 and MORC4 both appear to interact with hybrid chains of SUMO and 
ubiquitin, any discrete domain facilitating this apparent affinity is not located in 
the shared N-terminal regions of these proteins.  The affinity for SUMO-
ubiquitin hybrid chains does not appear to be generated by the shared CW-
type zinc fingers of these proteins as removing the zinc finger from either the 
N-terminal fragment or the C-terminal fragment (Figure 3.2-11, B, comparing 
Fragment A to B and C to D) does not affect the affinity of MORC3 for any of 
the resin types used in the SUMO-ubiquitin hybrid chain pull-down assay.  
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This leads to the conclusion that the apparent affinity MORC3 shows for 
SUMO-ubiquitin hybrid chains does not appear to be facilitated by a discrete 
sequence domain of MORC3, but this affinity may be facilitated by folding of 
the full length protein.  	  
3.3.4	   An	   assessment	   of	   the	   approach	   to	   detect	   SUMO-­‐ubiquitin	   hybrid	   chain	  
interacting	  proteins	  via	  primary	  sequence	  searches	  	  
 
The strategy for identifying SUMO-ubiquitin hybrid chain interacting 
proteins via primary sequence searches involved taking a list of already 
identified UIM containing proteins and searching the sequences of these 
proteins for SIM domains using the online PATTINPROT search tool.  To 
some extent this was successful, with 17 proteins previously identified to 
contain UIM domains also identified as containing SIM domains.  Interestingly, 
RNF168, HUWE1, EPN1, EPN2, EPS15L1 and RAP80 were identified in both 
the list generated by the SUMO-ubiquitin hybrid chain pull down assay and by 
primary sequence searches.  This adds confidence to the results gained from 
the mass spectrometry analysis of the SUMO-ubiquitin hybrid chain pull-down 
assay.  USP28, a ubiquitin protease known to contain one UIM domain was 
shown also to contain one high fidelity type SIM domain.  Interestingly the 
UIM and SIM domains were located in tandem, similar to the tandem SIM 
UIMUIM domain of RAP80.  The N-terminal domain of USP28 containing the 
SIM and UIM showed the highest affinity for both SUMO-ubiquitin hybrid chain 
containing resin types, however, it also showed affinity for the poly-SUMO 
only resin type and the poly-ubiquitin only resin type.  Primary sequence 
searches allowed proteins containing both ubiquitin binding domains and 
SIMs to be identified.  However, care must be taken when exploring whether 
these proteins are indeed bona fide SUMO-ubiquitin hybrid chain interacting 
proteins.  In the case of USP28, although proteins can contain both SUMO 
interacting and ubiquitin interacting sequence elements, this does not 
necessarily mean that the biological function of these sequence domains is to 
interact with SUMO-ubiquitin hybrid chains.  
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3.3.5	  Conclusions	  
	  	   The strategies set out above have successfully identified a group of 
proteins with the potential to interact specifically with hybrid chains of SUMO 
and ubiquitin.  A pull-down assay utilising hybrid chains of SUMO and 
ubiquitin was developed to allow for proteins to be identified that showed 
affinity specifically for SUMO, ubiquitin or SUMO-ubiquitin hybrid chains 
(Figures 3.2-5 & 3.2-6).  The hybrid chain pull-down assay coupled with high-
resolution mass spectrometry identified 30 proteins with specific affinity for 
SUMO-ubiquitin hybrid chains (Figure 3.2-7).  A number of interesting 
candidates were taken for further investigation.  Recombinant C5orf25 
(Figure 3.2-9, A-D), RNF168 (Figure 3.2-9, E-F), and MORC3 (Figure 3.2-
10) all showed similar affinity for SUMO-ubiquitin hybrid chains observed in 
the mass spec data.  This gives credence to the hypothesis that SUMO-
ubiquitin hybrid chains could form a new class of PTM; merging both the 
SUMO and ubiquitin modification systems.  Further work is required however 
define the domains responsible for the apparent interactions of C5orf25 and 
MORC3 for SUMO-ubiquitin hybrid chains.  The affinity of RNF168 for hybrid 
chains of SUMO and ubiquitin is hypothesised to be due to the presence of a 
tandem SIMSIM MIU domain located near the N-terminal region of the 
protein.  Again further mutational studies will be required to show the 
importance of this SIMSM MIU domain in the context of RNF168 and SUMO-
ubiquitin hybrid chains.  The BRCA 1A complex component RAP80, a protein 
previously observed to have the potential to interact with hybrid chains of 
SUMO and ubiquitin (Guzzo et al., 2012) was identified in both the SUMO-
ubiquitin hybrid chain pull-down assay (Figures 3.2-7 & 3.2-8) and the list of 
protein known to contain UIMs that also contain SIMs (Figure 3.2-13, B) 
making it the primary candidate for a bona fide SUMO-ubiquitin hybrid chains 
interacting protein.  As such it shows great potential for further study to 
elucidate a potential biological role for SUMO-ubiquitin hybrid chains.   
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4	   Exploring	   a	   role	   for	   SUMO-­‐ubiquitin	   hybrid	   chains	   in	   the	  
recruitment	  of	  RAP80	  to	  the	  sites	  of	  DNA	  repair	  	  
4.1	  Introduction	  
 
Identifying a number of proteins that showed affinity for hybrid chains of 
SUMO and ubiquitin is very interesting but without biological context it is hard 
to determine whether or not SUMO-ubiquitin hybrid chains and proteins 
capable of recognising said chains are relevant signalling/receptor 
mechanisms within the cell. 
4.1.1	  DNA	  damage	  response,	  RAP80	  and	  the	  BRCA	  1A	  complex	  	  
DNA lesions are highly toxic if not properly recognised and repaired. 
The presence of one unrepaired DNA double strand break (DSB) is sufficient 
to cause cell death or cancer (Jackson & Bartek 2009).  Eukaryotic cells have 
developed a complex set of signalling cascades involving activation of cell 
cycle check points and recruitment of factors involved in the recognition, 
signalling, and repairing of DNA to the sites of damage, known collectively as 
the DNA damage response (DDR) (Jackson & Bartek 2009).  DNA can be 
damaged in multiple ways and thus multiple systems are in place to repair 
these different types of DNA lesions, DSBs are the most cytotoxic of all DNA 
lesions.  DNA DSBs initiate a signalling cascade mediated by one of the 
master DNA damage signalling protein kinases ataxia telangiectasia mutated 
(ATM) after recognition by the MRE11-RAD50-NSB1 (MRN) complex (Maser 
et al., 1997; Falck et al., 2005) (Figure 4.1-1).  This results in repair of the 
DSBs by homologous recombination (HR) or non-homologous end joining 
(NHEJ) (Lundin et al., 2002).  HR is an error-free process utilising 
homologous sequence from sister chromatids to repair breaks.  Due to the 
requirement for sister chromatid sequence homology, HR can only function 
during the S and G2 phases of the cell cycle- after replication has occurred. 
NHEJ is an error-prone process but does not require sister chromatid 
sequence homology and thus is not restricted to specific cell cycle phases 
(Lundin et al., 2002). 
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Figure 4.1-1 The DNA damage response to DSBs. 
After a DSB, Histone H2Ax replaces the canonical H2A at the site of damage. The MRN 
complex is recruited which in turn recruits ATM. ATM phosphorylates (P) and recruits MDC1 
to the sites of damage. MDC1 is also SUMOylated at the sites of damage. The 
phosphorylation of MDC1 then engages RNF8. RNF8 is then thought to catalyse the mono-
ubiquitylation of targets near the site of damage. This mono-ubiquitylation then recruits 
RNF168 resulting in the poly-ubiquitylation of targets at the sites of damage. BRCA and 
53BP1 are then recruited to the DSB, initiating either the HR or NHEJ DNA repair pathways.   
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The decision between HR and NHEJ is mediated essentially by the 
recruitment of two important factors BRCA1 and 53BP1 (Figure 4.1-1) (Noon 
& Goodarzi 2011; Li & Greenberg 2012).  BRCA1 and 53BP1 are thought to 
perform opposing functions with respect to DNA end resection, which is vital 
for HR. 53BP1 acts to restrict DNA end resection and thus promotes repair by 
NHEJ (Noon & Goodarzi 2011), whereas BRCA1, through mechanisms that 
are not full understood initiates DNA end resection (Li & Greenberg 2012). 
After DNA end resection has been initiated NHEJ is suppressed and DSBs 
are repaired via HR (Chapman et al., 2012).  
 
BRCA1 is a known component of multiple protein complexes (Yu et al., 
1998; Cantor et al., 2001; Wang et al., 2007).  During the activation of HR the 
BRCA 1A complex is thought to be located at the sites of damage (Wang et 
al., 2007).  The BRCA 1A complex is composed of at least Abraxas, BRCC36, 
BRE, Merit40 and RAP80 (Wang et al., 2007).  Initially a key finding was that 
RAP80 mediated the association of the BRCA 1A complex with sites of DNA 
damage, by recognising and binding to K63 linked poly-ubiquitin chains that 
were thought to be anchored on K119 of phosphorylated histone H2Ax 
(phosphorylated at S139, commonly referred to as yH2Ax (Burma et al., 
2001)) which marks sites of DNA damage (Sobhian et al., 2007;Wu et al., 
2007).  This is because the double UIM containing N-terminal region of 
RAP80 was initially observed to be required for the correct association and 
retention of BRCA1 at the sites of DSBs (Sobhian et al., 2007).  This key 
finding and others that followed helped to cement the role of ubiquitylation in 
DDR.  
4.1.2	  SUMO,	  ubiquitin	  and	  the	  DNA	  damage	  response	  
 
Around the time that K63 linked poly-ubiquitin was identified as an 
important factor in the recruitment of BRCA1 to the sites of DSBs, two RING 
containing ubiquitin E3 ligases were identified as key factors in the DDR, 
RNF8 and RNF168 (Wang & Elledge 2007).  RNF8 and RNF168 work in 
tandem with the ubiquitin E2 conjugating enzyme Ubc13 and together act to 
catalyse the addition of K63 linked poly-ubiquitin chains to histones and most 
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probably other proteins involved in the DDR (Stewart et al., 2009; Doil et al., 
2009).  RNF8 recruitment to the sites of DSBs is facilitated by an interaction 
with phosphorylated MDC1.  MDC1 is recruited to site of DNA damage by the 
presence of yH2Ax and is then phosphorylated by ATM (Figure 4.1-1) (Stucki 
et al., 2005).  RNF8 acts to catalyse the mono-ubiquitylation of substrate 
proteins.  This mono-ubiquitin mark is then recognised and modified on K63 
by RNF168 resulting in the generation of K63 linked poly-ubiquitin, 
interestingly RNF168 may act as a negative regulator in the RNF8 response 
and thereby acting to limit excessive K63 linked poly-ubiquitin signalling 
(Gudjonsson et al., 2012).  Initially, It was this K63 linked poly-ubiquitin signal 
that was thought to be the primary recruitment mechanism for other DDR 
proteins including 53BP1, RAP80, and thus the BRCA 1A complex to sites of 
DNA damage (Lukas et al., 2011).  However more recent evidence has 
suggested a role of the STUbL RNF4 at the sites of DNA damage and 
importantly to the recruitment of the BRCA 1A complex to the sites of DNA 
damage via a RAP80 mediated interaction with SUMO-ubiquitin hybrid chains, 
suggesting SUMO plays a key role in the DDR (Figure 4.1-2) (Guzzo et al., 
2012).  
 
This was not the first observation of SUMO in the DDR however. 
SUMO was identified to have a role in the DDR in with the observation that in 
the yeast S. cerevisiae Rad52 is SUMOylated (Torres-Rosell et al., 2007). 
Rad52 is an important factor in DNA repair, promoting the annealing of 
complementary single stranded DNA.  The SUMOylation of Rad52 was 
dependent on Ubc9 and the E3 Siz2, a protein highly related to the human 
PIAS protein family. SUMOylation ablates the activity of Rad52 by functioning 
to exclude it from the nucleus (Torres-Rosell et al., 2007).  All mammalian 
SUMO isoforms have been observed at DSBs along with Ubc9 and the PIAS 
SUMO E3 ligases (Galanty et al., 2009; Morris et al., 2009).  SUMO, PIAS1 
and PIAS4 clearly have critical roles in the signalling of repair proteins at 
these sites.  Knockdown of either PIAS1 or PIAS4 impairs both HR and NHEJ 
by decreasing the levels of RNF168, 53BP1 and BRCA1 at these lesions, 
thus impairing DNA repair (Morris et al., 2009).  Interestingly, knockdown of 
RNF8 and RNF168 does not inhibit the accumulation of PIAS1 and PIAS4 to 
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sites of damage.  SUMO levels were reduced but not ablated, suggesting that 
DDR factors recruited to DSBs both prior and post RNF8/RNF168 activity can 
be SUMOylated.  
4.1.3	  SUMO-­‐ubiquitin	  hybrid	  chains	  at	  the	  sites	  of	  DNA	  damage	  
 
STUbLs were first connected to the DDR with the still not fully 
understood observation that HR in S. cerevisiae is regulated by the 
heterdimeric Slx5-Slx8 (Yang et al., 2006; Uzunova et al., 2007).  A hand full 
of complementary papers were more recently published on the role of the 
human STUbL RNF4 in HR suggesting its recruitment to DSBs was facilitated 
by the SUMOylation of key DDR proteins including MDC1 (Galanty et al., 
2012; Luo et al., 2012; Yin et al., 2012).  The partial knock down of RNF4 
resulted in a decrease in the presence of K63 linked poly-ubiquitin at DSBs 
(Yin et al., 2012).  These observations are in line with the model suggested by 
Guzzo and colleagues for RNF4-dependent SUMO-ubiquitin hybrid chain 
recruitment of RAP80 to the sites of DSBs (Guzzo et al., 2012), whereby, 
RNF4-generated K63 linked poly-ubiquitylated SUMO is required for the 
recruitment of the BRCA 1A complex, mediated by the tandem SIM UIMUIM 
domain of RAP80, to the sites of DNA damage (Figure 4.1-2).  If knocking 
down RNF4 lowers the levels of K63 linked poly-ubiquitin (Yin et al., 2012), 
and thus then SUMO2 modified by K63 linked poly-ubiquitin at the sites of 
DNA damage this could explain why the BRCA 1A complex and thus BRCA1 
is not recruited to the sites of DNA damage under these conditions (Guzzo et 
al., 2012).  Although ubiquitylated SUMO has been observed in cells 
(Tammsalu et al., 2014) and clearly a level of cooperativity exists between the 
SUMO and ubiquitin conjugation pathways in the DDR, with multiple 
substrates for each pathway known, its is unclear whether this cooperativity 
extends to any type of SUMO-ubiquitin hybrid chains forming at the sites of 
DSBs.  No potential substrates have yet been identified to anchor SUMO-
ubiquitin hybrid chains at the sites of DSBs.  However, yH2Ax is the primary 
candidate for RAP80 recruitment to sites of damage via the poly-ubiquitylation 
of K119.  It is interesting to note that recently SUMO2 has also been observed 
to modify K119 of histone H2Ax leaving open the possibility that Histone H2Ax 
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could anchor a SUMO-ubiquitin hybrid chain, but it is important to note that 
this observation was made not under specific genotoxic stress but after heat 
shock (Tammsalu et al., 2014).  
 
	  
Figure 4.1-2 RNF4-dependent RAP80 mediated recruitment of BRCA1. 
After the DDR to a DSB has been initiated, an as yet unidentified target protein at the site of 
the DSB is SUMOylated. This SUMOylated target substrate is then targeted by the STUbL 
RNF4 resulting in the K63 linked poly-ubiquitylation of the previously SUMOylated substrate. 
This SUMO-ubiquitin hybrid chain is then recognised by the BRCA 1A complex component 
RAP80. RAP80 then mediates the recruitment of BRCA1 (Guzzo et al., 2012). 
            
 
Clearly the roles of SUMO and ubiquitin in the DDR are very complex 
and not yet fully understood.  SUMO-ubiquitin hybrid chains acting as a 
signalling mechanism at the sites of DSBs is a compelling idea.  Firstly, the 
specificity that a hybrid SUMO-ubiquitin signal would impose on the system 
could regulate a very specific response at these sites.  Secondly, RNF4 and 
other essential enzymes from both the ubiquitylation and SUMOylation 
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pathways required to form such signals are known to be prevalent at these 
sites (Wang & Elledge 2007; Galanty et al., 2009; Morris et al., 2009; Galanty 
et al., 2012; Luo et al., 2012; Yin et al., 2012).  As RAP80 has been observed 
previously to have affinity for hybrid chains (see Figure 3.2-7), and as RNF4 
may have a role in the recruitment of the BRCA 1A complex to the sites of 
DSBs (Guzzo et al., 2012), the validity of RNF4-dependent SUMO-ubiquitin 
hybrid chain recruitment of RAP80 to the sites of DSBs during the DDR is 
worthy of further exploration.  
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4.2	  Results	  	  
Having identified a number of novel potential SUMO-ubiquitin hybrid 
chain interacting proteins via firstly, the affinity chromatography coupled 
proteomic approach, and secondly, using a primary sequence searching 
based approach, a biological role for SUMO-ubiquitin hybrid chains was then 
investigated.  
4.2.1	   BRCA	   1A	   complex	   component	   RAP80	   shows	   an	   association	   for	   SUMO	   and	  
ubiquitin	  in	  a	  cellular	  context	  	  
The mechanism by which the BRCA 1A complex is recruited to sites of 
DNA repair has been previously covered in the literature (Sobhian et al., 
2007; Wang et al., 2007), however the exact mechanism by which RAP80 
targets the BRCA 1A complex to sites of DNA repair is still under 
investigation.  Here, microscopy and proteomic based approaches were used 
to investigate the potential role, if any, that hybrid chains of SUMO and 
ubiquitin could play in recruiting RAP80 and the BRCA 1A complex to the 
sites of DNA damage. 
 
SUMO, ubiquitin and RAP80 are all known to be present at the sites of 
DNA repair during the DNA damage response (Sobhian et al., 2007; Wang et 
al., 2007; Doil et al., 2009; Morris et al., 2009).  Determining that all three of 
these proteins are present at the same DDR foci at the same time is critical to 
understanding whether SUMO-ubiquitin hybrid chains could play a role in 
recruiting RAP80 to the sites of DNA repair.  RAP80 has previously been 
shown to contain a tandem SIM UIMUIM domain in its N-terminal region 
(Figure 3.1-2) (Guzzo et al., 2012).  RAP80 was identified as a hybrid chain 
interacting protein in the SUMO-ubiquitin hybrid chain pull-down assay 
proteomic screen (Figure 3.2-7).  To determine whether the affinity observed 
between RAP80 and the poly-SUMO poly-ubiquitin hybrid chain type used in 
the proteomic screen was due to the tandem SIM UIMUIM of RAP80 a 
bacterially expressed RAP80 construct consisting of residues 1-150 which 
includes the tandem SIM UIMUIM domain (known as RAP80 SIM UIMUIM) 
was produced.  This construct was then tested in the SUMO-ubiquitin hybrid 
chain pull-down assay to determine whether the SIM UIMUIM domain was 
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facilitating the affinity observed for RAP80 for the poly-SUMO poly-ubiquitin 
hybrid chain type used in the proteomic screen (Figure 4.2-1, A).  As 
expected RAP80 SIM UIMUIM was found to be most abundant in the eluate 
from the poly-SUMO poly-ubiquitin containing pUb-4xSUMO2 resin type. 
Significantly less RAP80 SIM UIMUIM was detected in the eluates from K63 
pUb, 4xSUMO2 and Ub-4xSUMO2 when compared to the eluate from the 
pUb-4xSUMO2 resin type (Figure 4.2-1, B).  To determine whether RAP80 
can interact with SUMO and ubiquitin in vivo, a GFP-RAP80 expressing 
U2OS cell line was obtained and tested to determine whether RAP80 and 
SUMO, or RAP80 and ubiquitin co-localised at the sites of DNA repair. The 
GFP-RAP80 expressing U2OS cells were treated with 4 Gys of IR and 
allowed to recover for 90 minutes prior to fixation with PFA and preparation for 
analysis.  As expected, GFP-RAP80 is present in foci containing the DNA 
damage marker yH2Ax, after IR treatment (Figure 4.2-1, C top panels). 
Interestingly, ubiquitin (Figure 4.2-1, C middle panels) and SUMO (Figure 
4.2-1, C bottom panels) are found to be present in GFP-RAP80 positive foci 
after IR treatment.  
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Figure 4.2-1 RAP80 shows affinity for SUMO and ubiquitin in vitro and in vivo. 
A) SUMO-ubiquitin hybrid chain pull-down assay with recombinant RAP80 tandem SIM 
UIMUIM domain 1-150. Coomassie stained gel. The most prominent RAP80 band is 
associated with the pUb-4xSUMO2 resin type.  Load Control represents 50% of total protein 
incubated with resins. 
B) Quantification of SUMO-ubiquitin hybrid chain pull-down assay with RAP80 tandem SIM 
UIMUIM 1-150 domain. A significantly larger amount of RAP80 tandem SIM UIMUIM was 
found to be present in the eluate of the pUb-4xSUMO2 resin type than; Ub-4xSUMO2 
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(<0.005), 4xSUMO2 (<0.005), or K63 (<0.005) resin types. Experiment was conducted in 
triplicate. Error bars represent standard deviation from the mean.  
C) Microscopy analysis of GFP-RAP80 (full length RAP80) U2OS cells after treatment with 4 
Gys IR and recovery of 90 minutes. GFP-RAP80 is recruited to sites of yH2Ax foci after IR. 
Ubiquitin is associated with GFP-RAP80 foci after IR. SUMO is associated with GFP-RAP80 
after IR. Images are single Z planes. 	   	   	   	   	   	   	   	   	   	   	   	  
  
4.2.2	   A	   proximity	   ligation	   assay	   identifies	   a	   close	   association	   by	   SUMO	   and	  
ubiquitin	  in	  RAP80	  positive	  foci	  after	  DNA	  damage	  
 
Establishing the presence of SUMO and ubiquitin separately in close 
association with GFP-RAP80 positive foci after IR treatment shows the 
potential context for RAP80 to interact with both SUMO and ubiquitin together 
in vivo.  
 
 To establish whether SUMO, ubiquitin, and RAP80 are all closely 
associated together in vivo required a new approach.  The proximity ligation 
assay (PLA) uses antibodies coupled with short oligonucleotides, known as 
proximity probes, to establish whether two proteins are closely associated in a 
protein complex (Figure 4.2-2) (Gullberg et al., 2003). 
	  
Figure 4.2-2 The Proximity Ligation Assay. 
Schematic diagram represents the stages of a proximity ligation assay. Primary antibodies for 
two closely associated proteins are first added. Pairs of oligo-labeled secondary antibodies 
are then added, +/-, which correspond to the primary antibodies. The oligo are then ligated 
together, one + oligo to one – oligo. A rolling circular amplification is then carried out before 
fluorescent hybridization tags are added. Any closely associated proteins, within 40 nm, can 
then be visualized by microscopy.  
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The in situ PLA requires highly specific primary antibodies to firstly recognise 
two proteins that are in close proximity to one another.  A second set of oligo-
labeled secondary antibodies, specific for the primary antibodies are then 
added.  If the two proteins are in close proximity, the addition of a short 
oligonucleotide linker ligates the oligo-labeled secondary antibodies together.  
A rolling circular amplification step is then carried out to create a large piece 
of single stranded DNA.  Hybridisation tags specific for this newly generated 
DNA are then added and any positive PLA signals can be visualised by 
fluorescent microscopy (Figure 4.2-2).  In this way only proteins that are 
closely associated, less than 40 nm, can generate a positive PLA signal.  
Commercially available specific antibodies have been raised against RAP80 
(rabbit, Bethyl), SUMO (rabbit, Invitrogen; mouse, Hay lab generated), and 
ubiquitin (mouse, Merek), as such; the PLA is a potentially useful assay in the 
exploration of the association between RAP80, SUMO, and ubiquitin. 
 
 Firstly, PLAs were developed to probe the association of RAP80 with 
SUMO2, and RAP80 with ubiquitin (Figure 4.2-3).  GFP-RAP80 expressing 
U2OS cells were treated with 4 Gys of IR and allowed to recover for 90 
minutes.  Cells were then fixed with PFA and prepared for PLA.  Primary 
antibodies against RAP80 (rabbit) and either SUMO2 (mouse) or ubiquitin 
(mouse) were incubated with the fixed and permeabilised GFP-RAP80 U2OS 
cells.  The control reactions contained the primary RAP80 antibody but neither 
SUMO2 or ubiquitin primary antibodies were present.  Secondary oligo-
labeled antibodies that had been raised against rabbit or mouse 
Immunoglobulin were then incubated with the cells.  Ligation and amplification 
steps were carried out in accordance with 2.2.7.3.  When the SUMO2 
antibody was omitted from the RAP80/SUMO2 PLA, no signal was detected 
from the assay (Figure 4.2-3, A upper panels).  When both the RAP80 and 
SUMO2 antibodies were present, positive PLA signals were generated 
(Figure 4.2-3, A lower panels), suggesting that RAP80 and SUMO2 are in 
close proximity after DNA damage.  The positive RAP80/SUMO2 PLA signals 
are shown to co-localize with the GFP-RAP80 foci (Figure 4.2-3, B).  Warm 
colours represent complete co-localization between the PLA signal and GFP-
	   115	  
RAP80 foci.  Cooler colours represent regions where the signals do not co-
localize.  As with the RAP80/SUMO2 PLA, when the ubiquitin antibody is 
omitted from the RAP80/ubiquitin PLA, no signal was detected from the assay 
(Figure 4.2-3, C upper panels).  When both the RAP80 and ubiquitin 
antibodies were present, positive PLA signals were generated (Figure 4.2-3, 
C lower panels).  This suggests again that RAP80 and ubiquitin are in close 
proximity after DNA damage.  Several positive RAP80/ubiquitin PLA signals 
are shown to co-localize with the GFP-RAP80 foci (Figure 4.2-3, D). 
However, in both cases not all GFP-RAP80 positive foci are colocallised with 
positive PLA signals, perhaps suggesting diversity in the response. 
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Figure 4.2-3 A Proximity Ligation Assay to detect SUMO and ubiquitin closely 
associated with RAP80. 
	   117	  
A) Using the PLA assay to investigate the association of RAP80 and SUMO2 after 4Gys IR 
and 90 minute recovery. The top panel experiment omits the primary SUMO2 antibody for the 
PLA procedure as a negative control. Bottom panel experiment contains primary antibodies 
against SUMO2 and RAP80, thus the full compliment of antibodies required for a PLA signal 
to be generated. PLA signals are generated by this combination of antibody suggesting that 
SUMO2 and RAP80 are closely associated.  
B) Quantification of the co-localization map of the PLA signal with GFP-RAP80 was 
performed using the normalized mean deviation product (nMDP) values ranging from -1 to1. 
Negative indexes are represented by cold colours (blue), exclusion, with the indexes greater 
than 0 represented by warm colours (red), co-localization. Images were taken using a 
spinning disk confocal microscope. 
C) Using the PLA assay to investigate the association of RAP80 and ubiquitin after 4Gys IR 
and 90 minute recovery. Top panel experiment omits the primary ubiquitin antibody for the 
PLA procedure as a negative control. No PLA signal is detected. Bottom panel experiment 
contains primary antibodies against ubiquitin and RAP80, thus the full compliment of 
antibodies required for a PLA signal to be generated. PLA signals are generated by this 
combination of antibody suggesting that ubiquitin and RAP80 are closely associated.  
D) Quantification of the co-localization map of the PLA signal with GFP-RAP80 was 
performed using the normalized mean deviation product (nMDP) values ranging from -1 to1. 
Negative indexes are represented by cold colours (blue), exclusion, with the indexes greater 
than 0 represented by warm colours (red), col-localization. Images were taken using a 
spinning disk confocal microscope. 
            
 
 Co-localization between the PLA signals generated by RAP80/SUMO2 
and RAP80/ubiquitin pairs suggests that both SUMO and ubiquitin are not 
only present in RAP80 positive foci but are in close enough proximity to 
RAP80 that a direction interaction could be occurring. 
 
 A PLA was then established to detect a close association between 
SUMO2 and ubiquitin.  SUMO2 (Rabbit) and ubiquitin (Mouse) antibodies 
were used as the primary PLA probes.  Omitting the ubiquitin antibody from 
the SUMO2/ubiquitin PLA resulted in no positive signal being detected from 
the assay (Figure 4.2-4, A upper panels).  When both the SUMO2 and 
ubiquitin antibodies were present, positive PLA signals were generated 
(Figure 4.2-4, A lower panels).  Suggesting again that SUMO2 and ubiquitin 
are in close proximity after DNA damage inducing stimuli.  
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Figure 4.2-4 A Proximity Ligation Assay to detect SUMO-ubiquitin hybrid chains with 
RAP80 in close association. 
A) Using the PLA assay to investigate the association of RAP80 with SUMO-ubiquitin hybrid 
chains after 4Gys IR and 90 minute recovery. Top panel experiment omits the primary 
ubiquitin antibody for the PLA procedure as a negative control. No PLA signal is detected. 
Lower panel experiment contains primary antibodies against SUMO2 and ubiquitin, thus the 
full compliment of antibodies required for a PLA signal to be generated. PLA signals are 
generated by this combination of antibody suggesting that SUMO2 and ubiquitin are closely 
associated.  
B) Quantification of the co-localization map of the PLA signal with GFP-RAP80 was 
performed using the normalized mean deviation product (nMDP) values ranging from -1 to1. 
Negative indexes are represented by cold colours (blue), exclusion, with the indexes greater 
than 0 represented by warm colours (red), col-localization. Images were taken using a 
spinning disk confocal microscope. 
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Interestingly, positive PLA signals generated by this combination of 
SUMO2/ubiquitin antibody were observed to co-localize with GFP-RAP80 foci 
after DNA damage (Figure 4.2-4, B).  This suggests that RAP80, SUMO, and 
ubiquitin are indeed all closely associated in cells at the sites of DNA repair 
after DDR inducing stimulus.  The close association seen by positive PLA 
signals generated by the SUMO2/ubiquitin PLA does not definitively suggest 
SUMO-ubiquitin hybrid chains, however, taken into account with the co-
localisation of this signal with RAP80, a protein shown to have affinity for 
SUMO-ubiquitin hybrid chains, it does suggest that both SUMO and ubiquitin 
have a role with RAP80 at the sites of DNA repair. 
 
 4.2.2	  The	  role	  of	  STUbLs	  in	  the	  recruitment	  RAP80	  to	  sites	  of	  DNA	  repair 
	  
 The SUMO targeted ubiquitin E3 ligase RNF4, has been shown to be 
present at the sites of DNA damage (Galanty et al., 2012; Luo et al., 2012; Yin 
et al., 2012).  Recent work has described how knock out of RNF4 in DT40 
chicken cells, lowers the levels of K63 linked poly-ubiquitin at the sites of DNA 
damage (Yin et al., 2012).  Furthermore, RNF4 is suggested to have a role in 
recruiting BRCA1 to sites of DNA damage (Guzzo et al., 2012).  Due to the 
potential role RNF4 could play in the recruitment of RAP80 to sites of DNA 
repair via the generation of SUMO-ubiquitin hybrid chains, a CRISPR/Cas9 
generated knock out of RNF4 was generated in human colon carcinoma 
HCT116 cells. 
 
 Two ∆RNF4 HCT116 cell lines were gifted by Dr. J-F Maure, coded 
HCT116 ∆RNF4 B3-1, and HCT116 ∆RNF4 C2-2, along with the parental wild 
type HCT116 cell line.  RNF4 was present in the parental wild type HCT116, 
but was absent in both HCT116 ∆RNF4 B3-1 and HCT116 ∆RNF4 C2-2 cell 
lines (Figure 4.2-5, A top left hand panel).  RAP80, yH2Ax, ubiquitin, and 
SUMO protein levels, detectable via the antibodies used, were consistent 
between the wild type HCT116, HCT116 ∆RNF4 B3-1, and HCT116 ∆RNF4 
C2-2 cell lines (Figure 4.2-5, A). 
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Figure 4.2-5 SUMO2 and ubiquitin are recruited to the sites of DNA damage in RNF4 
knock out cells. 
A) Western blot analysis of HCT116 wt, HCT116 ΔRNF4 clone B3-1, and HCT116 ΔRNF4 
clone C2-2. RNF4 is present only in the extracts of the HCT116 wt cells. levels of RAP80, 
yH2Ax, Ubiquitin, and SUMO appear to be consistent between the HCT116 wt, HCT116 
ΔRNF4 clone B3-1, and HCT116 ΔRNF4 clone C2-2 cell lines. Actin western blot is used as 
load control.  
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B) Immunofluorescence microscopy analysis of the HCT116 wt, HCT116 ΔRNF4 clone B3-1, 
and HCT116 ΔRNF4 clone C2-2 cell lines. HCT116 cell were checked for the presence of 
SUMO2 and ubiquitin at sites of DNA repair. After DNA damage was induced by 4 Gys of IR, 
SUMO2 and ubiquitin could be seen to be present at the site of DNA repair in even when 
RNF4 was knocked out.  
            
 
Ubiquitin was present at the sites of DNA repair, shown via DNA damage 
marker, yH2Ax foci after IR in the wild type HCT116 cell line, and was also 
detected in the HCT116 ∆RNF4 B3-1 and HCT116 ∆RNF4 C2-2 cell lines 
(Figure 4.2-5, B upper panels).  As with ubiquitin association, SUMO2 was 
present at the sites of DNA repair, in all three cell lines (Figure 4.2-5, B lower 
panels). 	  
Although both SUMO and ubiquitin are present and seemingly 
unaffected by the lack of RNF4 at the site of DNA damage in the ∆RNF4 
HCT116 cell lines this does not necessarily suggest that RAP80 will still be 
recruited as normal to sites of DNA damage.  Thus, the percentage of RAP80 
positive yH2Ax foci were compared in the wild type HCT116 cells and in the 
HCT116 ∆RNF4 B3-1 and C2-2 cell lines (Figure 4.2-6). 
 
Levels of RAP80 recruitment to yH2Ax foci were then tested in both 
wild type HCT116 cells and the ∆RNF4 HCT116 cell lines.  After IR treatment, 
RAP80 was observed to be present at the sites of DNA damage in wild type 
HCT116 cells after 60 minutes.  Interestingly, RAP80 was also observed to be 
present at the sites of DNA damage in the RNF4 knock out cell line (Figure 
4.2-6, A).  This suggests that RNF4 is not required for RAP80 recruitment to 
the sites of DNA damage.  The observed number of cells with RAP80 positive 
yH2Ax foci in wild type HCT116 was not significantly altered in either the 
HCT116 ∆RNF4 B3-1 or HCT116 ∆RNF4 C2-2 cell lines (Figure 4.2-6, B). 
RAP80 recruitment to sites of DNA damage in HCT116 cells was therefore 
not ablated by the complete knockout of RNF4.  
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Figure 4.2-6 RAP80 is recruited to the sites of DNA damage in RNF4 knock out cells. 
A) Immunofluorescence microscopy analysis of RAP80 at the sites of DNA repair. HCT116 
cell were checked for the presence of RAP80 at sites of DNA repair. After DNA damage was 
induced by 4 Gys of IR, RAP80 could be seen to be present at the site of DNA repair even 
when RNF4 was knocked out. 
B) Quantification of co-locaization between endogenous RAP80 and yH2Ax in wild type 
HCT116, HCT116 ΔRNF4 B3-1, and HCT116 ΔRNF4 C2-2 cell lines. No significant difference 
was observed in percentage of cells containing both RAP80 and yH2Ax foci and possessed 1 
or more RAP80 positive yH2Ax foci from 3 independent experiments n<80 cells counted. 
Error bars represent standard deviation from the mean. 	   	   	   	   	   	   	   	   	   	   	   	  	  
Along with RNF4 another STUbL, RNF111, has been described to be 
present at the sites of DNA damage.  RNF111 contains two high fidelity SIM 
domains in its N-terminal region (Sun & Hunter 2012).  These SIM domains 
have been shown, like RNF4, to be important in the recruitment and E3 
activity of the protein (Poulsen et al., 2013).  Since knocking out RNF4 had no 
observable effect on the recruitment of RAP80 to the sites of DNA damage, 
RNF111 was also knocked down via siRNA to test for a possible role of this 
STUbL in the recruitment of RAP80 to the site of DNA damage. 
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Figure 4.2-7 Knock down of the STUbL RNF111 does not disrupt RAP80 recruitment to 
sites of DNA repair, even in a RNF4 null background.  
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A) Immunofluorescence staining microscopy analysis of endogenous RAP80 recruitment to 
yH2Ax foci under RNF111 knockdown on wild type HCT116, HCT116 ΔRNF4 B3-1, HCT116 
ΔRNF4 C2-2 cell lines. RAP80 is still recruited to site of DNA damage after siRNF111. 
Analyzed after 4 Gys of IR and 60 minute recovery.  
B) Western blot analysis of RNF111 siRNA knockdown. After 62 hours RNF111 was 
efficiently knocked down by a pool of siRNF111 in wild type HCT116, HCT116 ΔRNF4 B3-1, 
HCT116 ΔRNF4 C2-2 cell lines. 
C) Quantification of RAP80 positive foci in ΔRNF4 siRNF111 HCT116 cell lines. No significant 
difference was observed in percentage of cells containing both RAP80 and yH2Ax foci and 
possessed 1 or more RAP80 positive yH2Ax foci. Quantification from 3 independent 
experiments n<80 cells counted. Error bars represent standard deviation from the mean. 	   	   	   	   	   	   	   	   	   	   	   	  	  
RNF111 was effectively knocked down after 62 hours of treatment with siRNA 
for RNF111, While siNT had no effect on the levels of RNF111 in the wild type 
HCT116, HCT116 ∆RNF4 B3-1, or the HCT116 ∆RNF4 C2-2 cell lines 
(Figure 4.2-7, A).  RAP80 was recruited to the sites of DNA repair in the wild 
type HCT116 cells after RNF111 siRNA treatment (Figure 4.2-7, B lower left 
panel), and again RAP80 was recruited to yH2Ax positive foci both the 
ΔRNF4 HCT116 cell lines after siRNA treatment for RNF111 (Figure 4.2-7, B 
lower middle and right panels).  No observable divergence was seen in 
percentage of cells reporting RAP80 positive yH2Ax foci after RNF111 siRNA 
treatment in either wild type HCT116, HCT116 ∆RNF4 B3-1, or HCT116 
∆RNF4 C2-2 (Figure 4.2-7, C).  
 
 Another notable observation made when studying the HCT116 ∆RNF4 
cell lines was the large number of yH2Ax positive foci that were present in 
cells under normal cell culture growth conditions.  Non-treated wild type 
HCT116 cell contained very low number of yH2Ax foci, in most cases less 
than 5.  However, both ΔRNF4 cell lines contained markedly more yH2Ax foci 
under normal growth conditions (Figure 4.2-8, A & B).  Over 50% of the 
HCT116 ∆RNF4 cells that were positive for yH2Ax contained more than 5 
yH2Ax foci.  As both the HCT116 ∆RNF4 B3-1 and HCT116 ∆RNF4 C2-2 cell 
lines appeared to double and grow at a similar rate to the wild type cells, this 
appeared to suggest that the cells containing RNF4 could carry damage more 
easily through the cell cycle.  Each of the three HCT116 cell lines was then 
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prepared for flow cytometry and cell cycle analysis to determine if either the 
HCT116 ∆RNF4 B3-1 or HCT116 ∆RNF4 C2-2 cell lines differed to the wild 
type HCT116 cells in cell cycle composition.  
	  	  
Figure 4.2-8 RNF4 knock out HCT116 cell line show higher levels of endogenous yH2Ax 
foci than wild type HCT116 cells. 
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A) Immunofluorescence microscopy analysis of yH2Ax foci number in wild type HCT116, 
HCT116 ΔRNF4 B3-1, and HCT116 ΔRNF4 C2-2 cells. Under endogenous cell culture 
conditions both HCT116 ΔRNF4 cell lines present with a higher number of yH2Ax foci per cell 
than the wild type HCT116 cell line. All three cell lines show an increase in yH2Ax foci 
formation after DNA damage.  
B) Quantitation of yH2Ax foci numbers present in each cell line. Greater than 50% of HCT116 
ΔRNF4 B3-1 and HCT116 ΔRNF4 C2-2 contained greater than 5 yH2Ax foci under 
endogenous conditions, while 87% of wild type HCT116 cells contained less than 5 yH2Ax 
foci. After DNA damage inducing stimuli the number of yH2Ax foci increased in all three cell 
lines. Results are the average of 4 independent experiments, n>40 cells. 
C) Cell cycle analysis of wild type HCT116, HCT116 ΔRNF4 B3-1, HCT116 ΔRNF4 C2-2 cell 
lines. In each cell type the majority of cells were observed to be in the G1 cell cycle stage. No 
discernable differences were noted between the wild type HCT116 cells and the ΔRNF4 
HCT116 cell lines.  
            
 
However, no discernable differences were observed between the wild type 
and ∆RNF4 HCT116 cell lines under endogenous cell culture growth 
conditions (Figure 4.2-8, C).  The majority of cells from each cell line were in 
G1 and no large populations of, G0 or S phase cells indicating cells that may 
be facing difficulty progressing through the cell cycle were observed.  Thus 
although the HCT116 cells lacking RNF4 seemingly contained more yH2Ax 
foci under normal cell culture growth condition when compared to the parental 
wild type HCT116 cells this did not disrupt cell cycle progression.  
 
4.2.3	  Exploring	  the	  effect	  of	  SUMO	  proteases	  on	  RAP80	  associated	  proteins	  	  
 
Understanding the interplay between RAP80, SUMO and ubiquitin will 
help to understand whether SUMO-ubiquitin hybrid chains play a role in 
recruiting RAP80 to the sites of DNA damage.  SUMO proteases are a 
powerful tool to determine any interplay between RAP80 and SUMOylated 
proteins. 
 
Previous work has suggested that SUMO-ubiquitin hybrid chains 
anchor RAP80 near to the sites of DNA damage (Guzzo et al., 2012), and 
earlier work in this thesis supports the view that RAP80, SUMO and ubiquitin 
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are in close association at the sites of DNA damage.  If RAP80 is indeed 
anchored to the sites of DNA damage then removing the SUMO moiety of the 
SUMO-ubiquitin hybrid chain hypothetically anchoring RAP80 would separate 
the proteins anchoring the hybrid chain from RAP80, thus acting to remove 
the anchoring protein from any RAP80 containing protein complex (Figure4.2-
9, A).  In this manner an experiment was devised utilizing a SENP1 protease 
treatment of HEK 293 nuclear cell extracts in conjunction with a RAP80 
immunoprecipitions (IPs) to evaluate the association of SUMO, ubiquitin, and 
RAP80 associated protein complexes.  
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Figure 4.2-9 Hunting for SUMO-ubiquitin hybrid chain anchoring proteins using SENP1 
protease treatment. 
A) Schematic diagram represents the hypothesized action of a SUMO protease on a hybrid 
chain of SUMO and ubiquitin anchoring RAP80 to the sites of DNA damage. 
B) C) D) Western blot analysis of RAP80 immunoprecipitations from HEK 293 nuclear cell 
extracts that have been treated with SENP1 shows a close association of SUMO and 
ubiquitin in regards to the material immunoprecipitated with RAP80. Cells were either left 
untreated (No.T) or irradiated with 4 Gys and left for 60 mins to recover prior to nuclear 
extracts being prepared. extracts were treated with 10 µM SENP1 for 4 hours at room 
temperature, control pull downs were left at room temperature for 4 hours. B) α RAP80 
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western blot shows RAP80 is immunoprecipitated only after the RAP80 IP. Arrow heads 
indicate RAP80; isoform 1 is denoted by black arrow heads and isoform 2 is denoted by red 
arrow heads C) α SUMO2 western blot shows decrease of high molecular weight SUMO 
conjugates associated with RAP80 immunoprecipitated material after SENP1 treatment. This 
decrease is also present in the nuclear extracts after SENP1 treatment D) α ubiquitin western 
blot shows a decrease in the high molecular weight ubiquitin conjugates associated with the 
RAP80 immunoprecipitated material after SENP1 treatment. However, the same decrease in 
high molecular weight ubiquitin conjugates is not seen in the HEK 293 nuclear extracts. 
            
 
HEK293 cells were grown until 100% confluent on 20 10 cm dishes.  10 10 
cm dishes of 100% confluent cells were treated with 4 Gys IR followed by 60 
minutes recovery period, and the remaining 10 dishes were left untreated. 
Nuclear extracts were then prepared from both pools of cells. 2.5 mg of the 
cell extracts from the IR treated cells, and 2.5 mg from the untreated pool of 
cells were then incubated separately with SENP1 in accordance with 2.2.8.3.  
This resulted in four nuclear extract conditions; No treatment (No.T), No 
treatment with SENP1 treatement (No.T+SENP1), IR treatment (IR), IR 
treatment with SENP1 treatment (IR+SENP1).  Immunoprecipitations with the 
RAP80 antibody were then performed, before SDS-PAGE and western blot 
analysis were carried out.  RAP80 was successfully immunoprecipated from 
all cell extract treatment conditions via this protocol (Figure 4.2-9, B).  The 
SENP1 treatment was also successful in reducing the SUMOylation 
landscape of the nuclear cell extracts.  Material associated with the RAP80 
IPs from the non-SENP1 treated nuclear extracts, No.T and IR, contained 
highly SUMO2-modified material, where as the material associated with the 
RAP80 IPs associated with the SENP1 treated extracts contained less 
SUMOylated material (Figure 4.2-9, C).  This again suggests that RAP80 
associated protein complexes contain SUMO2.  As expected, SENP1 
treatment had no observable effect on the global ubiquitylation landscape of 
the No.T or IR treated nuclear extracts (Figure 4.2-9, D).  Importantly 
however, the SENP1 treatment reduced the apparent high molecular weight 
ubiquitin conjugates associated with the RAP80 immunopreciptated material. 
This suggests that the ubiquitin and SUMO modifications associated with 
RAP80 are highly cooperative, in that a portion of the proteins that are 
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associated with RAP80 in a SUMO dependent manner are also modified with 
ubiquitin.  
 
 Mass spectrometry analysis was then conducted to determine the 
effect SENP1 treatment had on RAP80 immunoprecipitated material from 
untreated and IR treated cell extracts. 
 
 The RAP80 IP experiment detailed above was repeated in triplicate 
before peptides were created in accordance with 2.2.8.1.  Samples were then 
processed using MaxQuant.  Analysis of the mass spectrometry data then 
showed that as expected, RAP80 was consistently immunoprecipated from all 
cell extract conditions (No.T, No.T+SENP1, IR, and IR+SENP1) (Figure 4.2-
10).  As expected, levels of SUMO1 and SUMO2 detected from the RAP80 
IPs were lower from the cell extracts that had been treated with SENP1 when 
compared to the extracts that had not been treated with SENP1.  Interestingly 
as seen in the western blot analysis, SENP1 treatment lowered the intensity 
of ubiquitin detected when compared to the RAP80 IPs from cell extracts not 
treated with SENP1, suggesting that the relative abundance of ubiquitin was 
lower after SENP1 treatment.  This again suggests that material associated 
with RAP80 in a SUMO specific manner is associated with ubiquitin, as 
removing the SUMOylated material associated with RAP80 also reduced the 
relative abundance of ubiquitin detected by mass spectrometry (Figure 4.2-
10).  
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Figure 4.2-10 Normalised intensity charts for RAP80, SUMO2, SUMO1 and ubiquitin for 
RAP80 IPs from HEK 293 nuclear cell extracts. 
Intensity data was normalised against the intensities reported for the 10 most abundantly 
found proteins across all IPs. RAP80 was consistently immunoprecipitated by the RAP80 
antibody. Relative abundance of both SUMO2 and SUMO1 was severely reduced from 
RAP80 IPs from SENP1 treated HEK293 nuclear cell extracts. Relative abundance of 
ubiquitin was reduced from RAP80 IPs from SENP1 treated HEK293 nuclear cell extract. 
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Global analysis of the data was then carried out to determine if the abundance 
of any proteins could be observed that decreased specifically with respect to 
the SENP1 treatment prior to the immunoprecipitation of RAP80 (Figure 4.2-
11, A).  Three of the most significantly reduced proteins from SENP1 treated 
RAP80 IPs in both non-treated and damaged cell extracts were C5orf25, 
TOPORs, and RAD54L2 (Figure 4.2-11, B & C).  All three proteins are known 
to be SUMO modified (Tammsalu et al 2014) (Figure 4.2-11, B).  Thus it is 
possible that these proteins are associated with RAP80 when SUMOylated. 
C5orf25 has a single SUMOylation site, TOPORs has four known 
SUMOylation sites, and RAD54L2 has 17 known SUMOylation sites.  C5orf25 
is a known SUMO interacting protein (Hunter & Sun 2012), but has also been 
observed like RAP80, to have affinity for SUMO-ubiquitin hybrid chains 
(Figure 3.2-10).  TOPORs, a ubiquitin E3 ligase, has been shown to interact 
with SUMO and has also been observed to show SUMO E3 ligase activity 
(Wenger et al., 2005).  RAD54L2, a DNA helicase, has been shown to contain 
SIMs and interact with SUMO (Ogawa et al., 2009).  All three proteins have 
the potential then to not only interact with SUMO non-covalently but also to be 
SUMOylated.  Thus, these proteins can only be said to interact with RAP80 
associated material in a SUMO specific manner as these proteins may be 
interacting non-covalently with other SUMOylated material associated with 
RAP80.  However, the known SUMOylation sites located within C5orf25, 
TOPORs, and RAD54L2 allows for the potential of these proteins to be 
modified by SUMO-ubiquitin hybrid chains.  
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Figure 4.2-11 Analysis of SENP1 treatment on RAP80 associated proteins. 
A) Red outlined points are SUMO2 and SUMO1. Green points are proteins that are 
significantly less abundant in the RAP80 IPs from the SENP1 treated cell extracts when 
compared to the RAP80 IPs from untreated cell extracts. 
B) List of top 5 most changed proteins after SENP1 treatment of RAP80 IPs.   
C) Normalised intensity charts for C5orf25, TOPORs, and RAD54L2. The relative abundance 
of C5orf25, TOPORs, and RAD54L2 were all severely reduced from RAP80 IPs from SENP1 
treated HEK293 nuclear cell extracts when compared to RAP80 IPs from untreated HEK293 
nuclear cell extracts. 
            
 
The interplay between SUMO and ubiquitin in the context of RAP80 is 
quite complex.  Decreasing the SUMOylation landscape of HEK 293 nuclear 
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cell extracts prior to RAP80 immunoprecipitiation severely reduces the RAP80 
associated hyper-ubiquitylated material, suggesting that SUMOylation is key 
for the association of a portion of ubiquitylated material with RAP80.  It is 
interesting to note that C5orf25, TOPORs and RAD54L2 are all known to be 
SUMO modified.  This suggests that these proteins could be interacting with 
RAP80 when SUMO modified, which in turn allows for the possibility that 
SUMO-ubiquitin hybrid chains could form on these proteins.  This approach 
identifies SUMO modification of RAP80 associated proteins as a key factor in 
the recruitment of ubiquitin modifications to RAP80 but to identify whether this 
cooperation between SUMOylation and ubiquitylation is the result of SUMO-
ubiquitin hybrid chains requires a different approach.  
4.2.4	  A	  SILAC	  based	  RAP80	  IP	  gel	  shift	  assay	  utilizing	  USP2	  and	  SENP1	  to	  evaluate	  
the	  potential	  for	  SUMO-­‐ubiquitin	  hybrid	  chain	  anchoring	  proteins	  	  	  	   Treating cell extracts with SENP1 prior to RAP80 immunoprecipitation 
has shown that some ubiquitin-associated proteins appear to be linked with 
RAP80 associated material in a SUMO dependent manner.  The intensity of 
ubiquitin recorded from the RAP80 associated material was reduced from 
SENP1 treated cell extracts when compared to the intensity of ubiquitin 
reported form cell extracts that had not been treated with SENP1.  This 
suggested a high degree of cooperativity between SUMO and ubiquitin 
modifications associated with RAP80, however, this does not definitively 
answer whether RAP80 is indeed interacting with proteins modified with 
SUMO-ubiquitin hybrid chains.  Thus, an experiment was designed to 
determine whether or not this apparent high degree of cooperativity was 
signalling the presence of SUMO-ubiquitin hybrid chain modified proteins or 
just proteins that are modified with homotypic chains of both SUMO and 
ubiquitin (Figure 4.2-12, A).  IR treated Light, Medium, and Heavy SILAC 
labelled HEK 293 cell extracts were prepared before separate RAP80 IPs 
were performed on each of the SILAC labelled nuclear extracts.  Protease 
treatments were then carried out on the RAP80 IP associated material; the 
Light RAP80 IP would be left untreated as a control, the Medium RAP80 IP 
would be treated with USP2 CaD to remove any ubiquitin modifications, and 
the Heavy RAP80 IP would be treated with SENP1 to remove any SUMO 
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modifications.  In the context of SUMO-ubiquitin hybrid chains this would allow 
the Light RAP80 IP sample to contain un-altered hybrid chains, but both the 
Medium RAP80 IP and Heavy RAP80 IP would no longer contain full SUMO-
ubiquitin hybrid chains.  In theory, the Medium RAP80 IP would now contain 
proteins only modified with the SUMO element of the SUMO-ubiquitin hybrid 
chain and the Heavy RAP80 IP having the hybrid chains removed completely. 
The RAP80 IPs from the three SILAC conditions could then be combined, and 
separated by molecular weight via SDS-PAGE.  The resulting protein-
containing gel could then be cut into multiple slices and protein intensities 
could be compared by apparent molecular weight (or slice) and SILAC label 
for each protein.  If the protein was modified by a SUMO-ubiquitin hybrid 
chain then the Light labelled protein would be observed to be a higher 
molecular weight than the predicted molecular weight of the unmodified 
protein, nearer the top of the gel.  The Medium labelled protein still containing 
the SUMO portion of the hybrid chain would be observed at a higher 
molecular weight than the predicted molecular weight of the unmodified 
protein but would not be observed as near to the top of the gel as the Light 
labelled sample.  The Heavy labelled sample would be close to the expected 
size of the unmodified protein and lower in the gel when compared to the 
Medium and Light RAP80 IP samples, as the SUMO-ubiquitin hybrid chains 
would be removed (Figure 4.2-12, A). 
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Figure 4.2-12 A SILAC based RAP80 IP gel shift assay utilizing USP2 and SENP1 to 
evaluate the potential for SUMO-ubiquitin hybrid chain anchoring proteins. 
A) Experimental flow diagram. Light, Medium, and Heavy SILAC labeled HEK 293 cells were 
treated with 4 Gys IR and left to recover for 60 minutes prior to nuclear extract preparation. 
RAP80 IPs were then performed separately on the Light, Medium, and Heavy nuclear 
extracts. Protease treatments were then carried on the RAP80 Immunoprecipitated material; 
the Light labeled RAP80 IP material was not treated with any protease, the Medium labeled 
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RAP80 material was treated with USP2 CaD, the Heavy labeled material was treated with 
SENP1.   
Western blot analysis of RAP80 Immunoprecipitated material with USP2 CaD, SENP1 and 
USP2 CaD + SENP1 treatments.  
B) RAP80 western blot. RAP80 is efficiently immunoprecipitated from cell extracts under 
these conditions. 
C) Ubiquitin western blot. High molecular weight ubiquitin conjugates are reduced after USP2 
CaD treatment, when compared with no treatment control RAP80 IP. SENP1 treatment 
moves the high molecular weight ubiquitin conjugates lower down the gel, when compared to 
the no treatment control RAP80 IP. As with the USP2 CaD only treatment, the USP2 CaD + 
SENP1 treatment reduces the high molecular weight ubiquitin conjugates.  
D) SUMO2 western blot. All three protease treatments reduce the high molecular weight 
SUMO2 conjugates observed in the no treatment control RAP80 IP. 
            
 
 
The experimental procedure detailed above was trialled on unlabelled 
HEK 293 cells, an additional USP2 CaD+SENP1 treatment was also tested 
along with the single USP2 CaD or SENP1 treatments before western blot 
analysis was carried out against RAP80, Ubiquitin, and SUMO2 (Figure 4.2-
12, B/C/D).  RAP80 was effectively immunoprecipitated and then detected by 
western blot in all the RAP80 IP trial conditions (Figure 4.2-12, B).  As 
expected high molecular weight ubiquitin conjugates were associated with the 
No treatment RAP80 IP, were severely reduced in the USP2 CaD treatment 
RAP80 IP.  The high molecular weight ubiquitin conjugates were also 
observed to shift down the gel in the SENP1 treatment RAP80 IP.  As 
expected the high molecular weight ubiquitin conjugates were again reduced 
in the USP2 CaD+SENP1 treatment RAP80 IP (Figure 4.2-12, C).  High 
molecular weight SUMO conjugates were associated with the No treatment 
RAP80 IP.  Interestingly, the USP2 CaD treatment reduces the observed high 
molecular weight SUMO modifications observed to be associated with the No 
treatment RAP80 IP.  As expected the SENP1 treatment and the USP2 
CaD+SENP1 severely reduced the high molecular weight SUMO 
modifications associated with the No treatment RAP80 IP (Figure 4.2-12, D). 
Thus both SUMO and ubiquitin modifications of RAP80 associated material 
are observed to be effected indirectly by the action of the other modifications’ 
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specific protease, USP2 CaD treatment was observed to reduce the apparent 
size of the high molecular weight SUMO conjugates associated with RAP80, 
and, SENP1 treatment observed to reduce the size of the high molecular 
weight ubiquitin modifications associated with RAP80.  
 
HEK 293 cells were grown in Light, Medium, or Heavy SILAC medium, 
extracts were then prepared and treated in accordance with 2.2.8.4 before the 
sample were combined and separated by SDS-PAGE.  The separated sample 
was then cut into 24 slices (Figure 4.2-13, A).  The distance from the top of 
the gel to the leading edge of the slice was measured and an approximate 
molecular weight range was given to each slice.  This would allow for any 
proteins observed in this slice to be given an approximate molecular weight 
and the minimum and maximum differences in molecular weights between 
slices to be determined.  Analysis of all proteins identified in the RAP80 IPs by 
apparent molecular weight was then conducted comparing the apparent 
molecular weight of the protein based on its average position (slice) in the gel 
against the predicted molecular weight of that protein.  This analysis suggests 
that the vast majority of proteins observed in the gel, fall within a +/- 20 kDa 
range of the predicted molecular weight of that protein (Figure 4.2-13, B). 
This suggests that the majority of proteins observed could not be heavily 
modified by SUMO and ubiquitin.  Apparent molecular weight can also be 
compared between SILAC labels.  Comparison of the apparent molecular 
weight of proteins from each sample gives the molecular weight difference 
after USP2 CaD treatment (Medium-Light), and SENP1 treatment (Heavy-
Light).  The difference in apparent molecular weight for each protein observed 
after USP2 CaD treatment was then compared to the difference in apparent 
molecular weight for each protein after SENP1 treatment (Figure 4.2-13, C). 
The distribution of the data suggests that as expected the apparent molecular 
weight of the vast majority of proteins observed is not altered by more then +/- 
20 kDa this suggests that these proteins could not be significantly modified by 
SUMO or ubiquitin.  Proteins that show a decrease in apparent molecular 
weight after both USP2 CaD and SENP1 treatments are circled in red (Figure 
4.2-13, C).  Surprisingly a large number of proteins are observed to increase 
in molecular weight after protease treatment.  This is likely a technical 
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discrepancy due to a complication with resolubilsing some of the proteins 
during the TCA precipitation used to concentrate the samples after protease 
treatment so that more of each sample could be analysed by SDS-PAGE. 
	  
Figure 4.2-13 Analyzing a SILAC based RAP80 IP gel shift assay utilizing USP2 and 
SENP1 to evaluate the potential for SUMO-ubiquitin hybrid chain anchoring proteins. 
A) Coomassie stained gel for Light, Medium, and Heavy labeled RAP80 IP samples. Red 
dashed lines outline the slices and are numbered appropriately.  
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B) Molecular weight analysis of proteins found in gel. The majority of proteins are found within 
20 kDa of their endogenous molecular weight. 
C) Comparison of difference in molecular weight of any given protein by SILAC labeling. The 
difference in molecular weight is given in daltons. Data in red are proteins that’s molecular 
weight decrease in the USP2 CaD (Medium) treated sample and the SENP1 (Heavy) treated 
samples when compared to the no treated samples (Light). 
 
 The distribution of a protein throughout the gel can then be compared 
with respect to the three SILAC labelled variants of that protein.  This can then 
be compared to the expected molecular weight of a protein and thus the 
expected position of that protein in the gel.  Light SILAC labelled ubiquitin that 
had not been treated with a protease is distributed evenly throughout the gel 
slices (Figure 4.2-14, A).  This would suggest that as expected, the Light 
labelled ubiquitin is predominantly conjugated to proteins.  The levels of the 
Medium labelled ubiquitin can be seen to spike in slice 22 and 24, roughly 
corresponding to the molecular weight of di- or mono-ubiquitin.  This suggests 
that the USP2 CaD protease treatment has resulted the deubiquitylation of 
proteins and the generation of free ubiquitin.  Interestingly, the levels of the 
Heavy labelled ubiquitin, that had been treated with SENP1, were observed to 
spike in slice 22, this observation could suggest SENP1 treatment results in 
the presence of mono-ubiquitylated SUMO species.  The levels of Light and 
Medium labelled SUMO2 are distributed evenly throughout the length of the 
gel (Figure 4.2-14, C).  This would suggest that the majority of Light and 
Medium labelled SUMO2 is predominantly conjugated to proteins.  The 
intensity of Heavy labelled SUMO2 is seen to spike in slice 23 corresponding 
to the endogenous molecular weight of SUMO2.  As expected, treating the 
Heavy labelled RAP80 IP with SENP1 deconjugated SUMO2 from proteins. A 
similar spike in slice 23 is seen for the Heavy labelled SUMO1 (Figure 4.2-14, 
B).  This suggests that SUMO1 was also deconjugated from proteins with 
SENP1 treatment. 
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Figure 4.2-14 Evaluating ubiquitin and SUMO interplay via SILAC based RAP80 IP gel 
shift assay utilizing USP2 and SENP1. 
Graphical representation of the percentage of total protein intensity for ubiquitin, SUMO2, and 
SUMO1 by slice for each SILAC label. Light (no treatment) sample is represented by purple 
line. Medium (USP2 CaD treatment) sample is represented by the blue line. Heavy (SENP1 
treatment) is represented by the orange line. Red dashed line represents the endogenous 
molecular weight of the protein.  
A) Ubiquitin from the Light sample is distributed across the gel, suggesting most ubiquitin is 
conjugated to proteins. Ubiquitin from the medium sample spikes slice 22 and 24 representing 
di- and monomeric free ubiquitin. Ubiquitin from the Heavy sample spikes at slice 22. 
B) SUMO1 from the light sample spikes at around slice 13 suggesting the majority of SUMO1 
is conjugated to proteins. SUMO1 from the medium sample spikes at 13 and 20/21 
suggesting that SUMO1 is conjugated to proteins. SUMO1 from the Heavy sample spikes at 
slice 23 suggesting mostly free SUMO1. 
C) SUMO2 from the Light sample is distributed across the gel suggesting conjugated 
SUMO2. SUMO2 from the Medium sample is distributed across the gel suggesting 
conjugated SUMO2. SUMO2 from the Heavy sample spikes at slice 23 suggesting mostly 
free SUMO2. 
            
 
 RAP80 was positively identified in the sample from all three SILAC 
labeled RAP80 IPs.  A RAP80 intensity spike was identified in Slice 12 
corresponding well to the predicted molecular weight of isoform 1 of RAP80 
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(Figure 4.2-15 top panel).  Three other RAP80 intensity spikes were 
identified corresponding well with the predicted molecular weight of RAP80 
isoforms 2,4 and 5 in slices 15, 18, and 21 respectively.  Four other members 
of the BRCA 1A complex were identified in all SILAC labeled RAP80 IPs. 
Interestingly, BRCC36, Merit40, Abraxas, and BRE are all identified in slices 
that correspond well to the predicted molecular weight of the each of the 
protein.  This suggests that these members of the BRCA 1A complex are not 
heavily modified.  Thus, members of the BRCA 1A complex do not appear to 
be modified with SUMO, ubiquitin, or SUMO-ubiquitin hybrid chains when 




Figure 4.2-15 Evaluating the BRCA 1A complex components via SILAC based RAP80 IP 
gel shift assay utilizing USP2 and SENP1. 
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RAP80 spikes at slice 12 for all SILAC labels representing the endogenous weight of RAP80 
isoform 1, three additional spikes at 15,18,21 correspond with the predicted molecular 
weights of the RAP80 isoforms 2, 4, and 5. BRCC36 was identified exclusively in slice 20 for 
all SILAC labels approximately representing the endogenous weight of BRCC36. Merit40 was 
identified exclusively in slice 18 for all SILAC labels approximately representing the molecular 
weight of Merit40. Abraxas was identified exclusively in slice 16 for all SILAC labels 
representing the endogenous molecular weight of the protein. BRE was identified exclusively 
in slice 17 representing the endogenous molecular weight of the protein.  
            
 
 44 proteins were observed to have lower apparent molecular weight 
after both USP2 CaD (Medium SILAC label), and SENP1 (Heavy SILAC label) 
treatments when compared to no treatment (Light SILAC label).  Of these, 22 
proteins shifted in a pattern consistent with the expected shift generated by 
the removal of a SUMO-ubiquitin hybrid chain by the USP2 CaD, or SENP1 
treatments specified above and the predicted unmodified molecular weight of 
protein in question (Figure 4.2-16, A).  
 
	  	  
Figure 4.2-16 Potential SUMO-ubiquitin hybrid chain anchoring proteins. 
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A) List of potential SUMO-ubiquitin hybrid chains anchoring proteins from SILAC based 
RAP80 immunoprecipitation. Proteins listed have intensity shift pattern associated with 
sequential removal of ubiquitin and SUMO modification after USP2 CaD, or SENP1 
treatment. 
B) S100A8 shows intensity pattern of a protein hypermodified by SUMO and ubiquitin. The 
peak intensity from the light sample is found in slice 3, suggesting a heavily modified version 
of S100A8. The peak intensity from the USP2 CaD treated Medium sample is found in slice 
22, suggesting a modified version of S100A8. The peak intensity of the SENP1 treated Heavy 
sample is found in slice 24, corresponding to the unmodified molecular weight of S100A8. 
With a predicted molecular weight of 10KDa, unmodified S100A8 should appear in slice 24 
(Red dashed line). Cartoon depicts potential modified species of S100A8 that could explain 
relative intensity peaks. S100A8 is coloured to match primary intensity peak for each SILAC 
label. SUMO is represented by red circle. Ubiquitin is represented by yellow boxes. 
            
 
S100A8, a calcium- and zinc-binding protein, was observed to shift in a 
pattern consistent with that expected of a protein modified with a hybrid chain 
of SUMO and ubiquitin (Figure 4.2-16, B).  The peak intensity of the Light 
labelled no treated S100A8 is observed in slice 3.  This corresponds to a 
hyper-modified S100A8, depicted below in cartoon form.  The peak intensity 
of the Medium labelled USP2 CaD treated S100A8 is observed in slice 22. 
This would suggest an apparent molecular weight of between 20-25 KDa, 
consistent with the predicted molecular weight of a mono SUMOylated 
S100A8.  The peak intensity of the Heavy labelled SENP1 treated S100A8 is 
observed in slice 24.  This corresponds well with the predicted molecular 
weight of 10 KDa for unmodified S100A8.  Thus, S100A8 shifts through the 
gel in a pattern consistent with that expected of a protein modified by a 
SUMO-ubiquitin hybrid chain.  Unfortunately, it is unknown if S100A8 is 
SUMO modified, however it does contain a number of lysine residues capable 
of accepting SUMO modifications, one of which is contained within putative 
inverted SUMO modification consensus motifs, D32-L33-K34-K35.  Therefore 
further work would be required to establish if S100A8 is indeed modified by 
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4.3	  Discussion	  	  
Signalling via hybrid chains of SUMO and ubiquitin would allow for a highly 
specific response to specific stimuli in vivo; due in part to the complex 
orchestration of numerous enzymes required to create such chains (Figure 
3.1-2).  Recruitment of RAP80 to the sites of DNA damage is conducted, at 
least in some respect, by the presence of K63 linked poly-ubiquitin chains 
modifying yH2Ax.  However, more recent evidence has suggested that 
RAP80 is capable of interacting with RNF4 generated SUMO-ubiquitin hybrid 
chains facilitating the recruitment of RAP80 and the BRCA 1A complex to the 
sites of DNA repair (Guzzo et al., 2012).   
4.3.1	  RAP80	  has	  affinity	  for	  both	  SUMO	  and	  ubiquitin	  in	  vitro	  and	  in	  vivo.	  	  
Guzzo and colleagues suggested that RAP80 has the potential to 
interact with hybrid chains of SUMO and ubiquitin (Guzzo et al., 2012).  The 
N-terminal region of RAP80 containing a domain composed of a SIM and two 
UIMs is thought to be capable of recruiting RAP80 to the sites of DNA 
damage (Guzzo et al., 2012).  Here, a truncation of RAP80 containing the 
tandem SIM UIMUIM domain (RAP80 1-150) was found in the elutate from 
both SUMO and ubiquitin containing resins types (Figure 4.2-1, A). 
Interestingly, the N-terminal of RAP80 was present in relatively higher levels 
in the eluate from the poly-SUMO poly-ubiquitin hybrid chain containing resin 
when compared to the either the mono-ubiquitin poly-SUMO hybrid chain, 
ubiquitin or SUMO chain containing resin types (Figure 4.2-1, A).  This 
corresponds well with the data generated from SUMO-ubiquitin hybrid chain 
pull down assay using cell extracts, where RAP80 was observed only in the 
eluate for the hybrid chains consisting of poly-ubiquitin poly-SUMO (Figure 
3.2-8).  Suggesting the poly-ubiquitin poly-SUMO hybrid chains are the 
preferential interaction substrate for RAP80 in these assays.  
 
It was also reported that RAP80 was recruited to sites of DNA damage 
due to the activity of RNF4 generating hybrid chains of SUMO and ubiquitin 
(Guzzo et al., 2012).  To determine whether RAP80 did indeed interact with 
SUMO and ubiquitin in tandem at the sites of DNA damage a in situ approach 
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was taken.  The proximity ligation assay is a strong and robust technique 
developed to allow observations of closely associated pairs of proteins to be 
determined (Gullberg et al., 2002).  Used in conjunction with GFP-tagged 
RAP80 expressing U2OS cells, PLAs were developed to study the association 
between RAP80 with SUMO, and RAP80 with ubiquitin (Figure 4.2-3).  This 
allowed observations to be made of a close association between RAP80 and 
SUMO, and RAP80 and ubiquitin in situ (Figure 4.2-3).  As RAP80 was seen 
to closely associate with both SUMO and ubiquitin, a PLA assay was then 
developed to determine whether RAP80 is associated with SUMO and 
ubiquitin in the same foci.  Positive signals from the SUMO/ubiquitin PLA were 
then shown to co-localize with GFP-RAP80 positive foci (Figure 4.2-4).  Thus, 
RAP80 appeared to have the potential to associate with both SUMO and 
ubiquitin at the same time in the same foci.  This however does not indicate 
the presence of SUMO-ubiquitin hybrid chains interacting with RAP80 but 
suggests that RAP80, SUMO and ubiquitin are all closely associated and 
gives credence to the hypothesis that RAP80 could be interacting with both 
SUMO and ubiquitin potentially in the form of a SUMO-ubiquitin hybrid chain. 
4.3.2	   Is	   there	   a	   role	   for	   STUbLs	   in	   the	   recruitment	  of	   RAP80	   to	   the	   sites	   of	  DNA	  
damage	  	  
If RAP80 is interacting with hybrid chains of SUMO and ubiquitin at the 
sites of DNA damage, STUbLs such as RNF4 and RNF111 are thought to be 
the primary candidates capable of building such chains.  As such, RAP80 
recruitment to the site of DNA damage was explored in CRISPR/CAS9 
∆RNF4 HCT116 cell lines.  HCT116 cells are human colorectal cancer cells 
commonly used in the study of homologous recombination (Huang et al., 
2008; Fattah et al., 2010; Mauro et al., 2012).  Recruitment of RAP80 
appeared to be unaffected in the ∆RNF4 HCT116 cell lines when compared to 
the parental wild type cell line (Figure 4.2-6).  After DNA damage, RAP80 is 
still recruited into yH2Ax positive foci.  In the RNF4 postitive parental HCT116 
cell line and both ∆RNF4 HCT116 cell line, approximately 45% of cells 
positive for yH2Ax and RAP80 had 1 or more RAP80 positive yH2Ax foci 
(Figure 4.2-6, B).  The average number of positive foci per cell was also 
unaltered in the ∆RNF4 HCT116 cells when compared to the RNF4 positive 
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wild type HCT116 cells (Data not shown).  Thus in the cell lines used, the 
complete ablation of RNF4 does not appear to have any affect on the 
recruitment of RAP80 to the sites of DNA damage.  RNF111, a newly 
identified STUbLs, has also been suggested to have a role in the DDR 
(Poulsen et al., 2013).  Partial knockdown of RNF111 by siRNA had a limited 
affect in the recruitment of RAP80 to yH2Ax positive foci in either RNF4 
positive HCT116 cells or ∆RNF4 HCT116 cell lines (Figure 4.2-7).  This is an 
interesting result as it demonstrates that neither RNF4 nor RNF111, the only 
well described mammalian STUbLs, play a critical role in the recruitment of 
RAP80 to the sites of DNA repair.  This extensively suggests two things; 
either another, as of yet unidentified STUbL, is important for the recruitment of 
RAP80 to the sites of DNA repair or perhaps STUbL-generated SUMO-
ubiquitin hybrid chains are not critical for the recruitment of RAP80 to the sites 
of DNA repair.  
 
∆RNF4 HCT116 cell lines used in these experiments contained large 
amounts of endogenous yH2Ax positive foci under normal growth conditions 
when compared to the wild type HCT116 cells (Figure 4.2-8).  These cells 
however appeared to have no difficulties growing and doubling as cell cycle 
analysis showed no discrepancy when compared to the wild type cells 
(Figure 4.2-8, C).  This suggests anomalies in these cells response to the 
DDR that may be affecting the results seen.  As a result, further analysis of 
these cells would be recommended.  The recruitment of RAP80 to sites of 
DNA damage could also be analysed after the complete knockout of RNF4 in 
another cell type commonly used in the study of the DDR such as human 
U2OS or HEK293 cells.  
 
4.3.3	  Are	  any	  proteins	  associated	  with	  RAP80	  via	  SUMO	  ubiquitin	  hybrid	  chains	  
  
 To determine whether the SUMO and ubiquitin observed to be in close 
association with RAP80 (Figure 4.2-1-4.2-4) is important for the recruitment 
of RAP80 to sites of DNA repair or for the recruitment of other RAP80 
associated proteins including other members of the BRCA 1A complex, two 
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RAP80 IP based experiments were devised.  Firstly, RAP80 was 
immunoprecipitated from HEK293 cells extracts under endogenous and IR 
treated conditions, then a SENP1 treatment designed to remove endogenous 
SUMO modifications was applied in the experiment.  This experimental set up 
allowed for proteins interacting with RAP80 in a SUMO specific manner to be 
identified.  Interestingly, western blot analysis of the RAP80 IPs from these 
extracts, suggested high molecular weight ubiquitin modification were 
dramatically decreased in the RAP80 associated material from the cell 
extracts treated with SENP1.  This suggests the removal of ubiquitin observed 
after the SENP1 treatment was associated with RAP80 in a SUMO dependent 
manner, that the ubiquitin is modifying proteins that also carry SUMO 
modifications, and that the SUMO modification is required for the interaction 
of the ubiquitin/SUMO/protein complex to RAP80.  Thus, in the context of the 
association with RAP80, SUMO and ubiquitin are observed to behave in a 
highly cooperative way.  It is interesting to note that the three proteins seen to 
change most dramatically between the RAP80 IPs from extracts not treated 
with SENP1, and the RAP80 IPs from extracts treated with SENP1; C5orf25, 
TOPORs, and RAD54L2 are all known to be SUMO modified.  The known 
SUMO modification of these proteins allows for the potential that these 
proteins could themselves be modified with hybrid chains of SUMO and 
ubiquitin.  However, some care must be taken with such assumptions as 
C5orf25, TOPORs, and RAD54L2 are also known to interact with SUMO non-
covalently via SUMO interaction motifs.  Therefore the SENP1 treatment 
could be reducing the association of these proteins with RAP80 by reducing 
the non-covalent interaction directed via SIM interactions of these proteins 
with the SUMO modifications associated with the RAP80 associated material. 
The identification of C5orf25 as a SUMO dependent RAP80 associated 
protein is intriguing.  C5orf25, like RAP80 was identified as a potential SUMO-
ubiquitin hybrid chain interacting protein in the proteomic data generated by 
the hybrid chain pull-down assay (Figure 3.2-7).  If a SUMO-ubiquitin hybrid 
chain does not directly modify C5orf25, then this could suggest that C5orf25 
displays affinity for similar SUMO/ubiquitin modification patterns as RAP80. 
This would however require further investigation to determine the 
combinations of SUMO and ubiquitin moieties that show the greatest affinity 
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for each protein.  However, this would not be too surprising given that they 
both show affinity for the same poly-SUMO poly-ubiquitin hybrid chain type 
used in the hybrid chain resin pull-down experiment (Figure 3.2-7).  If RAP80 
is indeed precipitating SUMO-ubiquitin hybrid chains it is possible RAP80 is 
not the only hybrid chain interacting protein associated with such chains. 
 
The second RAP80 immunoprecipitation based experiment was 
devised using Heavy, Medium, and Light SILAC labels to identify more 
robustly whether any proteins could be identified as anchoring SUMO-
ubiquitin hybrid chains via molecular weight gel shift assays.  Firstly, an 
immunoprecipitation with a RAP80 antibody was used to precipitate RAP80 
along with any potential SUMO-ubiquitin hybrid chain bound proteins from cell 
extracts created from cells grown separately in either Light, Medium, or Heavy 
labelled growth medium.  Subsequently, the Light, Medium, and Heavy 
labelled RAP80 Immunoprecipitated material were treated with; no protease 
(no treatment), USP2 CaD, or SENP1 treatments respectively.  These 
treatments were designed to hypothetically leave the hybrid chains unaltered, 
remove the ubiquitin element of the hybrid chain or remove the entire SUMO-
ubiquitin hybrid chain (Figure 4.2-12, A).  After the samples were combined 
and analysed by SDS-PAGE, the shift pattern of each protein with respect to 
SILAC label could be analysed (Figure 4.2-13).  Analysis of the BRCA 1A 
complex components for modification by hybrid chains of SUMO and ubiquitin 
shows no evidence for modification and thus the hypothesis that the BRCA 1A 
complex could be held together by SUMO-ubiquitin modifications proved 
unfounded (Figure 4.2-15).  By this method 22 proteins were identified as 
shifting through a gel in a pattern consistent with that expected of a protein 
that was modified by both SUMO and ubiquitin.  S100A8 shifted with the 
expected pattern of a protein modified by a SUMO-ubiquitin hybrid chain 
(Figure 4.2-16).  Unfortunately, no data is available that identifies S100A8 to 
be modified by either SUMO or ubiquitin and to verify this further study would 
be required. C5orf25, and TOPORs identified in the first RAP80 based IP 
were not identified in the SILAC based experiment.  RAD54L2 was identified 
in this experiment but was observed in all SILAC labels as an unmodified 
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protein with no shift through the gel, suggesting RAD54L2 under these 
conditions is not modified with a SUMO-ubiquitin hybrid chain. 
	  4.3.4	  Conclusion	  	  	  	   The N-terminal SIM UIMUIM tandem domain containing region of 
RAP80 (RAP80 1-150) appears to interact with both SUMO and ubiquitin, with 
a relatively higher degree of affinity shown for poly-SUMO poly-ubiquitin 
hybrid chains in vitro (Figure 4.2-1, A).  In a cellular context, SUMO, ubiquitin, 
and RAP80 are all closely associated after DNA damage inducing stimuli 
(Figure 4.2-4).  It appears that SUMO and ubiquitin play a cooperative role in 
their association with RAP80.  However, the degree of cooperativity is still 
unclear. Interestingly, complete knock out of the human STUbL RNF4 showed 
no effect on the recruitment of RAP80 to the sites of DNA damage (Figure 
4.2-6), suggesting that RNF4 generated SUMO-ubiquitin hybrid chains are not 
dependent for the recruitment of RAP80 and subsequently the BRCA 1A 
complex to the sites of DNA damage as had been previously suggested 
(Guzzo et al., 2012).  Likewise, siRNA knockdown of RNF111 showed no 
discernable effect on the recruitment of RAP80 to the sites of DNA damage 
(Figure 4.2-7).  Three known SUMO modified protein; C5orf25, TOPORs, and 
RAD54L2 were observed to interact with RAP80 associated material in a 
SUMO dependent manner, leading to the possibility these proteins could be 
modified by hybrid chains of SUMO and ubiquitin (Figure 4.2-11).  However, 
because all three proteins also contain SIMs the data was unable to 
discriminate between SUMO dependent non-covalent interactions with SUMO 
modified version of these proteins and RAP80 associated material or between 
these proteins and SUMO modified RAP80 associated material.  Utilising 
triple SILAC labelling with USP2 CaD and SENP1 treatment of RAP80 IPs 
allowed the development of an assay to detect SUMO-ubiquitin hybrid chain 
anchoring proteins (Figure 4.2-12).  Interesting, 22 proteins were identified 
from the RAP80 IPs that migrate through the gel consistent with the expected 
migration pattern of proteins modified with SUMO and ubiquitin (Figure 4.2-
16).  S100A8 was identified as shifting through the gel with a pattern expected 
of a protein modified by a SUMO-ubiquitin hybrid chain (Figure 4.2-16). 
However, further evidence would be required to discern whether S100A8 is 
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modified by SUMO-ubiquitin hybrid chains.  Also of note, during the SILAC 
mass spectrometry analysis no SUMO peptides were identified carrying the 
characteristic GlyGly motif that indicates ubiquitylation.  Thus it is difficult to 
definitively say that SUMO-ubiquitin hybrid chains modified those proteins or 
are even associated with RAP80.  Further optimisation of this experimental 
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5	  Conclusions	  	  	   Since the identification of the ubiquitin conjugation pathway almost 30 
years ago, the Ubl field has grown dramatically to become an important area 
for understanding many essential cellular processes.  Recent published data 
and evidence presented in this thesis has shown that the once thought distinct 
ubiquitin and SUMO conjugation pathways converge during several vital 
cellular functions. 
 
 In the first part of this thesis, a protocol was designed to identify 
proteins with the potential to interact in a specific manner with hybrid chains of 
SUMO and ubiquitin via affinity chromatography coupled with high-resolution 
mass spectrometry.  This was successful, identifying around 30 proteins that 
interacted specifically with hybrid chains of SUMO and ubiquitin (Figure 3.2-
7).  During the course of these experiments RAP80 was identified to contain 
an N-terminal region containing a tandem SIM UIMUIM domain that is 
capable of specifically interacting with K63 linked poly-ubiquitin modified 
SUMO2 (Guzzo et al., 2012).  Gratifyingly, RAP80 was also identified in our 
attempts to identify SUMO-ubiquitin hybrid chain interacting proteins (Figure 
3.2-7).  Additionally, RAP80 was identified with six other members of the 
BRCA 1A complex suggesting that this complex may as a whole have affinity 
for SUMO-ubiquitin hybrid chains (Figure 3.2-8).  A primary sequence search 
of proteins known to contain UIMs for SIMs was also carried out (Figure 3.2-
12).  Interestingly, if not unsurprisingly, several proteins were identified as 
having both UIMs and SIMs by this method were also shown to be potential 
SUMO-ubiquitin hybrid chain interacting proteins via our affinity 
chromatography coupled with high-resolution mass spectrometry.	   	   This both 
validated our primary approach and reinforced the concept that proteins 
critical for many different cellular functions have the domains necessary to 
recognise both SUMO and ubiquitin and could act as points of convergence 
between the ubiquitin and SUMO pathways. 
 
 In the second part of this thesis the potential interaction of RAP80 with 
hybrid chains of SUMO and ubiquitin was explored in a cellular context 
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focused around the sites of DSB after DNA damage.  A PLA was developed 
to observe closely associated SUMO and ubiquitin molecules in RAP80 
positive foci, suggesting that a high level of cooperativity exists between 
SUMO and ubiquitin modifications associated with RAP80 in a cellular context 
(Figure 4.2-4).  This was also observed when RAP80 IPs were carried out on 
cell extracts that had either been treated with SENP1 or left untreated (Figure 
4.2-9).  As expected SENP1 treatment of RAP80 immunoprecipitated material 
displayed a decrease in high molecular weight SUMO conjugated material 
when compared to RAP80 imunnoprecipitated material that was left 
untreated. Interestingly, SENP1 treatment of RAP80 immunopreciptated 
material resulted in a pronounced decrease in the levels of high molecular 
weight ubiquitin conjugates, suggesting this material was ubiquitinated in a 
SUMOylation dependent manner (Figure 4.2-9).  SENP1 treatment of RAP80 
immunoprecipited material also uncovered a handful of proteins that appear to 
be associated with RAP80 in a SUMO dependent manner, including C5orf25 
a proteins that was also identified to show affinity specifically for SUMO-
ubiquitin hybrid chains (Figure 4.2-11).  Importantly the STUbL RNF4 was 
observed to not be required for the recruitment of RAP80 to the sites of DNA 
damage, as in ∆RNF4 cell lines, RAP80 was observed at the sites of DNA 
damage (Figure 4.2-6).  Finally, the apparent affinity of RAP80 for hybrid 
chains of SUMO and ubiquitin was utilised in an attempt identify proteins that 
may anchor hybrid chains of SUMO and ubiquitin (Figure 4.2-12).  This 
experimental approach showed promise and successfully identified a handful 
of proteins with gel shift patterns consistent with that expects of proteins 
modified with a hybrid chain of SUMO and ubiquitin (Figure 4.2-16).  This 
included S100A8, however, further optimization of the experimental technique 
would be required to confirm that S100A8 was indeed linked to a hybrid chain 
of SUMO and ubiquitin.  Whether hybrid chains of SUMO and ubiquitin are 
critically important for the recruitment of RAP80 to the sites of DNA damage is 
still up for debate.  RNF4, the primary candidate for generating SUMO-
ubiquitin hybrid chains at the sites of damage does not appear to be required 
for the recruitment of RAP80 to the sites of DNA damage.  However, clearly a 
high degree of cooperativity exists between SUMO, ubiquitin, and RAP80.  
This cooperativity does not appear to extend to RNF4 generated SUMO-
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ubiquitin hybrid chains in the case for RAP80 recruitment to the sites of 
damage, but this does not rule out that these chains maybe important for 
other cellular processes.  
 
 The possibility of SUMO-ubiquitin hybrid chains acting as a signalling 
mechanism distinct from homotypic chains of SUMO and ubiquitin is of great 
interest to the SUMO, ubiquitin and greater PTM fields.  Recent advances in 
mass spectrometry analysis has allowed for the identification of SUMO 
modified by ubiquitin and vice versa, posing the question as to whether the 
PTM of proteins that themselves act as PTM could produce hybrid signal of 
both PTMs?  The generation of substrates that are both SUMOylated and 
ubiquitylated requires the recruitment and activation of enzymes from both 
SUMO and ubiquitin conjugation pathways.  Thus, a hybrid signal generated 
by the orchestration of both the SUMO and ubiquitin conjugation pathways 
would inherently be more specific than that of either the SUMO or ubiquitin 
conjugation pathways alone.  Protein specificity for these hybrid signals would 
also be increased as interaction elements for both SUMO and ubiquitin would 
be required to work in tandem, as seen in the N-terminal SIM UIMUIM domain 
of RAP80.  The vast number of different combination of SUMO-ubiquitin 
hybrid chains that could potentially be created, could act as a new reservoir of 
as yet untapped specific signals used to pinpoint protein complexes to very 
specific cellular events, bypassing the landscape of more commonly found 
SUMO or ubiquitin modifications in the cell under normal conditions.  In this 
respect it is also interesting to note that STUbLs have been evolutionary 
conserved from yeast to humans suggesting some biological pressure to 
conserve the action of these proteins in cells.  Thus, further work to identify 
potential biological roles for SUMO-ubiquitin hybrid chains would be of great 
interest to the Ubl field as a whole.	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Appendix	  
Appendix	  I	  
2.1.1	  General	  buffer	  list	  
 
Name    Components      
6X DNA loading buffer 60 mM Tris-HCL, 50 mM EDTA, 1%(w/v) SDS, 
30% (w/v) glycerol, 0.1% (w/v) bromophenolblue, 
pH 8.0 
6X SDS sample buffer 60 mM Tris-HCL, 1%(w/v) SDS, 10%(v/v) glycerol, 
100 mM DTT, 0.005 mM bromophenolblue, pH 6.8 
Coomassie Blue stain 4mg of Coomassie Blue R25 was dissolved in 
1000ml of Ethanol. 200ml of Acetic acid is then 
added with 800ml of distilled H2O. Solution is then 
stirred overnight and then filtered through filter 
paper. 
Destain 1 40% (v/v) EtOH, 7% (v/v) acetic acid 
Destain 2 5% (v/v) EtOH, 7% (v/v) acetic acid 
MES (1X) 50 mM MES, 50 mM Tris, 0.1% SDS, 1 mM EDTA 
pH 7.7 
MOPs (1x) 50 mM MOPs, 50 mM Tris, 0.1% SDS, 1 mM 
EDTA pH 7.3 
PBS(T) Phosphate-buffered saline (0.1% Tween) 
Reaction buffer 50 mM Tris pH 7.5, 150 mM NaCl, 0.1% NP-40 
Tris/Gly transfer buffer 25 mM Tris, 192 mM Glycine 20% EtOH 
TBS(T) Tris-buffered saline (0.1% Tween) 
Western blot stripping  0.2 M NaOH, 0.5 M NaCl 
Buffer 
    
2.1.2	  Antibodies	  list	  
 
Antibody  Species Application  Source   
53BP1  Mouse WB/IF   Bethyl Laboratories 
BRCA1  Mouse WB/IF   Santa Cruz Biotech 
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Morc3   Rabbit  WB/IP   Santa Cruz Biotech 
RAP80  Rabbit  WB/IF/IP/PLA Bethyl Laboratories 
SENP1  Rabbit  WB/IP   Cell Signalling 
SUMO2  Rabbit  WB/IF/PLA  Invitrogen 
SUMO2  Sheep  WB   Hay Lab stock 
Ubiquitin  Rabbit  WB   Invitrogen 
Ubiquitin (FK2) Mouse WB/IF/PLA  BIOMOL 
USP2   Rabbit  WB/IP   Cell signalling 
USP28 (m)  Rabbit  WB   Abcam 
USP28 (p)  Rabbit  IP   Bethyl Laboratories 
yH2A.x  Mouse WB/IF   MerekMillipore 
 
2.1.3	  PCR	  primer	  list	  
 
Morc 3 Full Length & Mutants 
• Full length F -  
TTTTTTGGATCCATGGCGGCGCAGCCACCCCGCG 
• Full length R - 
TTTTTTCTCGAGTTAAGTACTACTGATTTCACTCATTTGTTCACT 
• Morc3 A F - 
TTTTTTGGATCCATGGCGGCGCAGCCACCCCGCG 
• Morc3 A R - 
TTTTTTCTCGAGTTATTCAACTGGCAAATTTAGAGGATATTCTGT 
• Morc3 B F - 
TTTTTTGGATCCATGGCGGCGCAGCCACCCCGCG 
• Morc3 B R - 
TTTTTTCTCGAGTTAGGGATGTACCAAATCCTCATCTTCAGGTTC 
• Morc3 C F - 
TTTTTTGGATCCGAAGATATACAGAAGCGTCCTGATCAGACATGG 
• Morc3 C R - 
TTTTTTCTCGAGTTAAGTACTACTGATTTCACTCATTTGTTCACT 
• Morc3 D F - 
TTTTTTGGATCCCCCACTTATGAAAAAACCTACAAAAAGACCAAC 
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• Morc3 D R - 
TTTTTTCTCGAGTTAAGTACTACTGATTTCACTCATTTGTTCACT 
• Morc3 SIM Mutant 1 F - 
ATAAAAGCGGAGCATGCAGCAGCAGCAGTGGCATTCAACAAGC 
• Morc3 SIM Mutant 1 R - 
GCTTGTTGAATGCCACTGCTGCTGCTGCATGCTCCGCTTTTAT 
• Morc3 SIM Mutant 2 F - 
GATGATGATGGAGATGCAGCAGCAGCAGAAGAAAACAGTACCCC 
• Morc3 SIM Mutant 2 R - 
GGTACTGTTTTCTTCTGCTGCTGCTGCATCTCCATCATCATCATCA
CC  
• Morc3 SIM Mutant 3 F - 
GAACTGAGAAACCAGCTACTCCTTGTCACTGAGGAAAAAGAG 
• Morc3 SIM Mutant 3 R - 
CTCTTTTTCCTCAGTTGCTGCTGCTGCCTGGTTTCTCAGTTC 
• Morc3 SIM Mutant 4 F - 
TCAGCAAGTGAATTACGATGCAGCAGCAGCAGATGAGATTTTAGG
ACAAG 




USP2 Catalytic Domain 
• CaD F  - 
TTTTTTAAGCTTGCAATTCTAAGAGTGCCCAGGGTC 
• CaD R - 
TTTTTTCTCGAGTTACATTCGGGAGGGCGGG 
 
USP28 Full Length & Mutants 
• Full length F -  
TTTTTTGGATCCATGACTGCGGAGCTGCAGC 
• Full length R -  
TTTTTTAAGCTTTTATTTCACTGTCACAGTTGAAACTCCCTA 
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• SIM-UIM F -  
TTTTTTGGATCCATGACTGCGGAGCTGCAGC 
• SIM-UIM R -  
• TTTTTTAAGCTTTTAATTGGGGTTTTCTCCCCAGACTTCACA 
• SIM-ΔUIM F - 
TTTTTTGGATCCATGACTGCGGAGCTGCAGC 
• SIM-ΔUIM R - 
TTTTTTAAGCTTTTAATGTTTGTTATCATGAGTAAGGTCTAT 
• ΔSIM-UIM F - 
GCCGACGCCACTCATGATAACAAAGATGATCTTCAGGCTGCCATT
G 




2.1.4	  Reagent	  Kit	  list	  
 
Kits        Source   
Benzoase       Merekmillipore 
Duolink® Using PLA® In SITU Red    Sigma-Aldrich 
Starter Kit Mouse/Rabbit  
DC-Assay       Bio-Rad 
ECL Plus       Thermo Scientific  
KOD DNA Polymerase     Toyobo Life Sciences 
Phusion HF DNA Polymerase    Life Technologies 
QIAprep Miniprep Kit     Qiagen 
QIAprep PCR Purification      Qiagen 
QIAqick Gel Extraction     Qiagen 
Restriction Enymes (various)    NEB 
RNAiMAX       Life Technologies 
T4 DNA Ligase      NEB 
Novex NuPAGE 10% Bis-tris gels    Life Technologies 
Novex NuPAGE 4-12% Bis-tris gels   Life Technologies 
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2.1.5	  Plasmids	  &	  Vectors	  
 
Plasmid        Source   
pcDNA3.1+HA-C5orf25     DSTT 
pET-6His_TEV-RNF168     DSTT 
pGEX-6P-USP2      DSTT 
pGEX-6P-USP28      DSTT 
pHISTEV30a       Hay Lab Stocks 
pHISTEV30a -Ub-4xSUMO2ΔN11   Dr. A Plechanovova 
pHISTEV30a-4xSUMO2ΔN11    Dr. A Plechanovova 
pLou3-MBP-Ube2v2     Dr. A Plechanovova 
pSC-HA-Morc3      DSTT 
 
2.1.6	  Recombinant	  Proteins	  
 
Protein        Source   
4xSUMO2       Thesis author 
GST-UIM dimer      DSTT 
K63 pUb        DSTT 
Morc3        Thesis author  
Morc3 A/B/C/D      Thesis author 
pUb-4xSUMO2      Thesis author 
RNF4        Hay lab stocks 
SENP1       Dr. L Shen 
Tri K48 Ub       DSTT 
Ub-4xSUMO2      Thesis author 
Uba1        Hay lab stocks 
Ubc13        Hay lab stocks 
Ubiquitin       Hay lab stocks 
USP2 CaD (Asn259-Met605)    Thesis author 
USP28       Thesis author 
USP28 N-terminal Mutants     Thesis author 	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Appendix	  II	  
 
Full list of all proteins characterised with a given specificity for polymeric 
chains of SUMO, ubiquitin, or hybrid chains of SUMO and ubiquitin from the 
hybrid chain pull down assay after mass spectrometry analysis. 	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